POLR-Related Leukodystrophy

Mendelian MONDO:0100605 Pathograph 32 Show in embeddings browser Leukodystrophy

POLR-related leukodystrophy — usually called POLR3-related hypomyelinating leukodystrophy (POLR3-HLD) or 4H leukodystrophy — is an autosomal recessive hypomyelinating leukodystrophy caused by biallelic hypomorphic variants in genes encoding subunits of RNA polymerase III (Pol III): POLR3A, POLR3B, POLR1C, and rarely POLR3K. Pol III transcribes short non-coding RNAs (all nuclear-encoded tRNAs, 5S rRNA, 7SL, 7SK and others); partial loss of that output produces a strikingly tissue-restricted disease dominated by failure of central nervous system myelin deposition, together with dental, endocrine and ocular involvement. The eponymous "4H" tetrad is Hypomyelination, Hypodontia, Hypogonadotropic hypogonadism, plus (near-universal, recognized later) progressive myopia. This entry is the umbrella entity spanning the Pol III subunit genes; the POLR3A-specific OMIM phenotype is curated separately as Hypomyelinating Leukodystrophy 7.

Ask OpenScientist

Ask a research question about POLR-Related Leukodystrophy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

👪

Inheritance

Autosomal recessive inheritance HP:0000007

POLR-related leukodystrophy is inherited in an autosomal recessive manner. Each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing and prenatal diagnosis are possible once both familial pathogenic variants are known. Biallelic complete-null genotypes have not been observed, consistent with a requirement for residual Pol III activity. Expressivity is highly variable, ranging from a severe early-infantile course with death in the first years of life to attenuated adult-onset presentations; variability tracks the specific allele combination (severe versus hypomorphic) more than any identified modifier locus.

Autosomal recessive inheritance Expressivity: VARIABLE

Show evidence (1 reference)

PMID:22855961 SUPPORT Human Clinical

"POLR3-related leukodystrophy is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."

GeneReviews states the inheritance pattern and recurrence risks directly.

◆

Subtypes

POLR3A-related POLR3-HLD (HLD7) MONDO:0011897

POLR3A hgnc:30074

Caused by biallelic POLR3A variants (largest, catalytic Pol III subunit, RPC1). Historically ascertained through French-Canadian founder families with tremor-ataxia with central hypomyelination (TACH), and shown to be allelic with 4H syndrome and leukodystrophy with oligodontia. Associated with a more severe clinical course than POLR3B-related disease. A dedicated dismech entry, Hypomyelinating Leukodystrophy 7, curates this subtype in depth.

Show evidence (2 references)

PMID:21855841 SUPPORT Human Clinical

"In total, 14 recessive mutations were found in 19 individuals with TACH, 4H, or LO, establishing that these leukodystrophies are allelic."

Establishes POLR3A as a cause of the disorder and unifies three historically separate clinical labels into one allelic spectrum.

PMID:25339210 SUPPORT Human Clinical

"Mutations in POLR3A are associated with a more severe clinical course."

Supports POLR3A-related disease as the more severe end of the spectrum.

POLR3B-related POLR3-HLD (HLD8) MONDO:0013722

POLR3B hgnc:30348

Caused by biallelic POLR3B variants (second-largest Pol III subunit, RPC2, which forms the catalytic centre together with RPC1). Generally a milder disease course than POLR3A-related disease. The recurrent hypomorphic c.1568T>A (p.Val523Glu) allele is carried by most patients on one allele, and homozygosity for it produces a mild phenotype.

Show evidence (2 references)

PMID:22036172 SUPPORT Human Clinical

"We uncovered in three cases without POLR3A mutation recessive mutations in POLR3B, which codes for the second largest subunit of Pol III."

Original identification of POLR3B as a second causal Pol III subunit gene.

PMID:25339210 SUPPORT Human Clinical

"Most patients carried the common c.1568T>A POLR3B mutation on one allele, homozygosity for which causes a mild phenotype."

Documents the recurrent hypomorphic POLR3B allele and its milder effect.

POLR1C-related POLR3-HLD (HLD11) MONDO:0014666

POLR1C hgnc:20194

Caused by biallelic POLR1C variants. POLR1C encodes a subunit shared between RNA polymerase I and RNA polymerase III, making this subtype mechanistically distinctive: leukodystrophy-causing POLR1C variants selectively impair Pol III (not Pol I) assembly and nuclear import, whereas Treacher Collins syndrome-causing POLR1C variants leave polymerase assembly intact and instead disturb Pol I nucleolar targeting.

Show evidence (1 reference)

PMID:26151409 SUPPORT Human Clinical

"Here we report eight of these cases carrying recessive mutations in POLR1C, a gene encoding a shared POLR1 and POLR3 subunit, also mutated in some Treacher Collins syndrome (TCS) cases."

Identifies POLR1C as a third causal gene and flags the shared Pol I/Pol III subunit identity underlying the allelic relationship with Treacher Collins syndrome.

POLR3K-related POLR3-HLD

POLR3K hgnc:14121

An ultra-rare subtype caused by biallelic POLR3K variants (a small Pol III subunit). Only a handful of patients have been reported worldwide. Reported phenotypes span a severe early-onset, rapidly progressive end and a comparatively mild end with childhood intellectual and behavioural disturbance and later minor motor dysfunction. No distinct MONDO term exists for this subtype, so subtype_term is deliberately left unbound rather than mapped to a near-miss identifier.

Show evidence (2 references)

PMID:40225923 SUPPORT Human Clinical

"Here, we report the third patient worldwide with pathogenic variants in POLR3K and clinical features consistent with POLR3-HLD."

Establishes POLR3K as a causal gene and documents its extreme rarity.

PMID:30584594 SUPPORT Human Clinical

"Disease progression for both patients appeared in the most severe range of Pol III–related leukodystrophies in terms of age at onset (<18 months) and death (<20 years) and motor and cognitive development (no independent walking)"

Documents the severe end of the reported POLR3K phenotype.

Discussions and Knowledge Gaps

Why does partial loss of a ubiquitously required enzyme produce a white-matter-predominant disease, and what makes the oligodendrocyte lineage the most sensitive cell type?

KNOWLEDGE GAP OPEN polr_hld_oligodendrocyte_selective_vulnerability

Attached to

pathophysiology#Reduced Steady-State Pol III Subunit Protein in Cerebral White Matter pathophysiology#Oligodendrocyte Differentiation Arrest

Pol III transcribes tRNAs, 5S rRNA and other RNAs required by every cell, yet the clinical phenotype is dominated by hypomyelination. Two partial explanations exist and are not mutually exclusive: a regional gradient in steady-state subunit protein (greater loss in cerebral white matter than cortex in one autopsied brain) and an intrinsic sensitivity of oligodendrogenesis and myelination to reduced Pol III output. Neither has been shown to be sufficient, and the single-brain protein gradient has not been replicated.

Proposed experiments

Cell-type-resolved Pol III transcript and protein quantification in human brain

polr_hld_celltype_resolved_pol3_quantification

Quantify Pol III subunit protein and Pol III transcript output across oligodendrocyte-lineage, neuronal and astrocytic populations in post-mortem POLR3-HLD and control brain, to test whether the white-matter-predominant deficit is cell-intrinsic to the oligodendrocyte lineage rather than a bulk-tissue composition artefact.

Show evidence (1 reference)

PMID:34583988 SUPPORT Model Organism

"The findings suggest unique sensitivities of oligodendrogenesis and myelination to perturbations of Pol III transcription."

The authors frame lineage-selective sensitivity as a suggestion arising from the model, i.e., an open question rather than an established mechanism.

Which Pol III transcript class is the proximate driver of disease — the tRNA pool, 5S rRNA and ribosome biogenesis, 7SL and the signal recognition particle, or some combination that differs by causal gene?

CONTROVERSY OPEN polr_hld_which_transcript_deficit_drives_disease

Attached to

pathophysiology#Reduced Pol III Non-Coding Transcript Output pathophysiology#Reduced Mature tRNA Pool pathophysiology#Constrained Translational Capacity

Different studies nominate different transcript classes. The original POLR3A/POLR3B paper hypothesized tRNAs; a mouse time-course placed a global tRNA-pool reduction earliest and argued for a causal role in disease initiation; but POLR3K patient fibroblasts showed 5S rRNA and 7SL RNA most severely reduced, with the authors reasoning through ribosome function and signal recognition particle biology instead. It is unresolved whether these are competing accounts or gene-specific and assay-specific differences within a shared final pathway.

Proposed experiments

Matched multi-transcript-class profiling across causal genotypes

polr_hld_matched_transcript_class_profiling

Profile mature tRNA, 5S rRNA, 7SL and 7SK in a single harmonized assay across patient-derived oligodendrocyte-lineage cells carrying POLR3A, POLR3B, POLR1C and POLR3K genotypes, to determine whether the transcript hierarchy is genotype-dependent or an artefact of differing assays and cell types.

Show evidence (2 references)

PMID:39499645 SUPPORT Model Organism

"Thus, changes in the size and/or composition of the tRNA pool have a causal role in disease initiation."

States the tRNA-first position in the disagreement.

PMID:30584594 SUPPORT In Vitro

"transcription of both 5S rRNA and 7SL RNA was most severely reduced. 5S rRNA is a component of the large subunit of the ribosome and therefore important for ribosomal functioning."

States the ribosome and signal-recognition-particle position in the disagreement.

Which mouse models faithfully represent human POLR3-HLD, given that a constitutive knock-in of a bona fide human pathogenic allele produced no phenotype while lineage-restricted conditional models did?

HUMAN MODEL MISMATCH OPEN polr_hld_mouse_model_fidelity

Attached to

pathophysiology#Oligodendrocyte Differentiation Arrest pathophysiology#Deficient Central Nervous System Myelin Deposition

The Polr3a G672E constitutive knock-in carries a validated human founder allele yet showed normal behaviour, normal myelination and no significant change in brain Pol III transcripts. In contrast, Olig2-Cre-driven expression of pathogenic Polr3a and the conditional Polr3b delta-10 hypomorph both produce hypomyelination. This means a negative mouse result cannot be read as evidence against a mechanism, and that conclusions drawn from the conditional models inherit the assumption that lineage-restricted expression is a fair proxy for the constitutive human condition. Even the best conditional model omits gross motor deficits and cerebellar hypomyelination seen in severely affected patients, and no model reproduces the full human tetrad including hypogonadotropic hypogonadism.

Proposed experiments

Allelic series in a single mouse background

polr_hld_allelic_series_single_background

Compare constitutive, oligodendrocyte-lineage-conditional and whole-body-postnatal-inducible expression of the same pathogenic Polr3a allele on one genetic background, measuring myelination, Pol III transcript output and behaviour, to isolate whether developmental timing, compensation, or cell-type context explains the divergent results.

Show evidence (2 references)

PMID:28407788 SUPPORT Model Organism

"Cerebral and cerebellar Luxol Fast Blue staining and measurement of levels of myelin proteins showed no significant differences between the three groups, suggesting that myelination is not overtly impaired in Polr3a KI/KI and KI/KO mice."

The negative model result that creates the mismatch.

PMID:34583988 SUPPORT Model Organism

"In contrast, the gross motor defects and cerebellar hypomyelination that are common features of severely affected patients are absent in the mice, suggesting a relatively mild form of the disease in this conditional model."

Shows that even the positive conditional model is only a partial phenocopy.

Should "POLR-related leukodystrophy" (MONDO:0100605) include the RNA polymerase I gene POLR1A, or be restricted to Pol III subunit genes?

OPEN QUESTION OPEN polr_hld_umbrella_scope_pol_i_genes

Attached to

pathophysiology#Biallelic Hypomorphic Pol III Subunit Variant

The MONDO label says "POLR-related" and the definition says "any of the POLR genes, including POLR1C, POLR3A or POLR3B", which reads as open-ended, while the clinical literature almost uniformly says "POLR3-related". Biallelic POLR1A variants cause a clinically overlapping hypomyelinating leukodystrophy with cerebellar atrophy, but through Pol I rRNA processing and nucleolar and protein-homeostasis disruption rather than reduced Pol III transcript supply. POLR1C sits awkwardly across the boundary, being shared between the two polymerases while its leukodystrophy variants act specifically on Pol III. This entry is currently scoped to the Pol III subunit genes and treats POLR1A-related leukodystrophy as a differential; that decision should be revisited if the ontology or the clinical literature converges.

Show evidence (1 reference)

PMID:36917474 SUPPORT Human Clinical

"We confirm that POLR1A biallelic variants cause neurodegenerative disease, expand the knowledge of the clinical phenotype of the disorder"

Establishes POLR1A-related leukodystrophy as a real entity whose relationship to this umbrella needs an explicit scoping decision.

If diffuse hypomyelination is not obligate, what should the diagnostic entry criterion for POLR-related leukodystrophy be, and how many patients are being missed by MRI-gated testing?

KNOWLEDGE GAP OPEN polr_hld_hypomyelination_not_obligate

Attached to

phenotypes#Cerebral Hypomyelination imaging_findings#Atypical Selective Corticospinal Tract Involvement

The characteristic MRI pattern is the practical entry point to diagnosis, but eight molecularly confirmed patients have been reported without it, showing instead selective corticospinal tract involvement or isolated cerebellar atrophy. Separately, the hypomorphic POLR3A c.1909+22G>A allele produces spastic ataxia frequently without leukodystrophy imaging and accounts for roughly 3% of hereditary spastic paraplegia and ataxia index cases. The size of the missed population is unknown because ascertainment has historically been MRI-driven, which makes the denominator unmeasurable from existing cohorts.

Proposed experiments

Unbiased Pol III gene screening in imaging-negative ataxia cohorts

polr_hld_unbiased_screening_imaging_negative_cohorts

Sequence POLR3A, POLR3B, POLR1C and POLR3K in large ataxia and spastic paraplegia cohorts ascertained without any MRI requirement, and report the yield stratified by imaging pattern, to estimate what fraction of Pol III-related disease is invisible to hypomyelination-gated testing.

Show evidence (2 references)

PMID:27029625 SUPPORT Human Clinical

"Diffuse hypomyelination is not an obligatory feature of POLR3-related disorders."

Directly establishes that the diagnostic imaging gate is imperfect.

PMID:28459997 SUPPORT Human Clinical

"we screened a cohort of hereditary spastic paraplegia and cerebellar ataxia cases (n = 618) for mutations in POLR3A and identified compound heterozygous POLR3A mutations in ∼3.1% of index cases."

Quantifies a substantial POLR3A-related population ascertained outside the leukodystrophy imaging phenotype.

Does the in vitro ibuprofen rescue of oligodendroglial differentiation translate to any in vivo benefit, and is the lysosomal/mTOR arm relevant to the missense alleles that actually cause human disease?

KNOWLEDGE GAP OPEN polr_hld_ibuprofen_translation_gap

Attached to

pathophysiology#Lysosomal Mislocalization of Mutant Pol III Subunits pathophysiology#mTOR Signaling Suppression

The ibuprofen result is attractive because it is a repurposed, well-tolerated drug acting on a defined target. But the experiments used severe nonsense alleles (POLR3A p.Arg140Ter, POLR3B p.Arg550Ter) in a mouse oligodendroglial cell line, whereas human POLR3-HLD is caused by hypomorphic, largely missense genotypes and no patient has been reported with two nonsense alleles. Whether missense mutant subunits are also routed to lysosomes and suppress mTOR is untested, so the therapeutic hypothesis may rest on an allele class that does not occur biallelically in patients. No in vivo or human data exist.

Proposed experiments

Lysosomal localization and mTOR readout across the patient allele spectrum

polr_hld_lysosomal_localization_patient_alleles

Test whether recurrent patient missense alleles (for example POLR3B p.Val523Glu) reproduce the lysosomal mislocalization and mTOR suppression seen with nonsense alleles, and whether ibuprofen rescues differentiation in that context.

In vivo ibuprofen trial in a validated conditional mouse model

polr_hld_in_vivo_ibuprofen_trial

Administer ibuprofen to the conditional Polr3b delta-10 mouse during postnatal myelinogenesis and measure oligodendrocyte maturation and myelin thickness, to establish whether the in vitro rescue has any in vivo counterpart.

Show evidence (1 reference)

PMID:21855841 SUPPORT Human Clinical

"No individual was found to carry two nonsense mutations."

Establishes the allele-class mismatch between the human disease and the cell models used for the ibuprofen experiments.

Pol III also functions as a cytosolic DNA sensor driving interferon induction, and monoallelic POLR3A/POLR3C variants cause severe varicella zoster virus disease. Do biallelic POLR3-HLD patients also carry an antiviral-immunity defect, and should they be monitored for it?

OPEN QUESTION OPEN polr_hld_pol3_dna_sensing_arm

Attached to

pathophysiology#Biallelic Hypomorphic Pol III Subunit Variant

Pol III has a second, transcription-independent role as a cytosolic sensor of AT-rich DNA that drives type I interferon induction. Rare heterozygous POLR3A and POLR3C missense variants cause life-threatening varicella zoster virus infection in otherwise healthy children through impaired DNA-triggered interferon induction — a phenotype with no reported overlap with 4H leukodystrophy. It is unresolved whether the biallelic hypomorphic genotypes that cause POLR3-HLD also compromise this sensing function, whether the two functions are separably affected by different variant classes, and therefore whether POLR3-HLD patients warrant any specific antiviral vigilance. This entry does not model the DNA-sensing arm because no evidence connects it to the leukodystrophy phenotype.

Proposed experiments

DNA-triggered interferon induction in POLR3-HLD patient leukocytes

polr_hld_ifn_induction_in_patient_leukocytes

Measure interferon induction in response to synthetic and virus-derived cytosolic DNA in leukocytes from patients with biallelic POLR3-HLD genotypes, using the same assay that demonstrated the defect in monoallelic varicella-susceptibility patients, to determine whether the sensing and transcription functions are separably affected.

Show evidence (2 references)

PMID:28783042 SUPPORT Human Clinical

"We report 4 cases of acute severe VZV infection affecting the central nervous system or the lungs in unrelated, otherwise healthy children who are heterozygous for rare missense mutations in POLR3A (one patient), POLR3C (one patient), or both (two patients)."

Establishes a second, immunological disease mechanism for variants in Pol III subunit genes, distinct from the leukodystrophy phenotype.

PMID:28783042 SUPPORT In Vitro

"Leukocytes from all 4 patients tested exhibited poor IFN induction in response to synthetic or VZV-derived DNA."

Defines the functional assay that would need to be applied to POLR3-HLD patients to answer this question.

Should dopamine D2 receptor blockers (haloperidol, risperidone, metoclopramide) be recorded as agents to avoid in POLR-related leukodystrophy, and is there a citable source for that claim?

CURATION TODO OPEN polr_hld_agents_to_avoid_unverified

Attached to

phenotypes#Dystonia

The deep-research artifact for this entry asserted that dopamine D2 receptor blockers exacerbate the extrapyramidal and dystonic features of this population and flagged it as a drug-safety item to model. The claim is clinically plausible — D2 blockade worsening dystonia is a general pharmacological principle — but a targeted PubMed search found no source that makes it specifically about POLR3-related leukodystrophy, and the cached GeneReviews abstract does not contain an "Agents/Circumstances to Avoid" statement (the abstract is a condensed form of the full chapter, which may well carry one). A drug-safety assertion is exactly the kind of claim that must not be curated from an unverified secondary summary, so it is deliberately NOT recorded as a treatment or a note here. Resolution requires either the full GeneReviews chapter text or a primary source; if one is found, this should become an agents-to-avoid entry on the dystonia management treatment.

Proposed experiments

Locate a citable agents-to-avoid source

polr_hld_agents_to_avoid_source_hunt

Retrieve the full GeneReviews POLR3-Related Leukodystrophy chapter (NBK99167) and check its Agents/Circumstances to Avoid section, and search case-level literature for reported dystonia exacerbation after D2-blocker exposure in molecularly confirmed patients.

Should the cerebellar degenerative arm of POLR-related leukodystrophy declare conformance to the cerebellar_purkinje_degeneration module?

CURATION TODO OPEN polr_hld_cerebellar_module_conformance

Attached to

pathophysiology#Progressive Cerebellar Atrophy

Cerebellar atrophy with progressive ataxia is a cardinal feature, which makes cerebellar_purkinje_degeneration a natural conformance candidate. However, that module's key node is Purkinje neuron degeneration, and the available evidence here reports generic neuron and oligodendrocyte loss in mouse cerebra rather than Purkinje-specific degeneration in human tissue. Declaring conformance now would assert a cell-type specificity the evidence does not support, so it is deliberately deferred pending Purkinje-resolved neuropathology.

Show evidence (1 reference)

PMID:39499645 SUPPORT Model Organism

"cell-type-specific gene expression changes reflecting neuron and oligodendrocyte loss and microglial activation"

Reports neuronal loss without resolving whether Purkinje cells are the affected population, which is exactly the gap blocking a conformance claim.

⚙

Pathophysiology

Biallelic Hypomorphic Pol III Subunit Variant

The proximal molecular lesion is a pair of hypomorphic (not complete-null) variants in a gene encoding a subunit of RNA polymerase III — POLR3A, POLR3B, POLR1C, or POLR3K. No individual has been reported carrying two nonsense POLR3A alleles, consistent with a requirement for residual Pol III activity. Because Pol III is essential and ubiquitously expressed, disease arises from partial quantitative reduction of enzyme function rather than from its abolition.

Downstream

Impaired Pol III Complex Assembly and Nuclear Import Mutant subunits fail to support cytoplasmic assembly and nuclear import of the Pol III holoenzyme.

Reduced Steady-State Pol III Subunit Protein in Cerebral White Matter Hypomorphic alleles lower steady-state subunit protein, disproportionately in cerebral white matter.

Lysosomal Mislocalization of Mutant Pol III Subunits Some nonsense alleles produce aggregated mutant protein that is routed to lysosomes rather than to the nucleus.

Show evidence (2 references)

PMID:21855841 SUPPORT Human Clinical

"No individual was found to carry two nonsense mutations."

Direct evidence that biallelic complete loss of function is not observed, supporting a hypomorphic-variant disease mechanism.

PMID:22036172 SUPPORT Human Clinical

"Mutations in genes coding for Pol III subunits are a major cause of childhood-onset hypomyelinating leukodystrophies with prominent cerebellar dysfunction, oligodontia, and hypogonadotropic hypogonadism."

Establishes Pol III subunit variants as the causal lesion of the 4H phenotype.

Impaired Pol III Complex Assembly and Nuclear Import

Leukodystrophy-causing variants interfere with assembly of the multi-subunit Pol III holoenzyme in the cytoplasm and with its subsequent import into the nucleus, so less functional enzyme reaches chromatin. For POLR1C — a subunit shared with RNA polymerase I — this defect is selective for Pol III and spares Pol I, which is why POLR1C leukodystrophy variants do not produce the craniofacial phenotype caused by other POLR1C variants.

protein-containing complex assembly GO:0065003 ↓ DECREASED protein import into nucleus GO:0006606 ↓ DECREASED

Downstream

Reduced Pol III Occupancy at Target Genes Less assembled, nuclear-localized enzyme is available to occupy Pol III-transcribed genes.

Show evidence (1 reference)

PMID:26151409 SUPPORT In Vitro

"Using shotgun proteomics and ChIP sequencing, we demonstrate that leukodystrophy-causative mutations, but not TCS mutations, in POLR1C impair assembly and nuclear import of POLR3, but not POLR1"

Direct experimental demonstration of the assembly and nuclear-import defect and of its selectivity for Pol III over Pol I.

Reduced Steady-State Pol III Subunit Protein in Cerebral White Matter

Hypomorphic alleles reduce the steady-state amount of Pol III subunit protein, and this reduction is not uniform across tissues: immunoblotting of patient fibroblasts and of an autopsied 4H brain showed a significantly greater decrease in cerebral white matter than in cortex. This regional gradient is one of the few direct human observations bearing on why a ubiquitously required enzyme produces a white-matter-predominant disease.

white matter UBERON:0002316

Downstream

Oligodendrocyte Differentiation Arrest The white-matter-predominant protein deficit is proposed to underlie the selective vulnerability of the oligodendrocyte lineage.

Show evidence (1 reference)

PMID:21855841 SUPPORT Human Clinical

"documented a significant decrease in POLR3A levels, and there was a more significant decrease in the cerebral white matter compared to that in the cortex"

Human tissue evidence for a white-matter-predominant reduction in Pol III subunit protein.

Reduced Pol III Occupancy at Target Genes

With less assembled nuclear enzyme available, chromatin occupancy at Pol III-transcribed genes falls. ChIP-sequencing of mutant POLR1C showed reduced binding across the classes of Pol III-transcribed genes, including tRNA and 5S rRNA genes, while occupancy at the Pol I-transcribed ribosomal RNA gene was unchanged.

transcription by RNA polymerase III GO:0006383 ↓ DECREASED

Downstream

Reduced Pol III Non-Coding Transcript Output Lower promoter occupancy translates into lower non-coding RNA synthesis.

Show evidence (1 reference)

PMID:26151409 SUPPORT In Vitro

"We also demonstrated that the leukodystrophy-causing mutations affect POLR3, but not POLR1 assembly and nuclear import, leading to decrease binding to POLR3 target genes"

Establishes reduced chromatin occupancy at Pol III target genes as the step linking the assembly defect to reduced transcript output.

Reduced Pol III Non-Coding Transcript Output

Transcription of the Pol III repertoire falls: all nuclear-encoded tRNAs, 5S rRNA (a structural component of the large ribosomal subunit), 7SL RNA (the signal recognition particle RNA) and 7SK RNA. Which transcript classes are most affected varies by causal gene and assay — patient fibroblasts with a POLR3K variant showed 5S rRNA and 7SL RNA most severely reduced, whereas the earliest measurable change in a Polr3a mutant mouse was a global reduction in the mature tRNA pool.

tRNA transcription by RNA polymerase III GO:0042797 ↓ DECREASED

Downstream

Reduced Mature tRNA Pool Lower tRNA gene transcription shrinks and reshapes the mature tRNA pool.

Constrained Translational Capacity Reduced 5S rRNA and 7SL RNA supply constrains ribosome function and co-translational targeting independently of the tRNA route.

Integrated Stress and Innate Immune Response Induction Later in the disease course, reduced Pol III output is accompanied by induction of stress and innate immune programmes.

Impaired Odontogenesis The dental arm branches from the shared transcript deficit rather than from the oligodendrocyte route. A conditional Polr3b mouse develops hypodontia, so the lesion acts directly on tooth development, but the intervening steps between reduced Pol III output and disturbed odontogenesis are not established.

Hypothalamic-Pituitary Gonadotropic Insufficiency The endocrine arm likewise branches from the shared transcript deficit. No published work identifies the cell type or step through which reduced Pol III output impairs gonadotropin drive, so this edge records the branch point rather than a worked-out mechanism.

Impaired Somatic Growth Growth impairment branches from the same shared deficit and is not explained by the neurological disease. The intervening mechanism, including why growth hormone deficiency is present in only some affected individuals, is unresolved.

Show evidence (2 references)

PMID:30584594 SUPPORT In Vitro

"we compared the expression levels of some Pol III–transcribed RNAs in patient and control fibroblasts: transcription of both 5S rRNA and 7SL RNA was most severely reduced"

Human patient-derived cells directly demonstrate reduced Pol III transcript output.

PMID:22036171 SUPPORT Human Clinical

"We hypothesize that perturbation of Pol III target transcription, especially of tRNAs, could be a common pathological mechanism underlying POLR3A and POLR3B mutations."

Framed by the original authors as a hypothesis rather than a demonstrated result, so recorded as partial support for the shared-mechanism claim.

Lysosomal Mislocalization of Mutant Pol III Subunits

A mechanistically separate, cell-autonomous arm demonstrated in oligodendroglial cell models: severe nonsense alleles of POLR3A (p.Arg140Ter) and POLR3B (p.Arg550Ter) produce protein aggregates that are routed to lysosomes instead of to the nucleus, whereas wild-type subunits are not lysosomal. This is currently supported only by in vitro cell-line data, and uses an allele class not observed biallelically in patients.

oligodendrocyte precursor cell CL:0002453

lysosome GO:0005764

Downstream

mTOR Signaling Suppression The lysosomal burden of mislocalized mutant subunits suppresses lysosome-associated mTOR signaling.

Show evidence (2 references)

PMID:35076634 SUPPORT In Vitro

"an HLD7-associated nonsense mutation of Arg140-to-Ter (R140X) primarily localizes POLR3A proteins as protein aggregates into lysosomes in mouse oligodendroglial FBD-102b cells"

Direct in vitro evidence for lysosomal mislocalization of a POLR3A nonsense allele.

PMID:35225888 SUPPORT In Vitro

"a severe HLD8-associated nonsense mutation (Arg550-to-Ter (R550X)) primarily localizes POLR3B proteins as protein aggregates into lysosomes in the FBD-102b cell line as an oligodendroglial precursor cell model"

Shows the same lysosomal-mislocalization mechanism for a POLR3B nonsense allele, supporting it as a cross-gene arm.

mTOR Signaling Suppression

Expression of lysosomally mislocalized mutant Pol III subunits reduces signaling through the mechanistic target of rapamycin, the lysosome-anchored hub controlling anabolic growth. This is the node the ibuprofen rescue acts on, and the reason that lead is mechanistically framed as mTOR reactivation rather than as an anti-inflammatory effect.

Downstream

Oligodendrocyte Differentiation Arrest Suppressed mTOR signaling blocks the morphological differentiation programme of oligodendroglial cells.

Show evidence (2 references)

PMID:35076634 SUPPORT In Vitro

"Expression of the R140X mutant proteins, but not the wild type proteins, in cells decreased signaling through the mechanistic target of rapamycin (mTOR), controlling signal transduction around lysosomes."

Direct in vitro evidence that the POLR3A mutant suppresses mTOR signaling.

PMID:35225888 SUPPORT In Vitro

"Additionally, the expression of proteins with the R550X mutation in cells decreased lysosome-related signaling through the mechanistic target of rapamycin (mTOR)."

Independent replication of mTOR suppression for a POLR3B nonsense allele.

Reduced Mature tRNA Pool

The mature tRNA pool shrinks and shifts in composition. In a postnatal whole-body Polr3a mutant mouse, tRNA sequencing early in disease showed a global reduction and altered profile of mature tRNAs at a stage when no other Pol III transcript class had changed and stress programmes were not yet induced, placing this deficit upstream as a disease-initiating event.

Downstream

Constrained Translational Capacity A smaller, compositionally altered tRNA pool is expected to limit the rate and fidelity of protein synthesis.

Show evidence (1 reference)

PMID:39499645 SUPPORT Model Organism

"Earlier in the disease when integrated stress and innate immune responses are minimally induced, mature tRNA sequencing revealed a global reduction in tRNA levels and an altered tRNA profile but no changes in other Pol III transcripts. Thus, changes in the size and/or composition of the tRNA..."

Temporal ordering evidence placing the tRNA-pool deficit upstream of stress responses; mouse data, not yet confirmed in human tissue.

Constrained Translational Capacity

Reduced supply of Pol III products that serve protein synthesis — tRNAs, 5S rRNA as a structural component of the large ribosomal subunit, and 7SL RNA as the signal recognition particle RNA — is proposed to constrain translational capacity. This step is an inference: it is the mechanism the field invokes to connect reduced Pol III output to a myelination defect, but translational output has not been measured directly in patient oligodendrocytes, so both supporting citations are recorded as partial.

translation GO:0006412 ↓ DECREASED

Downstream

Oligodendrocyte Differentiation Arrest Oligodendrocyte maturation and the high translational demand of myelin protein synthesis are proposed to be especially sensitive to this constraint.

Show evidence (2 references)

PMID:22036171 SUPPORT Human Clinical

"Pol III is involved in the transcription of small noncoding RNAs, such as 5S ribosomal RNA and all transfer RNAs (tRNA)."

Establishes that the affected transcripts are the ones serving translation, without itself measuring translational output.

PMID:30584594 SUPPORT In Vitro

"Disruption in ribosomal regulation of mRNA translation may contribute to white matter developmenta"

The authors frame the translational link as a possible contribution ("may contribute"), which is why this is partial rather than full support.

Integrated Stress and Innate Immune Response Induction

As disease progresses in a Polr3a mutant mouse, cerebral transcriptomes show induction of innate immune and integrated stress response programmes alongside microglial activation. This is a secondary amplification arm rather than a disease-initiating event, since it is minimally induced at the stage when the tRNA deficit is already present.

Downstream

Progressive Cerebral Neurodegeneration Chronic stress and innate immune activation accompany progressive neuronal and oligodendrocyte loss.

Show evidence (1 reference)

PMID:39499645 SUPPORT Model Organism

"Transcriptome and immunohistochemistry analyses of cerebra during disease progression show a reduction in most Pol III transcripts, induction of innate immune and integrated stress responses and cell-type-specific gene expression changes reflecting neuron and oligodendrocyte loss and microglial..."

Documents the stress and innate-immune arm and its association with neuron and oligodendrocyte loss in the mouse model.

Oligodendrocyte Differentiation Arrest

Oligodendrocyte precursor cells fail to proliferate and differentiate into mature myelinating oligodendrocytes. Lineage tracing in a conditional Polr3b mouse model identified defective precursor proliferation and differentiation, with failure to generate an adequate number of mature oligodendrocytes during postnatal myelinogenesis, as the mechanism underlying hypomyelination.

oligodendrocyte precursor cell CL:0002453 oligodendrocyte CL:0000128

oligodendrocyte differentiation GO:0048709 ↓ DECREASED

Downstream

Deficient Central Nervous System Myelin Deposition Too few mature oligodendrocytes, each with reduced myelinating capacity, cannot lay down a normal myelin sheath.

Show evidence (2 references)

PMID:37635302 SUPPORT Model Organism

"Lineage tracing uncovered the underlying mechanism for the hypomyelinating phenotype: defective oligodendrocyte precursor proliferation and differentiation resulted in a failure to produce an adequate number of mature oligodendrocytes during postnatal myelinogenesis."

In vivo lineage-tracing evidence that precursor proliferation and differentiation failure is the proximate cause of hypomyelination.

PMID:34583988 SUPPORT Model Organism

"disease pathogenesis in the mice involves defects that reduce both the number of mature myelinating oligodendrocytes and the ability of these cells to produce a myelin sheath of normal thickness"

Independent mouse model showing both reduced mature oligodendrocyte number and reduced per-cell myelinating capacity.

Deficient Central Nervous System Myelin Deposition

Central myelin is never adequately deposited — a developmental and maturational deficit (hypomyelination), not destruction of previously normal myelin (demyelination). Structures that myelinate earliest in development are relatively spared, giving the characteristic MRI pattern of diffuse hypomyelination with relative T2 hypointensity of the ventrolateral thalamus, globus pallidus, optic radiation, corticospinal tract at the internal capsule, and dentate nucleus.

central nervous system myelination GO:0022010 ↓ DECREASED

white matter UBERON:0002316

Downstream

Progressive Cerebellar Atrophy Chronically hypomyelinated cerebellar tracts undergo progressive atrophy.

Progressive Cerebral Neurodegeneration Chronically hypomyelinated supratentorial tracts and their neurons undergo progressive degeneration.

Progressive Cerebellar Motor Dysfunction Deficient myelination of cerebellar and corticospinal pathways impairs motor control.

Show evidence (2 references)

PMID:34583988 SUPPORT Model Organism

"mice expressing pathogenic mutations in the largest Pol III subunit, Polr3a, specifically in Olig2-expressing cells, have impaired growth and developmental delay, deficits in cognitive, sensory, and fine sensorimotor function, and hypomyelination in multiple regions of the cerebrum and spinal cord"

Oligodendrocyte-lineage-restricted expression of a pathogenic Polr3a variant is sufficient to cause hypomyelination, supporting a cell-autonomous mechanism.

PMID:25339210 SUPPORT Human Clinical

"Systematic MRI review revealed that the combination of hypomyelination with relative T2 hypointensity of the ventrolateral thalamus, optic radiation, globus pallidus, and dentate nucleus, cerebellar atrophy, and thinning of the corpus callosum suggests the diagnosis."

Human imaging evidence for hypomyelination with a characteristic relative-sparing pattern.

Progressive Cerebellar Atrophy

Superimposed on the developmental hypomyelination is progressive loss of cerebellar volume, visible on serial imaging alongside thinning of the corpus callosum. The presence of an atrophic component on top of a developmental myelination deficit is what distinguishes the Pol III leukodystrophies from purely demyelinating disorders.

cerebellum UBERON:0002037

Downstream

Progressive Cerebellar Motor Dysfunction Cerebellar atrophy translates into worsening ataxia, tremor and dysarthria.

Show evidence (1 reference)

PMID:25339210 SUPPORT Human Clinical

"cerebellar atrophy, and thinning of the corpus callosum suggests the diagnosis"

Human imaging evidence for the superimposed cerebellar atrophic component.

Progressive Cerebral Neurodegeneration

A distinct supratentorial degenerative arm, characterized in mouse cerebra as neuron and oligodendrocyte loss with microglial activation and accompanying behavioural deficits. It is separated from the cerebellar node because the two rest on different evidence: the cerebellar claim is human imaging, this one is mouse neuropathology and transcriptomics.

neuron CL:0000540

Downstream

Progressive Cognitive Decline Cerebral neuronal loss contributes to later cognitive deterioration.

Show evidence (2 references)

PMID:39499645 SUPPORT Model Organism

"Polr3a mutant mice exhibit behavioral deficits, cerebral pathology and exocrine pancreatic atrophy."

Supports progressive cerebral pathology in a Pol III mutant model.

PMID:39499645 SUPPORT Model Organism

"cell-type-specific gene expression changes reflecting neuron and oligodendrocyte loss and microglial activation"

Identifies the cell populations lost in the cerebral degenerative arm.

Progressive Cerebellar Motor Dysfunction

The clinically dominant motor syndrome: progressive cerebellar dysfunction (ataxia, dysarthria, dysmetria, tremor), with lesser pyramidal (spasticity) and extrapyramidal (dystonia) involvement. Most patients present before age 6 years with gross motor delay or regression.

Show evidence (2 references)

PMID:22855961 SUPPORT Human Clinical

"Neurologic dysfunction, typically predominated by motor dysfunction"

GeneReviews states the motor-predominant character of the neurologic syndrome.

PMID:25339210 SUPPORT Human Clinical

"The majority of patients presented before 6 years with gross motor delay or regression."

Cohort evidence for the age and mode of motor presentation.

Progressive Cognitive Decline

Cognitive dysfunction is part of the neurologic syndrome but is generally later and less prominent than the motor deterioration, except in the late-onset subgroup where academic difficulty or cognitive plateau can be the presenting feature.

Show evidence (2 references)

PMID:22855961 SUPPORT Human Clinical

"and cognitive dysfunctions"

GeneReviews lists cognitive dysfunction among the neurologic features and ranks it below motor dysfunction, but the abstract does not itself time the decline, so this is recorded as partial support.

PMID:30584594 SUPPORT Human Clinical

"motor and cognitive development (no independent walking) and degradation"

Documents cognitive degradation, not merely static impairment, in two severely affected POLR3K patients.

Impaired Odontogenesis

Tooth development is disturbed independently of the CNS phenotype, producing delayed dentition, an abnormal order of eruption, abnormally placed or shaped teeth, and hypodontia or oligodontia. A conditional Polr3b mouse model reproduces hypodontia together with craniofacial abnormalities, supporting the dental arm as a direct consequence of reduced Pol III function rather than a secondary effect of neurological disease.

odontogenesis GO:0042476 ⚠ ABNORMAL

Show evidence (2 references)

PMID:37635302 SUPPORT Model Organism

"we characterized the Polr3bΔ10 mutation and developed an animal model that recapitulates features of POLR3-HLD caused by POLR3B mutations"

The model, whose reported features include hypodontia and craniofacial abnormalities alongside hypomyelination, supports a primary Pol III-dependent dental arm.

PMID:22855961 SUPPORT Human Clinical

"Abnormal dentition (delayed dentition, hypodontia, oligodontia, and abnormally placed or shaped teeth)."

GeneReviews defines the dental component of the tetrad.

Hypothalamic-Pituitary Gonadotropic Insufficiency

Insufficient gonadotropin drive to the gonads produces hypogonadotropic hypogonadism, manifesting as delayed, arrested, or absent puberty. This is the most common endocrine feature and one of the three defining "H"s, though it is not invariably present.

adenohypophysis UBERON:0002196

Show evidence (1 reference)

PMID:22855961 SUPPORT Human Clinical

"more commonly, hypogonadotropic hypogonadism manifesting as delayed, arrested, or absent puberty"

GeneReviews defines the endocrine component and its clinical manifestation.

Impaired Somatic Growth

Linear growth is impaired in roughly half of individuals. Growth hormone deficiency is demonstrable in some but not all of them, so the node is stated as the growth outcome rather than as a specific pituitary lesion. This is a separate endocrine axis from the gonadotropic one and is not universally coupled to it.

Show evidence (1 reference)

PMID:22855961 SUPPORT Human Clinical

"Endocrine abnormalities such as short stature (in ~50% of individuals) with or without growth hormone deficiency"

GeneReviews documents short stature with variable growth hormone deficiency as a distinct endocrine manifestation.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Digestive 1

Dysphagia HP:0002015

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:22855961 SUPPORT Human Clinical

"Special caution needs to be taken when managing dysphagia in this disorder as it is known to vary widely, even in a single day. Swallowing difficulties will progress over time"

GeneReviews documents both the progressive course and the striking day-to-day variability of dysphagia.

Endocrine 2

Hypogonadotropic Hypogonadism HP:0000044

Show evidence (1 reference)

PMID:22855961 SUPPORT Human Clinical

"more commonly, hypogonadotropic hypogonadism manifesting as delayed, arrested, or absent puberty"

GeneReviews defines the endocrine component of the tetrad.

Delayed Puberty FREQUENT HP:0000823

Show evidence (2 references)

PMID:22855961 SUPPORT Human Clinical

"manifesting as delayed, arrested, or absent puberty"

GeneReviews states the pubertal manifestation directly.

PMID:33005949 SUPPORT Human Clinical

"The most common endocrine abnormalities were delayed puberty (57/74; 77% overall, 64% in males, 89% in females) and short stature (57/93; 61%), when evaluated according to physician assessment."

A 150-patient international cross-sectional study gives 77% overall (89% in females, 64% in males), which lands in the FREQUENT band (30-79%). The band follows the overall figure rather than the higher female-only rate.

Eye 1

Progressive Myopia VERY_FREQUENT HP:0000545

Course: PROGRESSIVE

Show evidence (2 references)

PMID:22855961 SUPPORT Human Clinical

"Ocular abnormality in the form of myopia, typically progressing over several years and becoming severe."

GeneReviews describes the myopia and its progressive severe course.

PMID:25339210 SUPPORT Human Clinical

"Other than the typical neurologic, dental, and endocrine features, myopia was seen in almost all and short stature in 50%."

Quantitative cohort support for the VERY_FREQUENT band ("almost all" of 105 mutation-proven cases).

Head and Neck 3

Hypodontia HP:0000668

Show evidence (1 reference)

PMID:22855961 SUPPORT Human Clinical

"Abnormal dentition (delayed dentition, hypodontia, oligodontia, and abnormally placed or shaped teeth)."

GeneReviews itemizes hypodontia within the dental component.

Oligodontia HP:0000677

Show evidence (1 reference)

PMID:22036172 SUPPORT Human Clinical

"with prominent cerebellar dysfunction, oligodontia, and hypogonadotropic hypogonadism"

Names oligodontia as a core feature of the Pol III leukodystrophies.

Delayed Eruption of Teeth HP:0000684

Show evidence (1 reference)

PMID:22855961 SUPPORT Human Clinical

"Abnormal dentition (delayed dentition, hypodontia, oligodontia, and abnormally placed or shaped teeth)"

GeneReviews lists delayed dentition among the dental abnormalities.

Musculoskeletal 1

Spasticity HP:0001257

Show evidence (1 reference)

PMID:30584594 SUPPORT Human Clinical

"the severe spasticity and dystonia observed before age 10 years"

Documents spasticity in POLR3K-related disease; the quote is from the severe end of the spectrum, so it supports the association rather than a frequency band.

Nervous System 10

Cerebral Hypomyelination VERY_FREQUENT HP:0006808

Onset: CHILDHOOD

Show evidence (3 references)

PMID:22855961 SUPPORT Human Clinical

"POLR3-related leukodystrophy, a hypomyelinating leukodystrophy with specific features on brain MRI"

GeneReviews defines the disorder as a hypomyelinating leukodystrophy.

PMID:22855961 SUPPORT Human Clinical

"Age of onset is typically in early childhood but later-onset cases have also been reported."

GeneReviews statement of the typical onset window, backing the CHILDHOOD onset descriptor.

PMID:27029625 SUPPORT Human Clinical

"Diffuse hypomyelination is not an obligatory feature of POLR3-related disorders."

Qualifies the frequency claim: hypomyelination is characteristic but a minority of molecularly confirmed patients lack the diffuse pattern.

Ataxia VERY_FREQUENT HP:0001251

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:22036172 SUPPORT Human Clinical

"childhood-onset hypomyelinating leukodystrophies with prominent cerebellar dysfunction, oligodontia, and hypogonadotropic hypogonadism"

Establishes prominent cerebellar dysfunction as a core feature.

Motor Delay VERY_FREQUENT HP:0001270

Onset: CHILDHOOD

Show evidence (2 references)

PMID:25339210 SUPPORT Human Clinical

"The majority of patients presented before 6 years with gross motor delay or regression."

Cohort of 105 mutation-proven cases documents the presenting feature; the "majority" phrasing supports the VERY_FREQUENT band for delay-or-regression as a combined presentation, and the age window backing the onset descriptor.

PMID:25339210 SUPPORT Human Clinical

"Ten percent had an onset beyond 10 years."

Quantifies the later-onset minority, which is why the onset descriptor records a CHILDHOOD category with an explicit caveat rather than a hard ceiling.

Developmental Regression HP:0002376

Show evidence (1 reference)

PMID:25339210 SUPPORT Human Clinical

"presented before 6 years with gross motor delay or regression"

Documents regression as an alternative mode of presentation.

Dystonia HP:0001332

Show evidence (1 reference)

PMID:22855961 SUPPORT Human Clinical

"dystonia should be monitored and treated to prevent complications and improve the quality of life"

GeneReviews treats dystonia as an expected, clinically significant feature requiring active management.

Tremor HP:0001337

Show evidence (1 reference)

PMID:21855841 SUPPORT Human Clinical

"We mapped tremor-ataxia with central hypomyelination (TACH) to 10q22.3-23.1 in French-Canadian families"

Tremor is definitional to the TACH presentation, which this paper shows to be allelic with 4H.

Dysarthria HP:0001260

Show evidence (1 reference)

PMID:22855961 SUPPORT Human Clinical

"progressive cerebellar dysfunction"

The GeneReviews abstract names progressive cerebellar dysfunction, of which dysarthria is a standard component, but does not itemize dysarthria, so this is recorded as partial support.

Cognitive Decline Mental deterioration HP:0001268

Show evidence (2 references)

PMID:22855961 SUPPORT Human Clinical

"and cognitive dysfunctions"

GeneReviews lists cognitive dysfunction among the neurologic features, but the abstract does not describe deterioration over time, so this supports the association only.

PMID:30584594 SUPPORT Human Clinical

"motor and cognitive development (no independent walking) and degradation"

Documents cognitive degradation, not merely static impairment, in two severely affected patients.

Cerebellar Atrophy HP:0001272

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:25339210 SUPPORT Human Clinical

"cerebellar atrophy, and thinning of the corpus callosum suggests the diagnosis"

Cerebellar atrophy is part of the diagnostic imaging constellation.

Hypoplasia of the Corpus Callosum HP:0002079

Show evidence (1 reference)

PMID:22036171 SUPPORT Human Clinical

"a hypomyelinating syndrome characterized by diffuse cerebral hypomyelination with cerebellar atrophy and hypoplasia of the corpus callosum (HCAHC)"

Defines the HCAHC presentation later shown to be POLR3A/POLR3B-related.

Growth 1

Short Stature FREQUENT HP:0004322

Show evidence (2 references)

PMID:22855961 SUPPORT Human Clinical

"Endocrine abnormalities such as short stature (in ~50% of individuals) with or without growth hormone deficiency"

Provides both the association and the ~50% quantitative estimate supporting the FREQUENT band.

PMID:33005949 SUPPORT Human Clinical

"and short stature (57/93; 61%), when evaluated according to physician assessment"

Independent 150-patient cohort gives 61%, consistent with the GeneReviews ~50% estimate and with the FREQUENT band.

Other 1

Abnormal Thyroid Function OCCASIONAL Abnormality of thyroid physiology HP:0002926

Show evidence (1 reference)

PMID:33005949 SUPPORT Human Clinical

"Abnormal thyroid function was reported in 22% (13/59) of patients."

Direct quantitative support; 22% lands in the OCCASIONAL band (5-29%).

🧬

Genetic Associations

POLR3A (Biallelic hypomorphic variants in POLR3A, encoding the largest catalytic Pol III subunit (RPC1), cause POLR3-HLD. Together with POLR3B it accounts for the large majority of molecularly solved cases; in one referral series POLR3A variants were the more frequent of the two.)

Gene: POLR3A hgnc:30074 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (1 reference)

PMID:23355746 SUPPORT Human Clinical

"To date, our group has described 37 patients, of whom 27 have mutations in POLR3A and 10 in POLR3B, respectively."

Provides the per-gene case split in this referral series; ascertainment differs between series, so this is not a population estimate.

POLR3B (Biallelic variants in POLR3B, encoding the second-largest Pol III subunit (RPC2), cause a generally milder form. The recurrent c.1568T>A (p.Val523Glu) hypomorphic allele is carried on one allele by most POLR3B patients, and patients of European background are more likely to carry POLR3B than other Pol III gene variants. Variant classes include missense, nonsense and splice-site changes and also large exonic deletions, which matters for testing strategy: patients in whom only one POLR3B variant is found on sequencing may carry a copy-number allele in trans that requires deletion-sensitive analysis to detect.)

Gene: POLR3B hgnc:30348 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (2 references)

PMID:26045207 SUPPORT Human Clinical

"In a small proportion of patients, no mutation in either gene or only one mutation is found. Analysis of the POLR3B cDNA revealed a large deletion of exons 21-22 in one case and of exons 26-27 in another case."

Documents multi-exon POLR3B deletions as a real variant class and ties them to the single-variant-found diagnostic scenario.

PMID:25339210 SUPPORT Human Clinical

"Except for French Canadian patients, patients from European backgrounds were more likely to have POLR3B mutations than other populations."

Documents the ancestry-dependent distribution between the two major genes.

POLR1C (Biallelic POLR1C variants cause a minority of cases. POLR1C is shared between Pol I and Pol III; leukodystrophy-causing variants selectively disrupt Pol III biogenesis. Clinical and radiological features are compatible with POLR3-related leukodystrophy, but affected individuals do not necessarily display the full tetrad.)

Gene: POLR1C hgnc:20194 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (1 reference)

PMID:26151409 SUPPORT Human Clinical

"clinical and radiological characteristics of these eight cases were compatible with POLR3-related leukodystrophy; however, patients did not necessarily have all clinical"

Establishes POLR1C causality and the incomplete expression of the full tetrad in POLR1C-related disease.

POLR3K (Biallelic POLR3K variants are an ultra-rare cause. Reported genotypes include a C-terminal missense variant in trans with a large deletion removing the last exon, with demonstrated reduction of POLR3K RNA and of Pol III-transcribed RNAs in patient material.)

Gene: POLR3K hgnc:14121 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (1 reference)

PMID:40225923 SUPPORT Human Clinical

"Next-generation sequencing revealed a paternally inherited missense variant in POLR3K (c.322G>T; p.D108Y) and a maternally inherited large deletion, spanning approximately 17.8 kb from chr16:30,362-48,162."

Documents a compound-heterozygous POLR3K genotype including a copy-number allele, which sequence-only testing would miss.

🗃️

External Assertions

OMIM hypomyelinating leukodystrophy 7 (POLR3A)

OMIM disease record OMIM:607694

OMIM phenotype record for the POLR3A-related subtype (HLD7).

OMIM hypomyelinating leukodystrophy 8 (POLR3B)

OMIM disease record OMIM:614381

OMIM phenotype record for the POLR3B-related subtype (HLD8).

💊

Medical Actions

Multidisciplinary Supportive Care

Action: supportive care Ontology label: Supportive Care NCIT:C15747

No disease-modifying therapy exists. Management is symptomatic and supportive, delivered by a multidisciplinary team spanning neurology, genetics, rehabilitation, dentistry, endocrinology, ophthalmology, otolaryngology and primary care. Dysphagia management deserves particular care because swallowing ability varies widely, even within a single day, and dystonia should be monitored and treated to prevent complications.

Show evidence (1 reference)

PMID:22855961 SUPPORT Human Clinical

"Individualized care by a multidisciplinary team including a pediatric neurologist, clinical geneticist, physiotherapist, occupational therapist, speech and language pathologist, neuropsychologist, rehabilitation physician, dentist, endocrinologist, ophthalmologist, ear-nose-and-throat..."

GeneReviews management recommendation, quoted directly.

Physical and Occupational Therapy

Action: physical therapy Ontology label: Physical Therapy NCIT:C15302

Rehabilitation for progressive ataxia, spasticity and dystonia, forming part of the recommended multidisciplinary programme.

Target Phenotypes: Ataxia HP:0001251

Show evidence (1 reference)

PMID:22855961 SUPPORT Human Clinical

"physiotherapist, occupational therapist, speech and language pathologist"

GeneReviews includes physiotherapy and occupational therapy in the recommended care team.

Dysphagia Management and Surveillance

Action: supportive care Ontology label: Supportive Care NCIT:C15747

Proactive swallowing assessment, dietary texture modification, and escalation to gastrostomy when nutritional intake or aspiration risk demands. Swallowing ability is characteristically variable within a single day, so a single assessment can be misleading.

Target Phenotypes: Dysphagia HP:0002015

Show evidence (1 reference)

PMID:22855961 SUPPORT Human Clinical

"Special caution needs to be taken when managing dysphagia in this disorder as it is known to vary widely, even in a single day."

GeneReviews explicitly flags this management caution.

Dystonia Monitoring and Treatment

Action: supportive care Ontology label: Supportive Care NCIT:C15747

GeneReviews singles dystonia out for active monitoring and treatment, not merely observation, because untreated dystonia drives complications and quality-of-life loss. No POLR3-specific antidystonic agent or regimen has been established, so drug selection follows general dystonia practice; that is why this entry records the management imperative without naming a specific agent.

Target Phenotypes: Dystonia HP:0001332

Show evidence (1 reference)

PMID:22855961 SUPPORT Human Clinical

"dystonia should be monitored and treated to prevent complications and improve the quality of life"

GeneReviews states the management imperative verbatim.

Deep Brain Stimulation for Refractory Dystonic Tremor

Action: Surgical Procedure NCIT:C15329

Deep brain stimulation has been used for treatment-refractory dystonic arm tremor in POLR3A-related disease, with reported response. Evidence is limited to small case series in the attenuated POLR3A c.1909+22G>A spastic-ataxia phenotype rather than in classical childhood-onset 4H leukodystrophy, so this is recorded as a selected-patient option, not a general recommendation.

Target Phenotypes: Dystonia HP:0001332 Tremor HP:0001337

Show evidence (1 reference)

PMID:38700104 SUPPORT Human Clinical

"Two patients with dystonic arm tremor responded to deep brain stimulation."

Direct but small-n human evidence (two patients), which is why the treatment description scopes it to selected patients.

Endocrine Surveillance and Replacement Therapy

Action: supportive care Ontology label: Supportive Care NCIT:C15747

Systematic endocrine evaluation is warranted: in a 150-patient cohort, delayed puberty (77%) and short stature (61%) were the commonest abnormalities and abnormal thyroid function was found in 22%. Pubertal induction and sex-hormone replacement, growth-hormone assessment, and thyroid monitoring follow from these findings. Important caveat carried from the source: the same authors concluded that endocrine abnormalities are typically underinvestigated and that evidence-based management recommendations do not yet exist for this disorder, so this entry records surveillance and standard replacement practice rather than a validated protocol. Modality is recorded as OTHER because the node mixes a surveillance arm with pharmacological hormone replacement and so belongs to neither the behavioral/lifestyle nor a single drug bucket cleanly.

Target Phenotypes: Hypogonadotropic hypogonadism HP:0000044 Delayed puberty HP:0000823 Short stature HP:0004322

Show evidence (2 references)

PMID:33005949 SUPPORT Human Clinical

"we noted that endocrine abnormalities are typically underinvestigated in this patient population. A prospective study is required to formulate evidence-based recommendations for management of the endocrine manifestations of this disorder."

Supports the surveillance imperative while explicitly establishing that evidence-based management recommendations do not yet exist — the reason this treatment is framed as surveillance plus standard practice.

PMID:22855961 SUPPORT Human Clinical

"dentist, endocrinologist, ophthalmologist"

GeneReviews places endocrinology in the recommended multidisciplinary care team.

Genetic Counseling and Reproductive Options

Action: genetic counseling Ontology label: Genetic Counseling NCIT:C15240

Autosomal recessive recurrence-risk counseling (25% per pregnancy for carrier couples), with carrier testing for at-risk relatives and prenatal diagnosis available once both familial pathogenic variants are known.

Show evidence (1 reference)

PMID:22855961 SUPPORT Human Clinical

"Carrier testing for at-risk relatives and prenatal diagnosis for pregnancies at increased risk are possible if both pathogenic variants in the family are known."

GeneReviews genetic counseling recommendation, quoted directly.

Ibuprofen (investigational, preclinical only)

Action: Pharmacotherapy NCIT:C15986

Agent: ibuprofen CHEBI:5855

Ibuprofen, an NSAID that also acts as an mTOR signaling activator, reverses the defective oligodendroglial differentiation phenotype produced by severe POLR3A and POLR3B nonsense alleles in an oligodendroglial precursor cell line. This is a mechanism-based repurposing lead only: the evidence is entirely in vitro in a mouse cell line, there is no in vivo or human efficacy data, and it must not be read as a treatment recommendation.

Mechanism Target:

INHIBITS mTOR Signaling Suppression — Ibuprofen acts as an mTOR signaling activator, reversing the suppression caused by lysosomally mislocalized mutant Pol III subunits and releasing the differentiation block in vitro.

Show evidence (2 references)

PMID:35225888 SUPPORT In Vitro

"Ibuprofen, which is a non-steroidal anti-inflammatory drug (NSAID), improved the defects in their differentiation phenotypes and signaling through mTOR."

In vitro rescue in an oligodendroglial precursor cell model carrying a POLR3B nonsense allele. Cell-line evidence only.

PMID:35076634 SUPPORT In Vitro

"Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), which is also known as an mTOR signaling activator, ameliorated defects in differentiation with myelin marker protein expression and the related signaling in cells harboring the R140X mutant constructs."

Parallel in vitro rescue for a POLR3A nonsense allele, supporting a cross-gene mechanism. Cell-line evidence only.

🔬

Diagnosis

Brain MRI pattern recognition

Brain MRI is the diagnostic cornerstone. The combination of diffuse hypomyelination with relative T2 hypointensity of the ventrolateral thalamus, optic radiation, globus pallidus and dentate nucleus, plus cerebellar atrophy and corpus callosum thinning, suggests the diagnosis — and is especially valuable when the non-neurological cardinal features are absent. Atypical patterns exist, so an atypical MRI does not exclude the diagnosis.

Show evidence (1 reference)

PMID:25339210 SUPPORT Human Clinical

"MRI characteristics are helpful in addressing the diagnosis, especially if patients lack the cardinal non-neurologic features."

States the specific diagnostic role of MRI pattern recognition.

Molecular genetic testing of Pol III subunit genes

Definitive diagnosis requires identification of biallelic pathogenic variants in POLR3A, POLR3B or POLR1C (or, rarely, POLR3K). Because copy-number alleles occur, testing should be able to detect deletions as well as sequence variants.

Show evidence (2 references)

PMID:22855961 SUPPORT Human Clinical

"POLR3-related leukodystrophy is diagnosed by the combination of classic clinical findings, typical brain MRI features, and the presence of biallelic pathogenic variants in POLR3A, POLR3B, or POLR1C."

GeneReviews states the diagnostic triad including molecular confirmation.

PMID:40225923 SUPPORT Human Clinical

"a maternally inherited large deletion, spanning approximately 17.8 kb from chr16:30,362-48,162"

Concrete example of a copy-number allele that sequence-only analysis would not detect.

🩻

Imaging Findings

Diffuse Hypomyelination with Selective Relative T2 Hypointensity

The diagnostic hallmark: diffuse white matter hypomyelination combined with relative T2 hypointensity (i.e., comparatively preserved myelination) of the ventrolateral thalamus, optic radiation, globus pallidus, corticospinal tract at the internal capsule, and dentate nucleus — all structures that myelinate early in development.

Mri Diagnostic

Show evidence (1 reference)

PMID:25339210 SUPPORT Human Clinical

Defines the pattern-recognition criteria used clinically.

Closed Eye Sign (Preserved Medial Lemniscus Myelination)

At 3T, better myelination of the medial lemniscus produces a relatively hypointense signal of this structure on axial T2-weighted images — the "closed eye sign" — present in all patients in a 12-patient 3T series and useful in separating 4H leukodystrophy from Pelizaeus-Merzbacher disease.

Mri

Show evidence (1 reference)

PMID:29179231 SUPPORT Human Clinical

"All patients had better myelination of the medial lemniscus with a relatively hypointense signal of this structure on axial T2-weighted (T2W) images ("closed eye sign")."

Documents the sign and its presence in all 12 patients imaged at 3T.

Myelin Islets

Variable numbers of small T1-hyperintense, T2-hypointense dots, mostly in frontal and parietal white matter, present in all patients in the 3T series and corresponding histologically to perivascular myelin staining within hypomyelinated white matter.

Mri

Show evidence (1 reference)

PMID:29179231 SUPPORT Human Clinical

"Myelin islets were variable numbers of small T1 hyperintense and T2 hypointense dots, mostly in the frontal and parietal white matter, and present in all patients."

Describes the finding and its frequency in the 3T cohort.

Atypical Selective Corticospinal Tract Involvement

A minority of molecularly confirmed patients lack diffuse hypomyelination and instead show selective involvement of the corticospinal tracts at the posterior limbs of the internal capsules, or isolated moderate-to-severe cerebellar atrophy. Recognizing these patterns matters because the classic pattern cannot be used as a gate for genetic testing.

Mri

Show evidence (1 reference)

PMID:27029625 SUPPORT Human Clinical

"We identified 2 novel MRI patterns: 4 participants presented a selective involvement of the corticospinal tracts, specifically at the level of the posterior limbs of the internal capsules; 4 patients presented moderate to severe cerebellar atrophy."

Documents the two atypical imaging patterns in eight molecularly confirmed patients.

📊

Prevalence

Worldwide

Cases In Literature Not yet documented

No population-based prevalence or incidence estimate has been published. The disorder is known from case series; the largest single cohort comprised 105 mutation-proven individuals. Prevalence is deliberately left as NOT_YET_DOCUMENTED rather than estimated from case counts.

Show evidence (1 reference)

PMID:25339210 SUPPORT Human Clinical

"We performed a multinational cross-sectional observational study of the clinical, radiologic, and molecular characteristics of 105 mutation-proven cases."

Establishes the size of the largest published cohort, the basis for the CASES_IN_LITERATURE measure.

🔀

Differential Diagnoses

Conditions with similar clinical presentations that must be differentiated from POLR-Related Leukodystrophy:

Pelizaeus-Merzbacher disease and Pelizaeus-Merzbacher-like disease 1

Overlapping Features The archetypal hypomyelinating leukodystrophies and the closest imaging mimics. PLP1-related Pelizaeus-Merzbacher disease (X-linked) and GJC2-related Pelizaeus-Merzbacher-like disease 1 (autosomal recessive) both produce diffuse hypomyelination on MRI with nystagmus, hypotonia, tremor, titubation, ataxia and spasticity, overlapping substantially with the neurological presentation of POLR3-HLD.

Distinguishing Features

X-linked inheritance (PLP1) or a GJC2 genotype rather than biallelic Pol III subunit variants.
Absent dental, hypogonadotropic and myopic components; the non-neurological 4H tetrad is not part of PMD or PMLD1.
At 3T, POLR3-HLD shows better myelination of the medial lemniscus (the closed eye sign), which is not seen in PMD.

Show evidence (2 references)

PMID:22422208 SUPPORT Human Clinical

"Signs of PMD include nystagmus, hypotonia, tremors, titubation, ataxia, spasticity, athetotic movements and cognitive impairment; the major findings in SPG2 are leg weakness and spasticity. A diffuse pattern of hypomyelination is seen on magnetic resonance imaging (MRI) of PMD/SPG2 patients."

Documents the overlapping neurological and imaging features that drive the differential.

PMID:29179231 SUPPORT Human Clinical

"However, in 4H leukodystrophy there is clearly better myelination of the medial lemniscus, which is not present in PMD."

Provides an explicit imaging discriminator between the two conditions.

Wiedemann-Rautenstrauch (neonatal progeroid) syndrome

Overlapping Features A second allelic POLR3A disorder. Biallelic truncating and/or splicing POLR3A variants cause neonatal progeroid syndrome with intrauterine growth restriction, lipodystrophy, characteristic triangular facies and dental abnormalities — a genotype class distinct from the biallelic missense variants associated with hypomyelinating leukodystrophy.

Distinguishing Features

Neonatal presentation with progeroid features, lipodystrophy and pseudohydrocephalus rather than childhood hypomyelination.
Associated with biallelic truncating or splicing POLR3A genotypes, whereas 4H is associated with biallelic missense genotypes.

Show evidence (1 reference)

PMID:30414627 SUPPORT Human Clinical

"Bi-allelic missense variants in POLR3A have been associated with phenotypes distinct from WRS: hypogonadotropic hypogonadism and hypomyelinating leukodystrophy with or without oligodontia."

The authors themselves separate the WRS and leukodystrophy genotype-phenotype classes.

🐁

Animal Models

Olig2-Cre-driven expression of pathogenic Polr3a variants Mus musculus Conditional oligodendrocyte-lineage mouse model

Restricting expression of pathogenic Polr3a mutations to Olig2-expressing (oligodendrocyte-lineage) cells is sufficient to cause hypomyelination in cerebrum and spinal cord together with growth, cognitive, sensory and fine sensorimotor deficits, establishing a cell-autonomous oligodendroglial requirement for Pol III. Gross motor deficits and cerebellar hypomyelination, common in severely affected patients, are absent, so the model reproduces only part of the human phenotype.

Species

Mus musculus

Genotype

Olig2-Cre-driven expression of pathogenic Polr3a variants

Genes

POLR3A hgnc:30074

Show evidence (1 reference)

PMID:34583988 SUPPORT Model Organism

The authors themselves scope the model's fidelity, which is why it is recorded here with its limitation rather than as a full phenocopy.

Polr3b delta-10 conditional hypomorph (Pdgfra-Cre/ERT; R26-Stopfl-EYFP; Polr3bfl) Mus musculus Inducible conditional mouse model

The most complete published murine phenocopy: postnatally induced expression of the orthologous Polr3b delta-10 hypomorph reproduces hypomyelination, hypodontia and craniofacial abnormalities, and lineage tracing identified defective oligodendrocyte precursor proliferation and differentiation as the mechanism.

Species

Mus musculus

Genotype

Polr3b delta-10 conditional hypomorph (Pdgfra-Cre/ERT; R26-Stopfl-EYFP; Polr3bfl)

Genes

POLR3B hgnc:30348

Show evidence (1 reference)

PMID:37635302 SUPPORT Model Organism

"we characterized the Polr3bΔ10 mutation and developed an animal model that recapitulates features of POLR3-HLD caused by POLR3B mutations, shedding light on disease pathogenesis, and opening the door to the development of therapeutic interventions."

Establishes the model as a partial phenocopy spanning CNS and dental features.

Polr3a c.2015G>A (p.G672E) knock-in, homozygous and compound heterozygous with a null allele Mus musculus Constitutive knock-in mouse model (negative result)

Introducing the French-Canadian founder Polr3a mutation into mice produced no motor phenotype, no detectable myelination deficit, and no significant change in brain Pol III transcript levels — a negative result that contrasts with the oligodendrocyte-lineage conditional models and is a key caveat when interpreting mouse data for this disease.

Species

Mus musculus

Genotype

Polr3a c.2015G>A (p.G672E) knock-in, homozygous and compound heterozygous with a null allele

Genes

POLR3A hgnc:30074

Show evidence (1 reference)

PMID:28407788 REFUTE Model Organism

"We conclude that the first transgenic mice with a leukodystrophy-causing Polr3a mutation do not recapitulate the childhood-onset HLD observed in the majority of human patients"

Recorded as REFUTE with respect to the claim that this knock-in models human POLR3-HLD; it is a genuine negative model result, not a supporting one.

{ }

Source YAML

click to show

name: POLR-Related Leukodystrophy
creation_date: "2026-07-31T00:00:00Z"
category: Mendelian
disease_term:
  preferred_term: POLR-related (4H) leukodystrophy
  term:
    id: MONDO:0100605
    label: POLR-related leukodystrophy
description: >-
  POLR-related leukodystrophy — usually called POLR3-related hypomyelinating
  leukodystrophy (POLR3-HLD) or 4H leukodystrophy — is an autosomal recessive
  hypomyelinating leukodystrophy caused by biallelic hypomorphic variants in
  genes encoding subunits of RNA polymerase III (Pol III): POLR3A, POLR3B,
  POLR1C, and rarely POLR3K. Pol III transcribes short non-coding RNAs (all
  nuclear-encoded tRNAs, 5S rRNA, 7SL, 7SK and others); partial loss of that
  output produces a strikingly tissue-restricted disease dominated by failure of
  central nervous system myelin deposition, together with dental, endocrine and
  ocular involvement. The eponymous "4H" tetrad is Hypomyelination, Hypodontia,
  Hypogonadotropic hypogonadism, plus (near-universal, recognized later)
  progressive myopia. This entry is the umbrella entity spanning the Pol III
  subunit genes; the POLR3A-specific OMIM phenotype is curated separately as
  Hypomyelinating Leukodystrophy 7.
synonyms:
- 4H leukodystrophy
- 4H syndrome
- POLR3-related leukodystrophy
- POLR3-HLD
- Pol III-related leukodystrophy
- RNA polymerase III-related leukodystrophy
- Hypomyelination, hypodontia, hypogonadotropic hypogonadism
- Tremor-ataxia with central hypomyelination
- TACH
- Ataxia, delayed dentition and hypomyelination
- ADDH
- Leukodystrophy with oligodontia
- Hypomyelination with cerebellar atrophy and hypoplasia of the corpus callosum
- HCAHC
parents:
- Leukodystrophy
external_assertions:
- name: Orphanet POLR-related leukodystrophy record
  source: Orphanet
  assertion_type: disease_record
  external_id: Orphanet:289494
  description: >-
    Orphanet record for 4H leukodystrophy, the source of the MONDO:0100605
    definition and of its scoping across POLR1C, POLR3A and POLR3B.
- name: OMIM hypomyelinating leukodystrophy 7 (POLR3A)
  source: OMIM
  assertion_type: disease_record
  external_id: OMIM:607694
  description: OMIM phenotype record for the POLR3A-related subtype (HLD7).
- name: OMIM hypomyelinating leukodystrophy 8 (POLR3B)
  source: OMIM
  assertion_type: disease_record
  external_id: OMIM:614381
  description: OMIM phenotype record for the POLR3B-related subtype (HLD8).
- name: GeneReviews POLR3-Related Leukodystrophy chapter
  source: GeneReviews
  assertion_type: clinical_synopsis
  external_id: PMID:22855961
  description: >-
    Expert-curated GeneReviews chapter (Bernard & Vanderver) used as the
    phenotype and management baseline for this entry.

has_subtypes:
- name: POLR3A
  display_name: POLR3A-related POLR3-HLD (HLD7)
  subtype_term:
    preferred_term: Hypomyelinating leukodystrophy 7 (HLD7)
    term:
      id: MONDO:0011897
      label: leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism
  description: >-
    Caused by biallelic POLR3A variants (largest, catalytic Pol III subunit,
    RPC1). Historically ascertained through French-Canadian founder families
    with tremor-ataxia with central hypomyelination (TACH), and shown to be
    allelic with 4H syndrome and leukodystrophy with oligodontia. Associated
    with a more severe clinical course than POLR3B-related disease. A dedicated
    dismech entry, Hypomyelinating Leukodystrophy 7, curates this subtype in
    depth.
  genes:
  - preferred_term: POLR3A
    term:
      id: hgnc:30074
      label: POLR3A
  evidence:
  - reference: PMID:21855841
    reference_title: "Mutations of POLR3A encoding a catalytic subunit of RNA polymerase Pol III cause a recessive hypomyelinating leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In total, 14 recessive mutations were found in 19 individuals with TACH,
      4H, or LO, establishing that these leukodystrophies are allelic.
    explanation: >-
      Establishes POLR3A as a cause of the disorder and unifies three
      historically separate clinical labels into one allelic spectrum.
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in POLR3A are associated with a more severe clinical course."
    explanation: Supports POLR3A-related disease as the more severe end of the spectrum.
- name: POLR3B
  display_name: POLR3B-related POLR3-HLD (HLD8)
  subtype_term:
    preferred_term: Hypomyelinating leukodystrophy 8 (HLD8)
    term:
      id: MONDO:0013722
      label: "leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism"
  description: >-
    Caused by biallelic POLR3B variants (second-largest Pol III subunit, RPC2,
    which forms the catalytic centre together with RPC1). Generally a milder
    disease course than POLR3A-related disease. The recurrent hypomorphic
    c.1568T>A (p.Val523Glu) allele is carried by most patients on one allele,
    and homozygosity for it produces a mild phenotype.
  genes:
  - preferred_term: POLR3B
    term:
      id: hgnc:30348
      label: POLR3B
  evidence:
  - reference: PMID:22036172
    reference_title: "Recessive mutations in POLR3B, encoding the second largest subunit of Pol III, cause a rare hypomyelinating leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We uncovered in three cases without POLR3A mutation recessive mutations in
      POLR3B, which codes for the second largest subunit of Pol III.
    explanation: Original identification of POLR3B as a second causal Pol III subunit gene.
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most patients carried the common c.1568T>A POLR3B mutation on one allele,
      homozygosity for which causes a mild phenotype.
    explanation: Documents the recurrent hypomorphic POLR3B allele and its milder effect.
- name: POLR1C
  display_name: POLR1C-related POLR3-HLD (HLD11)
  subtype_term:
    preferred_term: Hypomyelinating leukodystrophy 11 (HLD11)
    term:
      id: MONDO:0014666
      label: "leukodystrophy, hypomyelinating, 11"
  description: >-
    Caused by biallelic POLR1C variants. POLR1C encodes a subunit shared between
    RNA polymerase I and RNA polymerase III, making this subtype mechanistically
    distinctive: leukodystrophy-causing POLR1C variants selectively impair Pol
    III (not Pol I) assembly and nuclear import, whereas Treacher Collins
    syndrome-causing POLR1C variants leave polymerase assembly intact and
    instead disturb Pol I nucleolar targeting.
  genes:
  - preferred_term: POLR1C
    term:
      id: hgnc:20194
      label: POLR1C
  evidence:
  - reference: PMID:26151409
    reference_title: "Recessive mutations in POLR1C cause a leukodystrophy by impairing biogenesis of RNA polymerase III."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we report eight of these cases carrying recessive mutations in
      POLR1C, a gene encoding a shared POLR1 and POLR3 subunit, also mutated in
      some Treacher Collins syndrome (TCS) cases.
    explanation: >-
      Identifies POLR1C as a third causal gene and flags the shared Pol I/Pol III
      subunit identity underlying the allelic relationship with Treacher Collins
      syndrome.
- name: POLR3K
  display_name: POLR3K-related POLR3-HLD
  description: >-
    An ultra-rare subtype caused by biallelic POLR3K variants (a small Pol III
    subunit). Only a handful of patients have been reported worldwide. Reported
    phenotypes span a severe early-onset, rapidly progressive end and a
    comparatively mild end with childhood intellectual and behavioural
    disturbance and later minor motor dysfunction. No distinct MONDO term exists
    for this subtype, so subtype_term is deliberately left unbound rather than
    mapped to a near-miss identifier.
  genes:
  - preferred_term: POLR3K
    term:
      id: hgnc:14121
      label: POLR3K
  evidence:
  - reference: PMID:40225923
    reference_title: "Novel Pathogenic Variants in POLR3K Cause POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we report the third patient worldwide with pathogenic variants in
      POLR3K and clinical features consistent with POLR3-HLD.
    explanation: Establishes POLR3K as a causal gene and documents its extreme rarity.
  - reference: PMID:30584594
    reference_title: "Mutation in POLR3K causes hypomyelinating leukodystrophy and abnormal ribosomal RNA regulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Disease progression for both patients appeared in the most severe range of
      Pol III–related leukodystrophies in terms of age at onset (<18 months) and
      death (<20 years) and motor and cognitive development (no independent
      walking)
    explanation: Documents the severe end of the reported POLR3K phenotype.

pathophysiology:
- name: Biallelic Hypomorphic Pol III Subunit Variant
  description: >-
    The proximal molecular lesion is a pair of hypomorphic (not complete-null)
    variants in a gene encoding a subunit of RNA polymerase III — POLR3A,
    POLR3B, POLR1C, or POLR3K. No individual has been reported carrying two
    nonsense POLR3A alleles, consistent with a requirement for residual Pol III
    activity. Because Pol III is essential and ubiquitously expressed, disease
    arises from partial quantitative reduction of enzyme function rather than
    from its abolition.
  biological_scale: MOLECULAR
  evidence:
  - reference: PMID:21855841
    reference_title: "Mutations of POLR3A encoding a catalytic subunit of RNA polymerase Pol III cause a recessive hypomyelinating leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "No individual was found to carry two nonsense mutations."
    explanation: >-
      Direct evidence that biallelic complete loss of function is not observed,
      supporting a hypomorphic-variant disease mechanism.
  - reference: PMID:22036172
    reference_title: "Recessive mutations in POLR3B, encoding the second largest subunit of Pol III, cause a rare hypomyelinating leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutations in genes coding for Pol III subunits are a major cause of
      childhood-onset hypomyelinating leukodystrophies with prominent cerebellar
      dysfunction, oligodontia, and hypogonadotropic hypogonadism.
    explanation: Establishes Pol III subunit variants as the causal lesion of the 4H phenotype.
  downstream:
  - target: Impaired Pol III Complex Assembly and Nuclear Import
    description: >-
      Mutant subunits fail to support cytoplasmic assembly and nuclear import of
      the Pol III holoenzyme.
  - target: Reduced Steady-State Pol III Subunit Protein in Cerebral White Matter
    description: >-
      Hypomorphic alleles lower steady-state subunit protein, disproportionately
      in cerebral white matter.
  - target: Lysosomal Mislocalization of Mutant Pol III Subunits
    description: >-
      Some nonsense alleles produce aggregated mutant protein that is routed to
      lysosomes rather than to the nucleus.

- name: Impaired Pol III Complex Assembly and Nuclear Import
  description: >-
    Leukodystrophy-causing variants interfere with assembly of the multi-subunit
    Pol III holoenzyme in the cytoplasm and with its subsequent import into the
    nucleus, so less functional enzyme reaches chromatin. For POLR1C — a subunit
    shared with RNA polymerase I — this defect is selective for Pol III and
    spares Pol I, which is why POLR1C leukodystrophy variants do not produce the
    craniofacial phenotype caused by other POLR1C variants.
  biological_scale: MOLECULAR
  biological_processes:
  - preferred_term: protein-containing complex assembly
    term:
      id: GO:0065003
      label: protein-containing complex assembly
    modifier: DECREASED
  - preferred_term: protein import into nucleus
    term:
      id: GO:0006606
      label: protein import into nucleus
    modifier: DECREASED
  evidence:
  - reference: PMID:26151409
    reference_title: "Recessive mutations in POLR1C cause a leukodystrophy by impairing biogenesis of RNA polymerase III."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Using shotgun proteomics and ChIP sequencing, we demonstrate that
      leukodystrophy-causative mutations, but not TCS mutations, in POLR1C
      impair assembly and nuclear import of POLR3, but not POLR1
    explanation: >-
      Direct experimental demonstration of the assembly and nuclear-import defect
      and of its selectivity for Pol III over Pol I.
  downstream:
  - target: Reduced Pol III Occupancy at Target Genes
    description: >-
      Less assembled, nuclear-localized enzyme is available to occupy Pol
      III-transcribed genes.

- name: Reduced Steady-State Pol III Subunit Protein in Cerebral White Matter
  description: >-
    Hypomorphic alleles reduce the steady-state amount of Pol III subunit
    protein, and this reduction is not uniform across tissues: immunoblotting of
    patient fibroblasts and of an autopsied 4H brain showed a significantly
    greater decrease in cerebral white matter than in cortex. This regional
    gradient is one of the few direct human observations bearing on why a
    ubiquitously required enzyme produces a white-matter-predominant disease.
  biological_scale: MOLECULAR
  locations:
  - preferred_term: white matter
    term:
      id: UBERON:0002316
      label: white matter
  evidence:
  - reference: PMID:21855841
    reference_title: "Mutations of POLR3A encoding a catalytic subunit of RNA polymerase Pol III cause a recessive hypomyelinating leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      documented a significant decrease in POLR3A levels, and there was a more
      significant decrease in the cerebral white matter compared to that in the
      cortex
    explanation: >-
      Human tissue evidence for a white-matter-predominant reduction in Pol III
      subunit protein.
  downstream:
  - target: Oligodendrocyte Differentiation Arrest
    description: >-
      The white-matter-predominant protein deficit is proposed to underlie the
      selective vulnerability of the oligodendrocyte lineage.

- name: Reduced Pol III Occupancy at Target Genes
  description: >-
    With less assembled nuclear enzyme available, chromatin occupancy at Pol
    III-transcribed genes falls. ChIP-sequencing of mutant POLR1C showed reduced
    binding across the classes of Pol III-transcribed genes, including tRNA and
    5S rRNA genes, while occupancy at the Pol I-transcribed ribosomal RNA gene
    was unchanged.
  biological_scale: MOLECULAR
  biological_processes:
  - preferred_term: transcription by RNA polymerase III
    term:
      id: GO:0006383
      label: transcription by RNA polymerase III
    modifier: DECREASED
  evidence:
  - reference: PMID:26151409
    reference_title: "Recessive mutations in POLR1C cause a leukodystrophy by impairing biogenesis of RNA polymerase III."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We also demonstrated that the leukodystrophy-causing mutations affect
      POLR3, but not POLR1 assembly and nuclear import, leading to decrease
      binding to POLR3 target genes
    explanation: >-
      Establishes reduced chromatin occupancy at Pol III target genes as the step
      linking the assembly defect to reduced transcript output.
  downstream:
  - target: Reduced Pol III Non-Coding Transcript Output
    description: Lower promoter occupancy translates into lower non-coding RNA synthesis.

- name: Reduced Pol III Non-Coding Transcript Output
  description: >-
    Transcription of the Pol III repertoire falls: all nuclear-encoded tRNAs, 5S
    rRNA (a structural component of the large ribosomal subunit), 7SL RNA (the
    signal recognition particle RNA) and 7SK RNA. Which transcript classes are
    most affected varies by causal gene and assay — patient fibroblasts with a
    POLR3K variant showed 5S rRNA and 7SL RNA most severely reduced, whereas the
    earliest measurable change in a Polr3a mutant mouse was a global reduction
    in the mature tRNA pool.
  biological_scale: MOLECULAR
  biological_processes:
  - preferred_term: tRNA transcription by RNA polymerase III
    term:
      id: GO:0042797
      label: tRNA transcription by RNA polymerase III
    modifier: DECREASED
  evidence:
  - reference: PMID:30584594
    reference_title: "Mutation in POLR3K causes hypomyelinating leukodystrophy and abnormal ribosomal RNA regulation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      we compared the expression levels of some Pol III–transcribed RNAs in
      patient and control fibroblasts: transcription of both 5S rRNA and 7SL RNA
      was most severely reduced
    explanation: >-
      Human patient-derived cells directly demonstrate reduced Pol III transcript
      output.
  - reference: PMID:22036171
    reference_title: "Mutations in POLR3A and POLR3B encoding RNA Polymerase III subunits cause an autosomal-recessive hypomyelinating leukoencephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We hypothesize that perturbation of Pol III target transcription,
      especially of tRNAs, could be a common pathological mechanism underlying
      POLR3A and POLR3B mutations.
    explanation: >-
      Framed by the original authors as a hypothesis rather than a demonstrated
      result, so recorded as partial support for the shared-mechanism claim.
  downstream:
  - target: Reduced Mature tRNA Pool
    description: >-
      Lower tRNA gene transcription shrinks and reshapes the mature tRNA pool.
  - target: Constrained Translational Capacity
    description: >-
      Reduced 5S rRNA and 7SL RNA supply constrains ribosome function and
      co-translational targeting independently of the tRNA route.
  - target: Integrated Stress and Innate Immune Response Induction
    description: >-
      Later in the disease course, reduced Pol III output is accompanied by
      induction of stress and innate immune programmes.
  - target: Impaired Odontogenesis
    description: >-
      The dental arm branches from the shared transcript deficit rather than from
      the oligodendrocyte route. A conditional Polr3b mouse develops hypodontia,
      so the lesion acts directly on tooth development, but the intervening steps
      between reduced Pol III output and disturbed odontogenesis are not
      established.
  - target: Hypothalamic-Pituitary Gonadotropic Insufficiency
    description: >-
      The endocrine arm likewise branches from the shared transcript deficit. No
      published work identifies the cell type or step through which reduced Pol
      III output impairs gonadotropin drive, so this edge records the
      branch point rather than a worked-out mechanism.
  - target: Impaired Somatic Growth
    description: >-
      Growth impairment branches from the same shared deficit and is not
      explained by the neurological disease. The intervening mechanism, including
      why growth hormone deficiency is present in only some affected individuals,
      is unresolved.

- name: Lysosomal Mislocalization of Mutant Pol III Subunits
  description: >-
    A mechanistically separate, cell-autonomous arm demonstrated in
    oligodendroglial cell models: severe nonsense alleles of POLR3A
    (p.Arg140Ter) and POLR3B (p.Arg550Ter) produce protein aggregates that are
    routed to lysosomes instead of to the nucleus, whereas wild-type subunits
    are not lysosomal. This is currently supported only by in vitro cell-line
    data, and uses an allele class not observed biallelically in patients.
  biological_scale: MOLECULAR
  cell_types:
  - preferred_term: oligodendrocyte precursor cell
    term:
      id: CL:0002453
      label: oligodendrocyte precursor cell
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  evidence:
  - reference: PMID:35076634
    reference_title: "Hypomyelinating Leukodystrophy 7 (HLD7)-Associated Mutation of POLR3A Is Related to Defective Oligodendroglial Cell Differentiation, Which Is Ameliorated by Ibuprofen."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      an HLD7-associated nonsense mutation of Arg140-to-Ter (R140X) primarily
      localizes POLR3A proteins as protein aggregates into lysosomes in mouse
      oligodendroglial FBD-102b cells
    explanation: Direct in vitro evidence for lysosomal mislocalization of a POLR3A nonsense allele.
  - reference: PMID:35225888
    reference_title: "Hypomyelinating Leukodystrophy 8 (HLD8)-Associated Mutation of POLR3B Leads to Defective Oligodendroglial Morphological Differentiation Whose Effect Is Reversed by Ibuprofen."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      a severe HLD8-associated nonsense mutation (Arg550-to-Ter (R550X))
      primarily localizes POLR3B proteins as protein aggregates into lysosomes
      in the FBD-102b cell line as an oligodendroglial precursor cell model
    explanation: >-
      Shows the same lysosomal-mislocalization mechanism for a POLR3B nonsense
      allele, supporting it as a cross-gene arm.
  downstream:
  - target: mTOR Signaling Suppression
    description: >-
      The lysosomal burden of mislocalized mutant subunits suppresses
      lysosome-associated mTOR signaling.

- name: mTOR Signaling Suppression
  description: >-
    Expression of lysosomally mislocalized mutant Pol III subunits reduces
    signaling through the mechanistic target of rapamycin, the lysosome-anchored
    hub controlling anabolic growth. This is the node the ibuprofen rescue acts
    on, and the reason that lead is mechanistically framed as mTOR reactivation
    rather than as an anti-inflammatory effect.
  biological_scale: MOLECULAR
  evidence:
  - reference: PMID:35076634
    reference_title: "Hypomyelinating Leukodystrophy 7 (HLD7)-Associated Mutation of POLR3A Is Related to Defective Oligodendroglial Cell Differentiation, Which Is Ameliorated by Ibuprofen."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Expression of the R140X mutant proteins, but not the wild type proteins,
      in cells decreased signaling through the mechanistic target of rapamycin
      (mTOR), controlling signal transduction around lysosomes.
    explanation: Direct in vitro evidence that the POLR3A mutant suppresses mTOR signaling.
  - reference: PMID:35225888
    reference_title: "Hypomyelinating Leukodystrophy 8 (HLD8)-Associated Mutation of POLR3B Leads to Defective Oligodendroglial Morphological Differentiation Whose Effect Is Reversed by Ibuprofen."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Additionally, the expression of proteins with the R550X mutation in cells
      decreased lysosome-related signaling through the mechanistic target of
      rapamycin (mTOR).
    explanation: Independent replication of mTOR suppression for a POLR3B nonsense allele.
  downstream:
  - target: Oligodendrocyte Differentiation Arrest
    description: >-
      Suppressed mTOR signaling blocks the morphological differentiation
      programme of oligodendroglial cells.

- name: Reduced Mature tRNA Pool
  description: >-
    The mature tRNA pool shrinks and shifts in composition. In a postnatal
    whole-body Polr3a mutant mouse, tRNA sequencing early in disease showed a
    global reduction and altered profile of mature tRNAs at a stage when no
    other Pol III transcript class had changed and stress programmes were not
    yet induced, placing this deficit upstream as a disease-initiating event.
  biological_scale: MOLECULAR
  evidence:
  - reference: PMID:39499645
    reference_title: "Molecular basis of neurodegeneration in a mouse model of Polr3-related disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Earlier in the disease when integrated stress and innate immune responses
      are minimally induced, mature tRNA sequencing revealed a global reduction
      in tRNA levels and an altered tRNA profile but no changes in other Pol III
      transcripts. Thus, changes in the size and/or composition of the tRNA pool
      have a causal role in disease initiation.
    explanation: >-
      Temporal ordering evidence placing the tRNA-pool deficit upstream of stress
      responses; mouse data, not yet confirmed in human tissue.
  downstream:
  - target: Constrained Translational Capacity
    description: >-
      A smaller, compositionally altered tRNA pool is expected to limit the rate
      and fidelity of protein synthesis.

- name: Constrained Translational Capacity
  description: >-
    Reduced supply of Pol III products that serve protein synthesis — tRNAs, 5S
    rRNA as a structural component of the large ribosomal subunit, and 7SL RNA
    as the signal recognition particle RNA — is proposed to constrain
    translational capacity. This step is an inference: it is the mechanism the
    field invokes to connect reduced Pol III output to a myelination defect, but
    translational output has not been measured directly in patient
    oligodendrocytes, so both supporting citations are recorded as partial.
  biological_scale: CELLULAR
  biological_processes:
  - preferred_term: translation
    term:
      id: GO:0006412
      label: translation
    modifier: DECREASED
  evidence:
  - reference: PMID:22036171
    reference_title: "Mutations in POLR3A and POLR3B encoding RNA Polymerase III subunits cause an autosomal-recessive hypomyelinating leukoencephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pol III is involved in the transcription of small noncoding RNAs, such as
      5S ribosomal RNA and all transfer RNAs (tRNA).
    explanation: >-
      Establishes that the affected transcripts are the ones serving translation,
      without itself measuring translational output.
  - reference: PMID:30584594
    reference_title: "Mutation in POLR3K causes hypomyelinating leukodystrophy and abnormal ribosomal RNA regulation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Disruption in ribosomal regulation of mRNA translation may contribute to
      white matter developmenta
    explanation: >-
      The authors frame the translational link as a possible contribution ("may
      contribute"), which is why this is partial rather than full support.
  downstream:
  - target: Oligodendrocyte Differentiation Arrest
    description: >-
      Oligodendrocyte maturation and the high translational demand of myelin
      protein synthesis are proposed to be especially sensitive to this
      constraint.

- name: Integrated Stress and Innate Immune Response Induction
  description: >-
    As disease progresses in a Polr3a mutant mouse, cerebral transcriptomes show
    induction of innate immune and integrated stress response programmes
    alongside microglial activation. This is a secondary amplification arm
    rather than a disease-initiating event, since it is minimally induced at the
    stage when the tRNA deficit is already present.
  biological_scale: CELLULAR
  evidence:
  - reference: PMID:39499645
    reference_title: "Molecular basis of neurodegeneration in a mouse model of Polr3-related disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Transcriptome and immunohistochemistry analyses of cerebra during disease
      progression show a reduction in most Pol III transcripts, induction of
      innate immune and integrated stress responses and cell-type-specific gene
      expression changes reflecting neuron and oligodendrocyte loss and
      microglial activation.
    explanation: >-
      Documents the stress and innate-immune arm and its association with neuron
      and oligodendrocyte loss in the mouse model.
  downstream:
  - target: Progressive Cerebral Neurodegeneration
    description: >-
      Chronic stress and innate immune activation accompany progressive neuronal
      and oligodendrocyte loss.

- name: Oligodendrocyte Differentiation Arrest
  conforms_to: "cns_myelin_failure#Oligodendrocyte Differentiation Arrest and Death"
  description: >-
    Oligodendrocyte precursor cells fail to proliferate and differentiate into
    mature myelinating oligodendrocytes. Lineage tracing in a conditional Polr3b
    mouse model identified defective precursor proliferation and differentiation,
    with failure to generate an adequate number of mature oligodendrocytes during
    postnatal myelinogenesis, as the mechanism underlying hypomyelination.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: oligodendrocyte precursor cell
    term:
      id: CL:0002453
      label: oligodendrocyte precursor cell
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: oligodendrocyte differentiation
    term:
      id: GO:0048709
      label: oligodendrocyte differentiation
    modifier: DECREASED
  evidence:
  - reference: PMID:37635302
    reference_title: "Hypomyelination, hypodontia and craniofacial abnormalities in a Polr3b mouse model of leukodystrophy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Lineage tracing uncovered the underlying mechanism for the hypomyelinating
      phenotype: defective oligodendrocyte precursor proliferation and
      differentiation resulted in a failure to produce an adequate number of
      mature oligodendrocytes during postnatal myelinogenesis.
    explanation: >-
      In vivo lineage-tracing evidence that precursor proliferation and
      differentiation failure is the proximate cause of hypomyelination.
  - reference: PMID:34583988
    reference_title: "Defective myelination in an RNA polymerase III mutant leukodystrophic mouse."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      disease pathogenesis in the mice involves defects that reduce both the
      number of mature myelinating oligodendrocytes and the ability of these
      cells to produce a myelin sheath of normal thickness
    explanation: >-
      Independent mouse model showing both reduced mature oligodendrocyte number
      and reduced per-cell myelinating capacity.
  downstream:
  - target: Deficient Central Nervous System Myelin Deposition
    description: >-
      Too few mature oligodendrocytes, each with reduced myelinating capacity,
      cannot lay down a normal myelin sheath.

- name: Deficient Central Nervous System Myelin Deposition
  conforms_to: "cns_myelin_failure#Deficient or Unstable CNS Myelin Sheath"
  description: >-
    Central myelin is never adequately deposited — a developmental and
    maturational deficit (hypomyelination), not destruction of previously normal
    myelin (demyelination). Structures that myelinate earliest in development are
    relatively spared, giving the characteristic MRI pattern of diffuse
    hypomyelination with relative T2 hypointensity of the ventrolateral thalamus,
    globus pallidus, optic radiation, corticospinal tract at the internal
    capsule, and dentate nucleus.
  biological_scale: TISSUE
  biological_processes:
  - preferred_term: central nervous system myelination
    term:
      id: GO:0022010
      label: central nervous system myelination
    modifier: DECREASED
  locations:
  - preferred_term: white matter
    term:
      id: UBERON:0002316
      label: white matter
  evidence:
  - reference: PMID:34583988
    reference_title: "Defective myelination in an RNA polymerase III mutant leukodystrophic mouse."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      mice expressing pathogenic mutations in the largest Pol III subunit,
      Polr3a, specifically in Olig2-expressing cells, have impaired growth and
      developmental delay, deficits in cognitive, sensory, and fine sensorimotor
      function, and hypomyelination in multiple regions of the cerebrum and
      spinal cord
    explanation: >-
      Oligodendrocyte-lineage-restricted expression of a pathogenic Polr3a variant
      is sufficient to cause hypomyelination, supporting a cell-autonomous
      mechanism.
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Systematic MRI review revealed that the combination of hypomyelination
      with relative T2 hypointensity of the ventrolateral thalamus, optic
      radiation, globus pallidus, and dentate nucleus, cerebellar atrophy, and
      thinning of the corpus callosum suggests the diagnosis.
    explanation: >-
      Human imaging evidence for hypomyelination with a characteristic
      relative-sparing pattern.
  downstream:
  - target: Progressive Cerebellar Atrophy
    description: >-
      Chronically hypomyelinated cerebellar tracts undergo progressive atrophy.
  - target: Progressive Cerebral Neurodegeneration
    description: >-
      Chronically hypomyelinated supratentorial tracts and their neurons undergo
      progressive degeneration.
  - target: Progressive Cerebellar Motor Dysfunction
    description: >-
      Deficient myelination of cerebellar and corticospinal pathways impairs
      motor control.

- name: Progressive Cerebellar Atrophy
  description: >-
    Superimposed on the developmental hypomyelination is progressive loss of
    cerebellar volume, visible on serial imaging alongside thinning of the
    corpus callosum. The presence of an atrophic component on top of a
    developmental myelination deficit is what distinguishes the Pol III
    leukodystrophies from purely demyelinating disorders.
  biological_scale: TISSUE
  locations:
  - preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  evidence:
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cerebellar atrophy, and thinning of the corpus callosum suggests the diagnosis"
    explanation: Human imaging evidence for the superimposed cerebellar atrophic component.
  downstream:
  - target: Progressive Cerebellar Motor Dysfunction
    description: Cerebellar atrophy translates into worsening ataxia, tremor and dysarthria.

- name: Progressive Cerebral Neurodegeneration
  description: >-
    A distinct supratentorial degenerative arm, characterized in mouse cerebra
    as neuron and oligodendrocyte loss with microglial activation and
    accompanying behavioural deficits. It is separated from the cerebellar node
    because the two rest on different evidence: the cerebellar claim is human
    imaging, this one is mouse neuropathology and transcriptomics.
  biological_scale: TISSUE
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:39499645
    reference_title: "Molecular basis of neurodegeneration in a mouse model of Polr3-related disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Polr3a mutant mice exhibit behavioral deficits, cerebral pathology and
      exocrine pancreatic atrophy.
    explanation: Supports progressive cerebral pathology in a Pol III mutant model.
  - reference: PMID:39499645
    reference_title: "Molecular basis of neurodegeneration in a mouse model of Polr3-related disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      cell-type-specific gene expression changes reflecting neuron and
      oligodendrocyte loss and microglial activation
    explanation: Identifies the cell populations lost in the cerebral degenerative arm.
  downstream:
  - target: Progressive Cognitive Decline
    description: Cerebral neuronal loss contributes to later cognitive deterioration.

- name: Progressive Cerebellar Motor Dysfunction
  description: >-
    The clinically dominant motor syndrome: progressive cerebellar dysfunction
    (ataxia, dysarthria, dysmetria, tremor), with lesser pyramidal (spasticity)
    and extrapyramidal (dystonia) involvement. Most patients present before age
    6 years with gross motor delay or regression.
  biological_scale: ORGANISM
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurologic dysfunction, typically predominated by motor dysfunction"
    explanation: GeneReviews states the motor-predominant character of the neurologic syndrome.
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The majority of patients presented before 6 years with gross motor delay
      or regression.
    explanation: Cohort evidence for the age and mode of motor presentation.

- name: Progressive Cognitive Decline
  description: >-
    Cognitive dysfunction is part of the neurologic syndrome but is generally
    later and less prominent than the motor deterioration, except in the
    late-onset subgroup where academic difficulty or cognitive plateau can be
    the presenting feature.
  biological_scale: ORGANISM
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "and cognitive dysfunctions"
    explanation: >-
      GeneReviews lists cognitive dysfunction among the neurologic features and
      ranks it below motor dysfunction, but the abstract does not itself time the
      decline, so this is recorded as partial support.
  - reference: PMID:30584594
    reference_title: "Mutation in POLR3K causes hypomyelinating leukodystrophy and abnormal ribosomal RNA regulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      motor and cognitive development (no independent walking) and degradation
    explanation: >-
      Documents cognitive degradation, not merely static impairment, in two
      severely affected POLR3K patients.

- name: Impaired Odontogenesis
  description: >-
    Tooth development is disturbed independently of the CNS phenotype, producing
    delayed dentition, an abnormal order of eruption, abnormally placed or
    shaped teeth, and hypodontia or oligodontia. A conditional Polr3b mouse
    model reproduces hypodontia together with craniofacial abnormalities,
    supporting the dental arm as a direct consequence of reduced Pol III function
    rather than a secondary effect of neurological disease.
  biological_scale: TISSUE
  biological_processes:
  - preferred_term: odontogenesis
    term:
      id: GO:0042476
      label: odontogenesis
    modifier: ABNORMAL
  evidence:
  - reference: PMID:37635302
    reference_title: "Hypomyelination, hypodontia and craniofacial abnormalities in a Polr3b mouse model of leukodystrophy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      we characterized the Polr3bΔ10 mutation and developed an animal model that
      recapitulates features of POLR3-HLD caused by POLR3B mutations
    explanation: >-
      The model, whose reported features include hypodontia and craniofacial
      abnormalities alongside hypomyelination, supports a primary Pol
      III-dependent dental arm.
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Abnormal dentition (delayed dentition, hypodontia, oligodontia, and
      abnormally placed or shaped teeth).
    explanation: GeneReviews defines the dental component of the tetrad.

- name: Hypothalamic-Pituitary Gonadotropic Insufficiency
  description: >-
    Insufficient gonadotropin drive to the gonads produces hypogonadotropic
    hypogonadism, manifesting as delayed, arrested, or absent puberty. This is
    the most common endocrine feature and one of the three defining "H"s, though
    it is not invariably present.
  biological_scale: ORGANISM
  locations:
  - preferred_term: adenohypophysis
    term:
      id: UBERON:0002196
      label: adenohypophysis
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      more commonly, hypogonadotropic hypogonadism manifesting as delayed,
      arrested, or absent puberty
    explanation: GeneReviews defines the endocrine component and its clinical manifestation.

- name: Impaired Somatic Growth
  description: >-
    Linear growth is impaired in roughly half of individuals. Growth hormone
    deficiency is demonstrable in some but not all of them, so the node is
    stated as the growth outcome rather than as a specific pituitary lesion.
    This is a separate endocrine axis from the gonadotropic one and is not
    universally coupled to it.
  biological_scale: ORGANISM
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Endocrine abnormalities such as short stature (in ~50% of individuals)
      with or without growth hormone deficiency
    explanation: >-
      GeneReviews documents short stature with variable growth hormone deficiency
      as a distinct endocrine manifestation.

phenotypes:
- category: Neurologic
  name: Cerebral Hypomyelination
  description: >-
    Diffuse deficiency of central nervous system myelin, the defining
    radiological feature and the first "H" of 4H leukodystrophy.
  phenotype_term:
    preferred_term: Cerebral hypomyelination
    term:
      id: HP:0006808
      label: Cerebral hypomyelination
    onset:
      onset_category: CHILDHOOD
      notes: >-
        GeneReviews gives early childhood as the typical age of onset, with
        later-onset cases reported.
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      POLR3-related leukodystrophy, a hypomyelinating leukodystrophy with
      specific features on brain MRI
    explanation: GeneReviews defines the disorder as a hypomyelinating leukodystrophy.
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Age of onset is typically in early childhood but later-onset cases have
      also been reported.
    explanation: >-
      GeneReviews statement of the typical onset window, backing the CHILDHOOD
      onset descriptor.
  - reference: PMID:27029625
    reference_title: "Diffuse hypomyelination is not obligate for POLR3-related disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diffuse hypomyelination is not an obligatory feature of POLR3-related disorders."
    explanation: >-
      Qualifies the frequency claim: hypomyelination is characteristic but a
      minority of molecularly confirmed patients lack the diffuse pattern.

- category: Neurologic
  name: Ataxia
  description: >-
    Progressive cerebellar ataxia is the dominant motor sign across the
    spectrum, and gave the historical labels TACH and ADDH their names.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
    clinical_course: PROGRESSIVE
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:22036172
    reference_title: "Recessive mutations in POLR3B, encoding the second largest subunit of Pol III, cause a rare hypomyelinating leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      childhood-onset hypomyelinating leukodystrophies with prominent cerebellar
      dysfunction, oligodontia, and hypogonadotropic hypogonadism
    explanation: Establishes prominent cerebellar dysfunction as a core feature.

- category: Neurologic
  name: Motor Delay
  description: >-
    Gross motor delay is the usual presenting feature, typically before age 6
    years.
  phenotype_term:
    preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
    onset:
      onset_category: CHILDHOOD
      notes: >-
        Most patients present before age 6 years, but about 10% present beyond
        age 10 and an attenuated adolescent/adult-onset arm exists (see the
        POLR3A c.1909+22G>A differential). No numeric bound is recorded on
        purpose: a max_age_years of 6 would read as a hard ceiling to a
        structured-query consumer and would contradict the later-onset minority,
        which a prose caveat cannot reach.
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The majority of patients presented before 6 years with gross motor delay
      or regression.
    explanation: >-
      Cohort of 105 mutation-proven cases documents the presenting feature; the
      "majority" phrasing supports the VERY_FREQUENT band for delay-or-regression
      as a combined presentation, and the age window backing the onset descriptor.
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ten percent had an onset beyond 10 years."
    explanation: >-
      Quantifies the later-onset minority, which is why the onset descriptor
      records a CHILDHOOD category with an explicit caveat rather than a hard
      ceiling.

- category: Neurologic
  name: Developmental Regression
  description: >-
    Loss of previously acquired motor skills, the alternative mode of
    presentation to primary motor delay.
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "presented before 6 years with gross motor delay or regression"
    explanation: Documents regression as an alternative mode of presentation.

- category: Neurologic
  name: Dystonia
  description: >-
    Extrapyramidal involvement, which can be treatment-refractory and requires
    active monitoring and treatment to prevent complications.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      dystonia should be monitored and treated to prevent complications and
      improve the quality of life
    explanation: >-
      GeneReviews treats dystonia as an expected, clinically significant feature
      requiring active management.

- category: Neurologic
  name: Spasticity
  description: >-
    Pyramidal tract involvement, framed by GeneReviews as a component of the
    neurologic syndrome that is less prominent than the cerebellar motor
    dysfunction, but which can be severe at the severe end of the spectrum.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:30584594
    reference_title: "Mutation in POLR3K causes hypomyelinating leukodystrophy and abnormal ribosomal RNA regulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the severe spasticity and dystonia observed before age 10 years
    explanation: >-
      Documents spasticity in POLR3K-related disease; the quote is from the severe
      end of the spectrum, so it supports the association rather than a frequency
      band.

- category: Neurologic
  name: Tremor
  description: >-
    Postural and action tremor, prominent enough in some families to have given
    rise to the historical designation tremor-ataxia with central hypomyelination
    (TACH).
  phenotype_term:
    preferred_term: Tremor
    term:
      id: HP:0001337
      label: Tremor
  evidence:
  - reference: PMID:21855841
    reference_title: "Mutations of POLR3A encoding a catalytic subunit of RNA polymerase Pol III cause a recessive hypomyelinating leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We mapped tremor-ataxia with central hypomyelination (TACH) to
      10q22.3-23.1 in French-Canadian families
    explanation: >-
      Tremor is definitional to the TACH presentation, which this paper shows to
      be allelic with 4H.

- category: Neurologic
  name: Dysarthria
  description: Cerebellar dysarthria, progressing with the motor syndrome.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "progressive cerebellar dysfunction"
    explanation: >-
      The GeneReviews abstract names progressive cerebellar dysfunction, of which
      dysarthria is a standard component, but does not itemize dysarthria, so this
      is recorded as partial support.

- category: Neurologic
  name: Dysphagia
  description: >-
    Swallowing difficulty that progresses over time and is characteristically
    variable, sometimes within a single day. It is a major driver of morbidity
    through aspiration and nutritional failure, and warrants specific management
    caution.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Special caution needs to be taken when managing dysphagia in this disorder
      as it is known to vary widely, even in a single day. Swallowing
      difficulties will progress over time
    explanation: >-
      GeneReviews documents both the progressive course and the striking
      day-to-day variability of dysphagia.

- category: Neurologic
  name: Cognitive Decline
  description: >-
    Cognitive dysfunction, generally later and milder than the motor
    deterioration except in late-onset presentations, and progressing to frank
    cognitive degradation at the severe end of the spectrum.
  phenotype_term:
    preferred_term: Mental deterioration
    term:
      id: HP:0001268
      label: Mental deterioration
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "and cognitive dysfunctions"
    explanation: >-
      GeneReviews lists cognitive dysfunction among the neurologic features, but
      the abstract does not describe deterioration over time, so this supports the
      association only.
  - reference: PMID:30584594
    reference_title: "Mutation in POLR3K causes hypomyelinating leukodystrophy and abnormal ribosomal RNA regulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      motor and cognitive development (no independent walking) and degradation
    explanation: >-
      Documents cognitive degradation, not merely static impairment, in two
      severely affected patients.

- category: Neurologic
  name: Cerebellar Atrophy
  description: >-
    Progressive loss of cerebellar volume, part of the diagnostic MRI
    constellation and, in a subset of atypical cases, the dominant or only
    imaging abnormality.
  phenotype_term:
    preferred_term: Cerebellar atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cerebellar atrophy, and thinning of the corpus callosum suggests the diagnosis"
    explanation: Cerebellar atrophy is part of the diagnostic imaging constellation.

- category: Neurologic
  name: Hypoplasia of the Corpus Callosum
  description: >-
    Thinning of the corpus callosum, which together with hypomyelination and
    cerebellar atrophy defined the historical HCAHC phenotype.
  phenotype_term:
    preferred_term: Hypoplasia of the corpus callosum
    term:
      id: HP:0002079
      label: Hypoplasia of the corpus callosum
  evidence:
  - reference: PMID:22036171
    reference_title: "Mutations in POLR3A and POLR3B encoding RNA Polymerase III subunits cause an autosomal-recessive hypomyelinating leukoencephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a hypomyelinating syndrome characterized by diffuse cerebral
      hypomyelination with cerebellar atrophy and hypoplasia of the corpus
      callosum (HCAHC)
    explanation: Defines the HCAHC presentation later shown to be POLR3A/POLR3B-related.

- category: Dental
  name: Hypodontia
  description: >-
    Congenital absence of teeth, the second "H" of 4H leukodystrophy, ranging to
    oligodontia in more severely affected individuals.
  phenotype_term:
    preferred_term: Hypodontia
    term:
      id: HP:0000668
      label: Hypodontia
  diagnostic: true
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Abnormal dentition (delayed dentition, hypodontia, oligodontia, and
      abnormally placed or shaped teeth).
    explanation: GeneReviews itemizes hypodontia within the dental component.

- category: Dental
  name: Oligodontia
  description: >-
    Absence of six or more teeth, the more severe end of the dental phenotype;
    it gave the historical label "leukodystrophy with oligodontia".
  phenotype_term:
    preferred_term: Oligodontia
    term:
      id: HP:0000677
      label: Oligodontia
  evidence:
  - reference: PMID:22036172
    reference_title: "Recessive mutations in POLR3B, encoding the second largest subunit of Pol III, cause a rare hypomyelinating leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with prominent cerebellar dysfunction, oligodontia, and hypogonadotropic hypogonadism"
    explanation: Names oligodontia as a core feature of the Pol III leukodystrophies.

- category: Dental
  name: Delayed Eruption of Teeth
  description: >-
    Delayed dentition and an abnormal order of eruption, often the earliest
    non-neurological clue and sometimes the only extra-neurological feature.
  phenotype_term:
    preferred_term: Delayed eruption of teeth
    term:
      id: HP:0000684
      label: Delayed eruption of teeth
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Abnormal dentition (delayed dentition, hypodontia, oligodontia, and
      abnormally placed or shaped teeth)
    explanation: GeneReviews lists delayed dentition among the dental abnormalities.

- category: Endocrine
  name: Hypogonadotropic Hypogonadism
  description: >-
    The third "H": deficient gonadotropin drive presenting as delayed, arrested,
    or absent puberty. The most common endocrine abnormality, though not
    invariably present.
  phenotype_term:
    preferred_term: Hypogonadotropic hypogonadism
    term:
      id: HP:0000044
      label: Hypogonadotropic hypogonadism
  diagnostic: true
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      more commonly, hypogonadotropic hypogonadism manifesting as delayed,
      arrested, or absent puberty
    explanation: GeneReviews defines the endocrine component of the tetrad.

- category: Endocrine
  name: Delayed Puberty
  description: >-
    Delayed or arrested pubertal development, the clinical expression of the
    gonadotropin deficit.
  phenotype_term:
    preferred_term: Delayed puberty
    term:
      id: HP:0000823
      label: Delayed puberty
  frequency: FREQUENT
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "manifesting as delayed, arrested, or absent puberty"
    explanation: GeneReviews states the pubertal manifestation directly.
  - reference: PMID:33005949
    reference_title: "Endocrine and Growth Abnormalities in 4H Leukodystrophy Caused by Variants in POLR3A, POLR3B, and POLR1C."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most common endocrine abnormalities were delayed puberty (57/74; 77%
      overall, 64% in males, 89% in females) and short stature (57/93; 61%),
      when evaluated according to physician assessment.
    explanation: >-
      A 150-patient international cross-sectional study gives 77% overall
      (89% in females, 64% in males), which lands in the FREQUENT band (30-79%).
      The band follows the overall figure rather than the higher female-only
      rate.

- category: Growth
  name: Short Stature
  description: >-
    Present in roughly half of individuals, with or without demonstrable growth
    hormone deficiency.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  frequency: FREQUENT
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Endocrine abnormalities such as short stature (in ~50% of individuals)
      with or without growth hormone deficiency
    explanation: >-
      Provides both the association and the ~50% quantitative estimate supporting
      the FREQUENT band.
  - reference: PMID:33005949
    reference_title: "Endocrine and Growth Abnormalities in 4H Leukodystrophy Caused by Variants in POLR3A, POLR3B, and POLR1C."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "and short stature (57/93; 61%), when evaluated according to physician assessment"
    explanation: >-
      Independent 150-patient cohort gives 61%, consistent with the GeneReviews
      ~50% estimate and with the FREQUENT band.

- category: Endocrine
  name: Abnormal Thyroid Function
  description: >-
    Abnormal thyroid function was found in about a fifth of systematically
    evaluated patients. It is not part of the classical tetrad and is easy to
    miss, which is one reason the authors of the cohort concluded that endocrine
    abnormalities are typically underinvestigated in this population.
  phenotype_term:
    preferred_term: Abnormality of thyroid physiology
    term:
      id: HP:0002926
      label: Abnormality of thyroid physiology
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:33005949
    reference_title: "Endocrine and Growth Abnormalities in 4H Leukodystrophy Caused by Variants in POLR3A, POLR3B, and POLR1C."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormal thyroid function was reported in 22% (13/59) of patients."
    explanation: >-
      Direct quantitative support; 22% lands in the OCCASIONAL band (5-29%).

- category: Ocular
  name: Progressive Myopia
  description: >-
    Myopia that typically progresses over several years and becomes severe
    before stabilizing. Seen in almost all patients in the largest cohort, and
    now generally regarded as a fourth cardinal feature alongside the original
    three "H"s.
  phenotype_term:
    preferred_term: Myopia
    term:
      id: HP:0000545
      label: Myopia
    clinical_course: PROGRESSIVE
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Ocular abnormality in the form of myopia, typically progressing over
      several years and becoming severe.
    explanation: GeneReviews describes the myopia and its progressive severe course.
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other than the typical neurologic, dental, and endocrine features, myopia
      was seen in almost all and short stature in 50%.
    explanation: >-
      Quantitative cohort support for the VERY_FREQUENT band ("almost all" of 105
      mutation-proven cases).

imaging_findings:
- name: Diffuse Hypomyelination with Selective Relative T2 Hypointensity
  modality: MRI
  description: >-
    The diagnostic hallmark: diffuse white matter hypomyelination combined with
    relative T2 hypointensity (i.e., comparatively preserved myelination) of the
    ventrolateral thalamus, optic radiation, globus pallidus, corticospinal
    tract at the internal capsule, and dentate nucleus — all structures that
    myelinate early in development.
  diagnostic: true
  evidence:
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Systematic MRI review revealed that the combination of hypomyelination
      with relative T2 hypointensity of the ventrolateral thalamus, optic
      radiation, globus pallidus, and dentate nucleus, cerebellar atrophy, and
      thinning of the corpus callosum suggests the diagnosis.
    explanation: Defines the pattern-recognition criteria used clinically.

- name: Closed Eye Sign (Preserved Medial Lemniscus Myelination)
  modality: MRI
  description: >-
    At 3T, better myelination of the medial lemniscus produces a relatively
    hypointense signal of this structure on axial T2-weighted images — the
    "closed eye sign" — present in all patients in a 12-patient 3T series and
    useful in separating 4H leukodystrophy from Pelizaeus-Merzbacher disease.
  evidence:
  - reference: PMID:29179231
    reference_title: "4H Leukodystrophy: Lessons from 3T Imaging."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients had better myelination of the medial lemniscus with a
      relatively hypointense signal of this structure on axial T2-weighted (T2W)
      images ("closed eye sign").
    explanation: Documents the sign and its presence in all 12 patients imaged at 3T.

- name: Myelin Islets
  modality: MRI
  description: >-
    Variable numbers of small T1-hyperintense, T2-hypointense dots, mostly in
    frontal and parietal white matter, present in all patients in the 3T series
    and corresponding histologically to perivascular myelin staining within
    hypomyelinated white matter.
  evidence:
  - reference: PMID:29179231
    reference_title: "4H Leukodystrophy: Lessons from 3T Imaging."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Myelin islets were variable numbers of small T1 hyperintense and T2
      hypointense dots, mostly in the frontal and parietal white matter, and
      present in all patients.
    explanation: Describes the finding and its frequency in the 3T cohort.

- name: Atypical Selective Corticospinal Tract Involvement
  modality: MRI
  description: >-
    A minority of molecularly confirmed patients lack diffuse hypomyelination
    and instead show selective involvement of the corticospinal tracts at the
    posterior limbs of the internal capsules, or isolated moderate-to-severe
    cerebellar atrophy. Recognizing these patterns matters because the classic
    pattern cannot be used as a gate for genetic testing.
  evidence:
  - reference: PMID:27029625
    reference_title: "Diffuse hypomyelination is not obligate for POLR3-related disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified 2 novel MRI patterns: 4 participants presented a selective
      involvement of the corticospinal tracts, specifically at the level of the
      posterior limbs of the internal capsules; 4 patients presented moderate to
      severe cerebellar atrophy.
    explanation: >-
      Documents the two atypical imaging patterns in eight molecularly confirmed
      patients.

genetic:
- name: POLR3A
  gene_term:
    preferred_term: POLR3A
    term:
      id: hgnc:30074
      label: POLR3A
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  association: >-
    Biallelic hypomorphic variants in POLR3A, encoding the largest catalytic Pol
    III subunit (RPC1), cause POLR3-HLD. Together with POLR3B it accounts for
    the large majority of molecularly solved cases; in one referral series
    POLR3A variants were the more frequent of the two.
  evidence:
  - reference: PMID:23355746
    reference_title: "Mutations in POLR3A and POLR3B are a major cause of hypomyelinating leukodystrophies with or without dental abnormalities and/or hypogonadotropic hypogonadism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To date, our group has described 37 patients, of whom 27 have mutations in
      POLR3A and 10 in POLR3B, respectively.
    explanation: >-
      Provides the per-gene case split in this referral series; ascertainment
      differs between series, so this is not a population estimate.
  case_fractions:
  - population: Single-group referral series of hypomyelinating leukodystrophy patients with typical Pol III features
    case_fraction_percent: 73.0
    cohort_size: 37
    notes: >-
      27 of 37 patients described by this group carried POLR3A variants. This is
      a clinically ascertained referral series, not a population estimate, and
      the split differs in other series.
    evidence:
    - reference: PMID:23355746
      reference_title: "Mutations in POLR3A and POLR3B are a major cause of hypomyelinating leukodystrophies with or without dental abnormalities and/or hypogonadotropic hypogonadism."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        our group has described 37 patients, of whom 27 have mutations in POLR3A
        and 10 in POLR3B
      explanation: Numerator and denominator for the case fraction.

- name: POLR3B
  gene_term:
    preferred_term: POLR3B
    term:
      id: hgnc:30348
      label: POLR3B
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  association: >-
    Biallelic variants in POLR3B, encoding the second-largest Pol III subunit
    (RPC2), cause a generally milder form. The recurrent c.1568T>A (p.Val523Glu)
    hypomorphic allele is carried on one allele by most POLR3B patients, and
    patients of European background are more likely to carry POLR3B than other
    Pol III gene variants. Variant classes include missense, nonsense and
    splice-site changes and also large exonic deletions, which matters for
    testing strategy: patients in whom only one POLR3B variant is found on
    sequencing may carry a copy-number allele in trans that requires
    deletion-sensitive analysis to detect.
  evidence:
  - reference: PMID:26045207
    reference_title: "Large exonic deletions in POLR3B gene cause POLR3-related leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In a small proportion of patients, no mutation in either gene or only one
      mutation is found. Analysis of the POLR3B cDNA revealed a large deletion
      of exons 21-22 in one case and of exons 26-27 in another case.
    explanation: >-
      Documents multi-exon POLR3B deletions as a real variant class and ties them
      to the single-variant-found diagnostic scenario.
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Except for French Canadian patients, patients from European backgrounds
      were more likely to have POLR3B mutations than other populations.
    explanation: Documents the ancestry-dependent distribution between the two major genes.

- name: POLR1C
  gene_term:
    preferred_term: POLR1C
    term:
      id: hgnc:20194
      label: POLR1C
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  association: >-
    Biallelic POLR1C variants cause a minority of cases. POLR1C is shared
    between Pol I and Pol III; leukodystrophy-causing variants selectively
    disrupt Pol III biogenesis. Clinical and radiological features are
    compatible with POLR3-related leukodystrophy, but affected individuals do
    not necessarily display the full tetrad.
  evidence:
  - reference: PMID:26151409
    reference_title: "Recessive mutations in POLR1C cause a leukodystrophy by impairing biogenesis of RNA polymerase III."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      clinical and radiological characteristics of these eight cases were
      compatible with POLR3-related leukodystrophy; however, patients did not
      necessarily have all clinical
    explanation: >-
      Establishes POLR1C causality and the incomplete expression of the full
      tetrad in POLR1C-related disease.

- name: POLR3K
  gene_term:
    preferred_term: POLR3K
    term:
      id: hgnc:14121
      label: POLR3K
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  frequency: ultra-rare; a handful of patients reported worldwide
  association: >-
    Biallelic POLR3K variants are an ultra-rare cause. Reported genotypes
    include a C-terminal missense variant in trans with a large deletion
    removing the last exon, with demonstrated reduction of POLR3K RNA and of Pol
    III-transcribed RNAs in patient material.
  evidence:
  - reference: PMID:40225923
    reference_title: "Novel Pathogenic Variants in POLR3K Cause POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Next-generation sequencing revealed a paternally inherited missense
      variant in POLR3K (c.322G>T; p.D108Y) and a maternally inherited large
      deletion, spanning approximately 17.8 kb from chr16:30,362-48,162.
    explanation: >-
      Documents a compound-heterozygous POLR3K genotype including a copy-number
      allele, which sequence-only testing would miss.

inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  expressivity: VARIABLE
  description: >-
    POLR-related leukodystrophy is inherited in an autosomal recessive manner.
    Each sib of an affected individual has a 25% chance of being affected, a 50%
    chance of being an asymptomatic carrier, and a 25% chance of being
    unaffected and not a carrier. Carrier testing and prenatal diagnosis are
    possible once both familial pathogenic variants are known. Biallelic
    complete-null genotypes have not been observed, consistent with a
    requirement for residual Pol III activity. Expressivity is highly variable,
    ranging from a severe early-infantile course with death in the first years of
    life to attenuated adult-onset presentations; variability tracks the specific
    allele combination (severe versus hypomorphic) more than any identified
    modifier locus.
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      POLR3-related leukodystrophy is inherited in an autosomal recessive
      manner. At conception, each sib of an affected individual has a 25% chance
      of being affected, a 50% chance of being an asymptomatic carrier, and a
      25% chance of being unaffected and not a carrier.
    explanation: GeneReviews states the inheritance pattern and recurrence risks directly.

prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: NOT_YET_DOCUMENTED
  notes: >-
    No population-based prevalence or incidence estimate has been published. The
    disorder is known from case series; the largest single cohort comprised 105
    mutation-proven individuals. Prevalence is deliberately left as
    NOT_YET_DOCUMENTED rather than estimated from case counts.
  evidence:
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We performed a multinational cross-sectional observational study of the
      clinical, radiologic, and molecular characteristics of 105 mutation-proven
      cases.
    explanation: >-
      Establishes the size of the largest published cohort, the basis for the
      CASES_IN_LITERATURE measure.

diagnosis:
- name: Brain MRI pattern recognition
  description: >-
    Brain MRI is the diagnostic cornerstone. The combination of diffuse
    hypomyelination with relative T2 hypointensity of the ventrolateral
    thalamus, optic radiation, globus pallidus and dentate nucleus, plus
    cerebellar atrophy and corpus callosum thinning, suggests the diagnosis —
    and is especially valuable when the non-neurological cardinal features are
    absent. Atypical patterns exist, so an atypical MRI does not exclude the
    diagnosis.
  evidence:
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MRI characteristics are helpful in addressing the diagnosis, especially if
      patients lack the cardinal non-neurologic features.
    explanation: States the specific diagnostic role of MRI pattern recognition.

- name: Molecular genetic testing of Pol III subunit genes
  description: >-
    Definitive diagnosis requires identification of biallelic pathogenic
    variants in POLR3A, POLR3B or POLR1C (or, rarely, POLR3K). Because
    copy-number alleles occur, testing should be able to detect deletions as
    well as sequence variants.
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      POLR3-related leukodystrophy is diagnosed by the combination of classic
      clinical findings, typical brain MRI features, and the presence of
      biallelic pathogenic variants in POLR3A, POLR3B, or POLR1C.
    explanation: GeneReviews states the diagnostic triad including molecular confirmation.
  - reference: PMID:40225923
    reference_title: "Novel Pathogenic Variants in POLR3K Cause POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a maternally inherited large deletion, spanning approximately 17.8 kb from
      chr16:30,362-48,162
    explanation: >-
      Concrete example of a copy-number allele that sequence-only analysis would
      not detect.

treatments:
- name: Multidisciplinary Supportive Care
  description: >-
    No disease-modifying therapy exists. Management is symptomatic and
    supportive, delivered by a multidisciplinary team spanning neurology,
    genetics, rehabilitation, dentistry, endocrinology, ophthalmology,
    otolaryngology and primary care. Dysphagia management deserves particular
    care because swallowing ability varies widely, even within a single day, and
    dystonia should be monitored and treated to prevent complications.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  therapeutic_modality: BEHAVIORAL
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Individualized care by a multidisciplinary team including a pediatric
      neurologist, clinical geneticist, physiotherapist, occupational therapist,
      speech and language pathologist, neuropsychologist, rehabilitation
      physician, dentist, endocrinologist, ophthalmologist,
      ear-nose-and-throat specialist, and primary care physician is recommended.
    explanation: GeneReviews management recommendation, quoted directly.

- name: Physical and Occupational Therapy
  description: >-
    Rehabilitation for progressive ataxia, spasticity and dystonia, forming part
    of the recommended multidisciplinary programme.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  therapeutic_modality: BEHAVIORAL
  target_phenotypes:
  - preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "physiotherapist, occupational therapist, speech and language pathologist"
    explanation: >-
      GeneReviews includes physiotherapy and occupational therapy in the
      recommended care team.

- name: Dysphagia Management and Surveillance
  description: >-
    Proactive swallowing assessment, dietary texture modification, and
    escalation to gastrostomy when nutritional intake or aspiration risk
    demands. Swallowing ability is characteristically variable within a single
    day, so a single assessment can be misleading.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  therapeutic_modality: BEHAVIORAL
  target_phenotypes:
  - preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Special caution needs to be taken when managing dysphagia in this disorder
      as it is known to vary widely, even in a single day.
    explanation: GeneReviews explicitly flags this management caution.

- name: Dystonia Monitoring and Treatment
  description: >-
    GeneReviews singles dystonia out for active monitoring and treatment, not
    merely observation, because untreated dystonia drives complications and
    quality-of-life loss. No POLR3-specific antidystonic agent or regimen has
    been established, so drug selection follows general dystonia practice; that
    is why this entry records the management imperative without naming a
    specific agent.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  therapeutic_modality: BEHAVIORAL
  target_phenotypes:
  - preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      dystonia should be monitored and treated to prevent complications and
      improve the quality of life
    explanation: GeneReviews states the management imperative verbatim.

- name: Deep Brain Stimulation for Refractory Dystonic Tremor
  description: >-
    Deep brain stimulation has been used for treatment-refractory dystonic arm
    tremor in POLR3A-related disease, with reported response. Evidence is limited
    to small case series in the attenuated POLR3A c.1909+22G>A spastic-ataxia
    phenotype rather than in classical childhood-onset 4H leukodystrophy, so this
    is recorded as a selected-patient option, not a general recommendation.
  treatment_term:
    preferred_term: Surgical Procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  therapeutic_modality: DEVICE
  target_phenotypes:
  - preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  - preferred_term: Tremor
    term:
      id: HP:0001337
      label: Tremor
  evidence:
  - reference: PMID:38700104
    reference_title: "POLR3A-related disorders: From spastic ataxia to generalised dystonia and long-term efficacy of deep brain stimulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two patients with dystonic arm tremor responded to deep brain stimulation."
    explanation: >-
      Direct but small-n human evidence (two patients), which is why the
      treatment description scopes it to selected patients.

- name: Endocrine Surveillance and Replacement Therapy
  description: >-
    Systematic endocrine evaluation is warranted: in a 150-patient cohort,
    delayed puberty (77%) and short stature (61%) were the commonest
    abnormalities and abnormal thyroid function was found in 22%. Pubertal
    induction and sex-hormone replacement, growth-hormone assessment, and thyroid
    monitoring follow from these findings. Important caveat carried from the
    source: the same authors concluded that endocrine abnormalities are typically
    underinvestigated and that evidence-based management recommendations do not
    yet exist for this disorder, so this entry records surveillance and standard
    replacement practice rather than a validated protocol. Modality is recorded
    as OTHER because the node mixes a surveillance arm with pharmacological
    hormone replacement and so belongs to neither the behavioral/lifestyle nor a
    single drug bucket cleanly.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  therapeutic_modality: OTHER
  target_phenotypes:
  - preferred_term: Hypogonadotropic hypogonadism
    term:
      id: HP:0000044
      label: Hypogonadotropic hypogonadism
  - preferred_term: Delayed puberty
    term:
      id: HP:0000823
      label: Delayed puberty
  - preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:33005949
    reference_title: "Endocrine and Growth Abnormalities in 4H Leukodystrophy Caused by Variants in POLR3A, POLR3B, and POLR1C."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we noted that endocrine abnormalities are typically underinvestigated in
      this patient population. A prospective study is required to formulate
      evidence-based recommendations for management of the endocrine
      manifestations of this disorder.
    explanation: >-
      Supports the surveillance imperative while explicitly establishing that
      evidence-based management recommendations do not yet exist — the reason
      this treatment is framed as surveillance plus standard practice.
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "dentist, endocrinologist, ophthalmologist"
    explanation: >-
      GeneReviews places endocrinology in the recommended multidisciplinary care
      team.

- name: Genetic Counseling and Reproductive Options
  description: >-
    Autosomal recessive recurrence-risk counseling (25% per pregnancy for
    carrier couples), with carrier testing for at-risk relatives and prenatal
    diagnosis available once both familial pathogenic variants are known.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  therapeutic_modality: BEHAVIORAL
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Carrier testing for at-risk relatives and prenatal diagnosis for
      pregnancies at increased risk are possible if both pathogenic variants in
      the family are known.
    explanation: GeneReviews genetic counseling recommendation, quoted directly.

- name: Ibuprofen (investigational, preclinical only)
  description: >-
    Ibuprofen, an NSAID that also acts as an mTOR signaling activator, reverses
    the defective oligodendroglial differentiation phenotype produced by severe
    POLR3A and POLR3B nonsense alleles in an oligodendroglial precursor cell
    line. This is a mechanism-based repurposing lead only: the evidence is
    entirely in vitro in a mouse cell line, there is no in vivo or human
    efficacy data, and it must not be read as a treatment recommendation.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ibuprofen
      term:
        id: CHEBI:5855
        label: ibuprofen
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: mTOR Signaling Suppression
    treatment_effect: INHIBITS
    description: >-
      Ibuprofen acts as an mTOR signaling activator, reversing the suppression
      caused by lysosomally mislocalized mutant Pol III subunits and releasing
      the differentiation block in vitro.
  evidence:
  - reference: PMID:35225888
    reference_title: "Hypomyelinating Leukodystrophy 8 (HLD8)-Associated Mutation of POLR3B Leads to Defective Oligodendroglial Morphological Differentiation Whose Effect Is Reversed by Ibuprofen."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Ibuprofen, which is a non-steroidal anti-inflammatory drug (NSAID),
      improved the defects in their differentiation phenotypes and signaling
      through mTOR.
    explanation: >-
      In vitro rescue in an oligodendroglial precursor cell model carrying a
      POLR3B nonsense allele. Cell-line evidence only.
  - reference: PMID:35076634
    reference_title: "Hypomyelinating Leukodystrophy 7 (HLD7)-Associated Mutation of POLR3A Is Related to Defective Oligodendroglial Cell Differentiation, Which Is Ameliorated by Ibuprofen."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), which is also
      known as an mTOR signaling activator, ameliorated defects in
      differentiation with myelin marker protein expression and the related
      signaling in cells harboring the R140X mutant constructs.
    explanation: >-
      Parallel in vitro rescue for a POLR3A nonsense allele, supporting a
      cross-gene mechanism. Cell-line evidence only.

animal_models:
- species: Mus musculus
  genotype: Olig2-Cre-driven expression of pathogenic Polr3a variants
  category: Conditional oligodendrocyte-lineage mouse model
  description: >-
    Restricting expression of pathogenic Polr3a mutations to Olig2-expressing
    (oligodendrocyte-lineage) cells is sufficient to cause hypomyelination in
    cerebrum and spinal cord together with growth, cognitive, sensory and fine
    sensorimotor deficits, establishing a cell-autonomous oligodendroglial
    requirement for Pol III. Gross motor deficits and cerebellar hypomyelination,
    common in severely affected patients, are absent, so the model reproduces
    only part of the human phenotype.
  genes:
  - preferred_term: POLR3A
    term:
      id: hgnc:30074
      label: POLR3A
  evidence:
  - reference: PMID:34583988
    reference_title: "Defective myelination in an RNA polymerase III mutant leukodystrophic mouse."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In contrast, the gross motor defects and cerebellar hypomyelination that
      are common features of severely affected patients are absent in the mice,
      suggesting a relatively mild form of the disease in this conditional
      model.
    explanation: >-
      The authors themselves scope the model's fidelity, which is why it is
      recorded here with its limitation rather than as a full phenocopy.

- species: Mus musculus
  genotype: Polr3b delta-10 conditional hypomorph (Pdgfra-Cre/ERT; R26-Stopfl-EYFP; Polr3bfl)
  category: Inducible conditional mouse model
  description: >-
    The most complete published murine phenocopy: postnatally induced expression
    of the orthologous Polr3b delta-10 hypomorph reproduces hypomyelination,
    hypodontia and craniofacial abnormalities, and lineage tracing identified
    defective oligodendrocyte precursor proliferation and differentiation as the
    mechanism.
  genes:
  - preferred_term: POLR3B
    term:
      id: hgnc:30348
      label: POLR3B
  evidence:
  - reference: PMID:37635302
    reference_title: "Hypomyelination, hypodontia and craniofacial abnormalities in a Polr3b mouse model of leukodystrophy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      we characterized the Polr3bΔ10 mutation and developed an animal model that
      recapitulates features of POLR3-HLD caused by POLR3B mutations, shedding
      light on disease pathogenesis, and opening the door to the development of
      therapeutic interventions.
    explanation: Establishes the model as a partial phenocopy spanning CNS and dental features.

- species: Mus musculus
  genotype: Polr3a c.2015G>A (p.G672E) knock-in, homozygous and compound heterozygous with a null allele
  category: Constitutive knock-in mouse model (negative result)
  description: >-
    Introducing the French-Canadian founder Polr3a mutation into mice produced
    no motor phenotype, no detectable myelination deficit, and no significant
    change in brain Pol III transcript levels — a negative result that contrasts
    with the oligodendrocyte-lineage conditional models and is a key caveat when
    interpreting mouse data for this disease.
  genes:
  - preferred_term: POLR3A
    term:
      id: hgnc:30074
      label: POLR3A
  evidence:
  - reference: PMID:28407788
    reference_title: "Absence of neurological abnormalities in mice homozygous for the Polr3a G672E hypomyelinating leukodystrophy mutation."
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We conclude that the first transgenic mice with a leukodystrophy-causing
      Polr3a mutation do not recapitulate the childhood-onset HLD observed in
      the majority of human patients
    explanation: >-
      Recorded as REFUTE with respect to the claim that this knock-in models human
      POLR3-HLD; it is a genuine negative model result, not a supporting one.

differential_diagnoses:
- name: Pelizaeus-Merzbacher disease and Pelizaeus-Merzbacher-like disease 1
  description: >-
    The archetypal hypomyelinating leukodystrophies and the closest imaging
    mimics. PLP1-related Pelizaeus-Merzbacher disease (X-linked) and
    GJC2-related Pelizaeus-Merzbacher-like disease 1 (autosomal recessive) both
    produce diffuse hypomyelination on MRI with nystagmus, hypotonia, tremor,
    titubation, ataxia and spasticity, overlapping substantially with the
    neurological presentation of POLR3-HLD.
  distinguishing_features:
  - "X-linked inheritance (PLP1) or a GJC2 genotype rather than biallelic Pol III subunit variants."
  - "Absent dental, hypogonadotropic and myopic components; the non-neurological 4H tetrad is not part of PMD or PMLD1."
  - "At 3T, POLR3-HLD shows better myelination of the medial lemniscus (the closed eye sign), which is not seen in PMD."
  evidence:
  - reference: PMID:22422208
    reference_title: "Pelizaeus-Merzbacher disease, Pelizaeus-Merzbacher-like disease 1, and related hypomyelinating disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Signs of PMD include nystagmus, hypotonia, tremors, titubation, ataxia,
      spasticity, athetotic movements and cognitive impairment; the major
      findings in SPG2 are leg weakness and spasticity. A diffuse pattern of
      hypomyelination is seen on magnetic resonance imaging (MRI) of PMD/SPG2
      patients.
    explanation: >-
      Documents the overlapping neurological and imaging features that drive the
      differential.
  - reference: PMID:29179231
    reference_title: "4H Leukodystrophy: Lessons from 3T Imaging."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, in 4H leukodystrophy there is clearly better myelination of the
      medial lemniscus, which is not present in PMD.
    explanation: Provides an explicit imaging discriminator between the two conditions.

- name: POLR3A-related hereditary spastic ataxia (deep-intronic c.1909+22G>A)
  description: >-
    An allelic POLR3A disorder that is not a leukodystrophy. Compound
    heterozygosity involving the deep-intronic c.1909+22G>A variant produces
    adolescent-onset progressive spastic ataxia with tremor and dental problems,
    and accounts for around 3% of hereditary spastic paraplegia and cerebellar
    ataxia index cases — a far larger ascertained population than classic 4H.
    Because the gene is the same, this is a differential for the interpretation
    of a POLR3A genotype rather than for the clinical presentation alone.
  distinguishing_features:
  - "Adolescent or adult onset of spastic ataxia rather than early-childhood motor delay or regression."
  - "MRI shows hyperintensities along the superior cerebellar peduncles instead of the typical diffuse hypomyelination pattern."
  - "Hypodontia is accompanied by early, severe and aggressive periodontal disease, which is not typical of classic 4H."
  evidence:
  - reference: PMID:28459997
    reference_title: "Hypomorphic mutations in POLR3A are a frequent cause of sporadic and recessive spastic ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Instead of the typical hypomyelination magnetic resonance imaging pattern
      associated with classical POLR3A mutations, cases carrying c.1909+22G>A
      demonstrated hyperintensities along the superior cerebellar peduncles.
    explanation: >-
      Directly contrasts the imaging phenotype of this allele with classic
      POLR3-HLD.

- name: Wiedemann-Rautenstrauch (neonatal progeroid) syndrome
  description: >-
    A second allelic POLR3A disorder. Biallelic truncating and/or splicing
    POLR3A variants cause neonatal progeroid syndrome with intrauterine growth
    restriction, lipodystrophy, characteristic triangular facies and dental
    abnormalities — a genotype class distinct from the biallelic missense
    variants associated with hypomyelinating leukodystrophy.
  distinguishing_features:
  - "Neonatal presentation with progeroid features, lipodystrophy and pseudohydrocephalus rather than childhood hypomyelination."
  - "Associated with biallelic truncating or splicing POLR3A genotypes, whereas 4H is associated with biallelic missense genotypes."
  evidence:
  - reference: PMID:30414627
    reference_title: "Bi-allelic POLR3A Loss-of-Function Variants Cause Autosomal-Recessive Wiedemann-Rautenstrauch Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Bi-allelic missense variants in POLR3A have been associated with
      phenotypes distinct from WRS: hypogonadotropic hypogonadism and
      hypomyelinating leukodystrophy with or without oligodontia.
    explanation: >-
      The authors themselves separate the WRS and leukodystrophy
      genotype-phenotype classes.

- name: POLR1C-related Treacher Collins syndrome
  description: >-
    An allelic POLR1C disorder with a completely different phenotype —
    mandibulofacial dysostosis rather than leukodystrophy. It matters here
    because the discriminator is molecular and mechanistic: leukodystrophy
    variants impair Pol III assembly and nuclear import, whereas the Treacher
    Collins variant leaves polymerase assembly intact and instead disrupts Pol I
    targeting to the nucleolus.
  distinguishing_features:
  - "Craniofacial dysostosis without hypomyelination, the dental-plus-endocrine tetrad, or progressive neurological decline."
  - "Mechanistically separable, because Treacher Collins-causing POLR1C variants do not impair Pol III assembly or nuclear import."
  evidence:
  - reference: PMID:26151409
    reference_title: "Recessive mutations in POLR1C cause a leukodystrophy by impairing biogenesis of RNA polymerase III."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      we demonstrate that leukodystrophy-causative mutations, but not TCS
      mutations, in POLR1C impair assembly and nuclear import of POLR3, but not
      POLR1
    explanation: Provides the experimental basis for separating the two POLR1C disorders.

- name: De novo POLR3B-related ataxia, spasticity and demyelinating neuropathy
  description: >-
    A monoallelic, de novo POLR3B disorder distinct from recessive POLR3-HLD.
    Its existence means a single heterozygous POLR3B variant in a patient with
    ataxia and neuropathy should not be dismissed as carrier status, and that
    peripheral nerve involvement points away from classic 4H.
  distinguishing_features:
  - "De novo heterozygous rather than biallelic POLR3B genotype."
  - "Prominent demyelinating peripheral neuropathy, which is not a feature of classic POLR3-HLD."
  evidence:
  - reference: PMID:33417887
    reference_title: "De Novo Variants in POLR3B Cause Ataxia, Spasticity, and Demyelinating Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Bi-allelic pathogenic variants in POLR3B are a well-established cause of
      hypomyelinating leukodystrophy.
    explanation: >-
      The paper contrasts the established biallelic leukodystrophy phenotype with
      the newly described de novo monoallelic neuropathy phenotype named in its
      title.

- name: POLR1A-related hypomyelinating leukodystrophy
  description: >-
    A biallelic RNA polymerase I subunit disorder that also produces
    hypomyelinating leukodystrophy with cerebellar atrophy, but through a
    different molecular route — aberrant rRNA processing, abnormal nucleolar
    homeostasis, disturbed protein homeostasis and endoplasmic reticulum stress.
    Whether it belongs inside the "POLR-related leukodystrophy" umbrella is an
    open scoping question recorded under discussions.
  distinguishing_features:
  - "Pol I (rRNA transcription) rather than Pol III (tRNA and 5S rRNA transcription) is the affected polymerase."
  - "Mechanism runs through nucleolar and protein-homeostasis disruption rather than reduced Pol III transcript supply."
  evidence:
  - reference: PMID:36917474
    reference_title: "A homozygous POLR1A variant causes leukodystrophy and affects protein homeostasis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Extensive in vitro experiments in fibroblasts from Patient 1 documented
      that the mutated POLR1A led to aberrant rRNA processing and degradation,
      and abnormal nucleolar homeostasis.
    explanation: >-
      Establishes the mechanistically distinct Pol I route to a clinically
      overlapping leukodystrophy.

discussions:
- discussion_id: polr_hld_oligodendrocyte_selective_vulnerability
  prompt: >-
    Why does partial loss of a ubiquitously required enzyme produce a
    white-matter-predominant disease, and what makes the oligodendrocyte lineage
    the most sensitive cell type?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Reduced Steady-State Pol III Subunit Protein in Cerebral White Matter
  - pathophysiology#Oligodendrocyte Differentiation Arrest
  rationale: >-
    Pol III transcribes tRNAs, 5S rRNA and other RNAs required by every cell,
    yet the clinical phenotype is dominated by hypomyelination. Two partial
    explanations exist and are not mutually exclusive: a regional gradient in
    steady-state subunit protein (greater loss in cerebral white matter than
    cortex in one autopsied brain) and an intrinsic sensitivity of
    oligodendrogenesis and myelination to reduced Pol III output. Neither has
    been shown to be sufficient, and the single-brain protein gradient has not
    been replicated.
  proposed_experiments:
  - experiment_id: polr_hld_celltype_resolved_pol3_quantification
    name: Cell-type-resolved Pol III transcript and protein quantification in human brain
    description: >-
      Quantify Pol III subunit protein and Pol III transcript output across
      oligodendrocyte-lineage, neuronal and astrocytic populations in
      post-mortem POLR3-HLD and control brain, to test whether the
      white-matter-predominant deficit is cell-intrinsic to the oligodendrocyte
      lineage rather than a bulk-tissue composition artefact.
  evidence:
  - reference: PMID:34583988
    reference_title: "Defective myelination in an RNA polymerase III mutant leukodystrophic mouse."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The findings suggest unique sensitivities of oligodendrogenesis and
      myelination to perturbations of Pol III transcription.
    explanation: >-
      The authors frame lineage-selective sensitivity as a suggestion arising from
      the model, i.e., an open question rather than an established mechanism.

- discussion_id: polr_hld_which_transcript_deficit_drives_disease
  prompt: >-
    Which Pol III transcript class is the proximate driver of disease — the tRNA
    pool, 5S rRNA and ribosome biogenesis, 7SL and the signal recognition
    particle, or some combination that differs by causal gene?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#Reduced Pol III Non-Coding Transcript Output
  - pathophysiology#Reduced Mature tRNA Pool
  - pathophysiology#Constrained Translational Capacity
  rationale: >-
    Different studies nominate different transcript classes. The original
    POLR3A/POLR3B paper hypothesized tRNAs; a mouse time-course placed a global
    tRNA-pool reduction earliest and argued for a causal role in disease
    initiation; but POLR3K patient fibroblasts showed 5S rRNA and 7SL RNA most
    severely reduced, with the authors reasoning through ribosome function and
    signal recognition particle biology instead. It is unresolved whether these
    are competing accounts or gene-specific and assay-specific differences within
    a shared final pathway.
  proposed_experiments:
  - experiment_id: polr_hld_matched_transcript_class_profiling
    name: Matched multi-transcript-class profiling across causal genotypes
    description: >-
      Profile mature tRNA, 5S rRNA, 7SL and 7SK in a single harmonized assay
      across patient-derived oligodendrocyte-lineage cells carrying POLR3A,
      POLR3B, POLR1C and POLR3K genotypes, to determine whether the transcript
      hierarchy is genotype-dependent or an artefact of differing assays and
      cell types.
  evidence:
  - reference: PMID:39499645
    reference_title: "Molecular basis of neurodegeneration in a mouse model of Polr3-related disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Thus, changes in the size and/or composition of the tRNA pool have a
      causal role in disease initiation.
    explanation: States the tRNA-first position in the disagreement.
  - reference: PMID:30584594
    reference_title: "Mutation in POLR3K causes hypomyelinating leukodystrophy and abnormal ribosomal RNA regulation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      transcription of both 5S rRNA and 7SL RNA was most severely reduced. 5S
      rRNA is a component of the large subunit of the ribosome and therefore
      important for ribosomal functioning.
    explanation: States the ribosome and signal-recognition-particle position in the disagreement.

- discussion_id: polr_hld_mouse_model_fidelity
  prompt: >-
    Which mouse models faithfully represent human POLR3-HLD, given that a
    constitutive knock-in of a bona fide human pathogenic allele produced no
    phenotype while lineage-restricted conditional models did?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Oligodendrocyte Differentiation Arrest
  - pathophysiology#Deficient Central Nervous System Myelin Deposition
  rationale: >-
    The Polr3a G672E constitutive knock-in carries a validated human founder
    allele yet showed normal behaviour, normal myelination and no significant
    change in brain Pol III transcripts. In contrast, Olig2-Cre-driven
    expression of pathogenic Polr3a and the conditional Polr3b delta-10 hypomorph
    both produce hypomyelination. This means a negative mouse result cannot be
    read as evidence against a mechanism, and that conclusions drawn from the
    conditional models inherit the assumption that lineage-restricted expression
    is a fair proxy for the constitutive human condition. Even the best
    conditional model omits gross motor deficits and cerebellar hypomyelination
    seen in severely affected patients, and no model reproduces the full human
    tetrad including hypogonadotropic hypogonadism.
  proposed_experiments:
  - experiment_id: polr_hld_allelic_series_single_background
    name: Allelic series in a single mouse background
    description: >-
      Compare constitutive, oligodendrocyte-lineage-conditional and
      whole-body-postnatal-inducible expression of the same pathogenic Polr3a
      allele on one genetic background, measuring myelination, Pol III
      transcript output and behaviour, to isolate whether developmental timing,
      compensation, or cell-type context explains the divergent results.
  evidence:
  - reference: PMID:28407788
    reference_title: "Absence of neurological abnormalities in mice homozygous for the Polr3a G672E hypomyelinating leukodystrophy mutation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Cerebral and cerebellar Luxol Fast Blue staining and measurement of levels
      of myelin proteins showed no significant differences between the three
      groups, suggesting that myelination is not overtly impaired in Polr3a
      KI/KI and KI/KO mice.
    explanation: The negative model result that creates the mismatch.
  - reference: PMID:34583988
    reference_title: "Defective myelination in an RNA polymerase III mutant leukodystrophic mouse."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In contrast, the gross motor defects and cerebellar hypomyelination that
      are common features of severely affected patients are absent in the mice,
      suggesting a relatively mild form of the disease in this conditional
      model.
    explanation: Shows that even the positive conditional model is only a partial phenocopy.

- discussion_id: polr_hld_umbrella_scope_pol_i_genes
  prompt: >-
    Should "POLR-related leukodystrophy" (MONDO:0100605) include the RNA
    polymerase I gene POLR1A, or be restricted to Pol III subunit genes?
  kind: OPEN_QUESTION
  status: OPEN
  attaches_to:
  - pathophysiology#Biallelic Hypomorphic Pol III Subunit Variant
  rationale: >-
    The MONDO label says "POLR-related" and the definition says "any of the POLR
    genes, including POLR1C, POLR3A or POLR3B", which reads as open-ended, while
    the clinical literature almost uniformly says "POLR3-related". Biallelic
    POLR1A variants cause a clinically overlapping hypomyelinating leukodystrophy
    with cerebellar atrophy, but through Pol I rRNA processing and nucleolar and
    protein-homeostasis disruption rather than reduced Pol III transcript supply.
    POLR1C sits awkwardly across the boundary, being shared between the two
    polymerases while its leukodystrophy variants act specifically on Pol III.
    This entry is currently scoped to the Pol III subunit genes and treats
    POLR1A-related leukodystrophy as a differential; that decision should be
    revisited if the ontology or the clinical literature converges.
  evidence:
  - reference: PMID:36917474
    reference_title: "A homozygous POLR1A variant causes leukodystrophy and affects protein homeostasis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We confirm that POLR1A biallelic variants cause neurodegenerative disease,
      expand the knowledge of the clinical phenotype of the disorder
    explanation: >-
      Establishes POLR1A-related leukodystrophy as a real entity whose relationship
      to this umbrella needs an explicit scoping decision.

- discussion_id: polr_hld_hypomyelination_not_obligate
  prompt: >-
    If diffuse hypomyelination is not obligate, what should the diagnostic entry
    criterion for POLR-related leukodystrophy be, and how many patients are
    being missed by MRI-gated testing?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Cerebral Hypomyelination
  - imaging_findings#Atypical Selective Corticospinal Tract Involvement
  rationale: >-
    The characteristic MRI pattern is the practical entry point to diagnosis,
    but eight molecularly confirmed patients have been reported without it,
    showing instead selective corticospinal tract involvement or isolated
    cerebellar atrophy. Separately, the hypomorphic POLR3A c.1909+22G>A allele
    produces spastic ataxia frequently without leukodystrophy imaging and
    accounts for roughly 3% of hereditary spastic paraplegia and ataxia index
    cases. The size of the missed population is unknown because ascertainment
    has historically been MRI-driven, which makes the denominator unmeasurable
    from existing cohorts.
  proposed_experiments:
  - experiment_id: polr_hld_unbiased_screening_imaging_negative_cohorts
    name: Unbiased Pol III gene screening in imaging-negative ataxia cohorts
    description: >-
      Sequence POLR3A, POLR3B, POLR1C and POLR3K in large ataxia and spastic
      paraplegia cohorts ascertained without any MRI requirement, and report the
      yield stratified by imaging pattern, to estimate what fraction of Pol
      III-related disease is invisible to hypomyelination-gated testing.
  evidence:
  - reference: PMID:27029625
    reference_title: "Diffuse hypomyelination is not obligate for POLR3-related disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diffuse hypomyelination is not an obligatory feature of POLR3-related disorders."
    explanation: Directly establishes that the diagnostic imaging gate is imperfect.
  - reference: PMID:28459997
    reference_title: "Hypomorphic mutations in POLR3A are a frequent cause of sporadic and recessive spastic ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we screened a cohort of hereditary spastic paraplegia and cerebellar
      ataxia cases (n = 618) for mutations in POLR3A and identified compound
      heterozygous POLR3A mutations in ∼3.1% of index cases.
    explanation: >-
      Quantifies a substantial POLR3A-related population ascertained outside the
      leukodystrophy imaging phenotype.

- discussion_id: polr_hld_ibuprofen_translation_gap
  prompt: >-
    Does the in vitro ibuprofen rescue of oligodendroglial differentiation
    translate to any in vivo benefit, and is the lysosomal/mTOR arm relevant to
    the missense alleles that actually cause human disease?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Lysosomal Mislocalization of Mutant Pol III Subunits
  - pathophysiology#mTOR Signaling Suppression
  rationale: >-
    The ibuprofen result is attractive because it is a repurposed, well-tolerated
    drug acting on a defined target. But the experiments used severe nonsense
    alleles (POLR3A p.Arg140Ter, POLR3B p.Arg550Ter) in a mouse oligodendroglial
    cell line, whereas human POLR3-HLD is caused by hypomorphic, largely missense
    genotypes and no patient has been reported with two nonsense alleles. Whether
    missense mutant subunits are also routed to lysosomes and suppress mTOR is
    untested, so the therapeutic hypothesis may rest on an allele class that does
    not occur biallelically in patients. No in vivo or human data exist.
  proposed_experiments:
  - experiment_id: polr_hld_lysosomal_localization_patient_alleles
    name: Lysosomal localization and mTOR readout across the patient allele spectrum
    description: >-
      Test whether recurrent patient missense alleles (for example POLR3B
      p.Val523Glu) reproduce the lysosomal mislocalization and mTOR suppression
      seen with nonsense alleles, and whether ibuprofen rescues differentiation
      in that context.
  - experiment_id: polr_hld_in_vivo_ibuprofen_trial
    name: In vivo ibuprofen trial in a validated conditional mouse model
    description: >-
      Administer ibuprofen to the conditional Polr3b delta-10 mouse during
      postnatal myelinogenesis and measure oligodendrocyte maturation and myelin
      thickness, to establish whether the in vitro rescue has any in vivo
      counterpart.
  evidence:
  - reference: PMID:21855841
    reference_title: "Mutations of POLR3A encoding a catalytic subunit of RNA polymerase Pol III cause a recessive hypomyelinating leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "No individual was found to carry two nonsense mutations."
    explanation: >-
      Establishes the allele-class mismatch between the human disease and the cell
      models used for the ibuprofen experiments.

- discussion_id: polr_hld_pol3_dna_sensing_arm
  prompt: >-
    Pol III also functions as a cytosolic DNA sensor driving interferon
    induction, and monoallelic POLR3A/POLR3C variants cause severe varicella
    zoster virus disease. Do biallelic POLR3-HLD patients also carry an
    antiviral-immunity defect, and should they be monitored for it?
  kind: OPEN_QUESTION
  status: OPEN
  attaches_to:
  - pathophysiology#Biallelic Hypomorphic Pol III Subunit Variant
  rationale: >-
    Pol III has a second, transcription-independent role as a cytosolic sensor
    of AT-rich DNA that drives type I interferon induction. Rare heterozygous
    POLR3A and POLR3C missense variants cause life-threatening varicella zoster
    virus infection in otherwise healthy children through impaired DNA-triggered
    interferon induction — a phenotype with no reported overlap with 4H
    leukodystrophy. It is unresolved whether the biallelic hypomorphic genotypes
    that cause POLR3-HLD also compromise this sensing function, whether the two
    functions are separably affected by different variant classes, and therefore
    whether POLR3-HLD patients warrant any specific antiviral vigilance. This
    entry does not model the DNA-sensing arm because no evidence connects it to
    the leukodystrophy phenotype.
  proposed_experiments:
  - experiment_id: polr_hld_ifn_induction_in_patient_leukocytes
    name: DNA-triggered interferon induction in POLR3-HLD patient leukocytes
    description: >-
      Measure interferon induction in response to synthetic and virus-derived
      cytosolic DNA in leukocytes from patients with biallelic POLR3-HLD
      genotypes, using the same assay that demonstrated the defect in
      monoallelic varicella-susceptibility patients, to determine whether the
      sensing and transcription functions are separably affected.
  evidence:
  - reference: PMID:28783042
    reference_title: "Inborn errors in RNA polymerase III underlie severe varicella zoster virus infections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report 4 cases of acute severe VZV infection affecting the central
      nervous system or the lungs in unrelated, otherwise healthy children who
      are heterozygous for rare missense mutations in POLR3A (one patient),
      POLR3C (one patient), or both (two patients).
    explanation: >-
      Establishes a second, immunological disease mechanism for variants in Pol
      III subunit genes, distinct from the leukodystrophy phenotype.
  - reference: PMID:28783042
    reference_title: "Inborn errors in RNA polymerase III underlie severe varicella zoster virus infections."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Leukocytes from all 4 patients tested exhibited poor IFN induction in
      response to synthetic or VZV-derived DNA.
    explanation: >-
      Defines the functional assay that would need to be applied to POLR3-HLD
      patients to answer this question.

- discussion_id: polr_hld_agents_to_avoid_unverified
  prompt: >-
    Should dopamine D2 receptor blockers (haloperidol, risperidone,
    metoclopramide) be recorded as agents to avoid in POLR-related
    leukodystrophy, and is there a citable source for that claim?
  kind: CURATION_TODO
  status: OPEN
  attaches_to:
  - phenotypes#Dystonia
  rationale: >-
    The deep-research artifact for this entry asserted that dopamine D2 receptor
    blockers exacerbate the extrapyramidal and dystonic features of this
    population and flagged it as a drug-safety item to model. The claim is
    clinically plausible — D2 blockade worsening dystonia is a general
    pharmacological principle — but a targeted PubMed search found no source
    that makes it specifically about POLR3-related leukodystrophy, and the
    cached GeneReviews abstract does not contain an "Agents/Circumstances to
    Avoid" statement (the abstract is a condensed form of the full chapter,
    which may well carry one). A drug-safety assertion is exactly the kind of
    claim that must not be curated from an unverified secondary summary, so it
    is deliberately NOT recorded as a treatment or a note here. Resolution
    requires either the full GeneReviews chapter text or a primary source; if
    one is found, this should become an agents-to-avoid entry on the dystonia
    management treatment.
  proposed_experiments:
  - experiment_id: polr_hld_agents_to_avoid_source_hunt
    name: Locate a citable agents-to-avoid source
    description: >-
      Retrieve the full GeneReviews POLR3-Related Leukodystrophy chapter
      (NBK99167) and check its Agents/Circumstances to Avoid section, and search
      case-level literature for reported dystonia exacerbation after D2-blocker
      exposure in molecularly confirmed patients.

- discussion_id: polr_hld_cerebellar_module_conformance
  prompt: >-
    Should the cerebellar degenerative arm of POLR-related leukodystrophy
    declare conformance to the cerebellar_purkinje_degeneration module?
  kind: CURATION_TODO
  status: OPEN
  attaches_to:
  - pathophysiology#Progressive Cerebellar Atrophy
  rationale: >-
    Cerebellar atrophy with progressive ataxia is a cardinal feature, which makes
    cerebellar_purkinje_degeneration a natural conformance candidate. However,
    that module's key node is Purkinje neuron degeneration, and the available
    evidence here reports generic neuron and oligodendrocyte loss in mouse
    cerebra rather than Purkinje-specific degeneration in human tissue. Declaring
    conformance now would assert a cell-type specificity the evidence does not
    support, so it is deliberately deferred pending Purkinje-resolved
    neuropathology.
  evidence:
  - reference: PMID:39499645
    reference_title: "Molecular basis of neurodegeneration in a mouse model of Polr3-related disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      cell-type-specific gene expression changes reflecting neuron and
      oligodendrocyte loss and microglial activation
    explanation: >-
      Reports neuronal loss without resolving whether Purkinje cells are the
      affected population, which is exactly the gap blocking a conformance claim.

notes: >-
  Scope: this entry is the umbrella POLR-related (4H) leukodystrophy entity
  (MONDO:0100605). The POLR3A-specific OMIM phenotype HLD7 (MONDO:0011897) has
  its own dismech entry, Hypomyelinating Leukodystrophy 7, whose `parents:` entry
  is set to this entry's exact `name` ("POLR-Related Leukodystrophy") so the
  cross-reference resolves by string; that entry carries POLR3A-specific detail, while this one
  carries the cross-gene Pol III mechanism, the gene-level subtypes, imaging
  criteria, differentials and open questions. Population prevalence, formal
  survival statistics and a validated disease-specific quality-of-life instrument
  were sought and not found in the literature reviewed; they are recorded as not
  established rather than estimated.

references:
- reference: PMID:22855961
  title: "POLR3-Related Leukodystrophy."
  tags:
  - GeneReviews

📚

References & Deep Research

References

PMID:22855961

POLR3-Related Leukodystrophy.

No top-level findings curated for this source.

Deep Research

Claude Code ▸

POLR-Related (POLR3-Related) Leukodystrophy — Comprehensive Research Report

claude-haiku-4-5-20251001, claude-sonnet-5 2026-07-31T06:04:59.091747

POLR-Related (POLR3-Related) Leukodystrophy — Comprehensive Research Report

1. Disease Information

Overview. POLR-related leukodystrophy — formally POLR3-related leukodystrophy (POLR3-HLD), and historically called 4H leukodystrophy (Hypomyelination, Hypodontia, Hypogonadotropic Hypogonadism) — is an autosomal recessive, progressive hypomyelinating leukodystrophy caused by biallelic pathogenic variants in genes encoding subunits of RNA polymerase III (Pol III): POLR3A, POLR3B, POLR1C, and the recently identified POLR3K. A related but genetically/mechanistically distinct disorder, caused by POLR1A variants, produces an overlapping hypomyelinating leukodystrophy phenotype (sometimes grouped under the broader "POLR-related leukodystrophy" umbrella) as well as a distinct craniofacial dysostosis syndrome.

Five previously described, phenotypically overlapping entities are now recognized as a single clinical-molecular spectrum (GeneReviews, NCBI Bookshelf NBK99167): - 4H syndrome — Hypomyelination, Hypodontia, Hypogonadotropic Hypogonadism - ADDH — Ataxia, Delayed Dentition, Hypomyelination - TACH — Tremor-Ataxia with Central Hypomyelination - LO — Leukodystrophy with Oligodontia - HCAHC — Hypomyelination with Cerebellar Atrophy and Hypoplasia of the Corpus callosum

Key identifiers: | Resource | Identifier | |---|---| | MONDO | MONDO:0100605 (POLR3-related leukodystrophy) | | Orphanet | ORPHA289494 | | OMIM (HLD7, POLR3A) | #607694 | | OMIM (HLD8, POLR3B) | #614381 | | OMIM gene loci | POLR3A 614258; POLR3B 614366; POLR1C 610060; POLR1A 616404 | | GeneReviews | NBK99167 (Wolf, Vanderver, Bernard — "POLR3-Related Leukodystrophy") | | MedlinePlus Genetics | "Pol III–related leukodystrophy" | | NIH GTR condition | C5679947 |

Common synonyms: 4H leukodystrophy; RNA polymerase III–related leukodystrophy; Pol III–related leukodystrophy; tremor-ataxia with central hypomyelination (TACH); ataxia, delayed dentition and hypomyelination (ADDH); leukodystrophy with oligodontia (LO); hypomyelination with cerebellar atrophy and hypoplasia of the corpus callosum (HCAHC); hypomyelinating leukodystrophy 7 (HLD7, POLR3A); hypomyelinating leukodystrophy 8 (HLD8, POLR3B); hypomyelinating leukodystrophy 11 (HLD11, POLR1C).

Evidence base: Information is derived almost entirely from aggregated case series and cohort studies in the medical literature (the largest being Wolf et al. 2014, Neurology 83:1898–1905, PMID 25339210, describing 105 individuals), rather than from large-scale EHR/population registries — this is consistent with an ultra-rare Mendelian disorder. Model-organism (mouse) data supplement human natural-history data for mechanistic claims.

2. Etiology

Disease causal factors: POLR3-HLD is a purely genetic/Mendelian disorder — there are no known environmental, infectious, or acquired causes. Disease results from biallelic (homozygous or compound heterozygous) pathogenic variants in genes encoding Pol III subunits or Pol III assembly factors.

Genetic risk factors (causal genes and approximate allelic contribution, per GeneReviews NBK99167): | Gene | Locus | Approx. % of solved cases | Sequencing detection rate | |---|---|---|---| | POLR3B | 12q23.3 | ~49% | ~97% | | POLR3A | 10q22.3 | ~41% | ~100% | | POLR1C | 6p21.1 | ~5% | ~100% | | POLR3K | 16p13.3 | Very rare (3 cases reported to date; Perrier et al. 2024, Human Mutation, DOI 10.1155/2024/8807171) | n/a | | Unsolved | — | ~5% | — |

Notably, no individual with biallelic complete-null (loss-of-function) alleles in POLR3A or POLR3B has been described, suggesting some residual Pol III function is required for embryonic/fetal viability — a genotype-lethality constraint analogous to other essential-gene recessive disorders.

Risk factors: - Genetic: consanguinity (increases biallelic-variant risk in any AR disorder); population founder variants — e.g., the POLR3A c.1909+22G>A splice variant is enriched in individuals of European ancestry and produces an attenuated, adolescent/adult-onset spastic-ataxia phenotype without overt leukodystrophy (gnomAD v2.1: ~0.2% allele frequency, 289/129,138 alleles, European non-Finnish population); French-Canadian founder POLR3A variants were the basis of the original TACH gene-mapping study (Bernard et al. 2011, PMID 21855841). - Environmental: none identified — this is a monogenic disease with fully genetically determined etiology.

Protective factors: No genetic or environmental protective factors have been reported. Hypomorphic ("mild") alleles function as within-gene modifiers of severity (see Genotype-Phenotype section below) rather than true "protective" variants in trans with a pathogenic allele.

Gene-environment interactions: None established; disease penetrance and expressivity are driven by the specific combination of hypomorphic vs. severe alleles rather than by environmental modifiers.

3. Phenotypes

POLR3-HLD/4H leukodystrophy has a characteristic tetrad: neurologic dysfunction, dental abnormalities, endocrine (hypogonadotropic) abnormalities, and ocular abnormality (myopia). Non-neurologic features are not invariably present, especially in atypical/POLR1A-driven or late-onset cases.

Neurologic phenotypes

Phenotype	HPO term (suggested)	Onset/Course	Frequency
Motor developmental delay/regression	HP:0001270 (Motor delay) / HP:0002376 (Developmental regression)	Median onset ~9 months; usually <2 years	85.7% present with motor delay, abnormal gait, and intellectual disability in first 2 years (per natural-history cohort data)
Cerebellar ataxia	HP:0001251	Progressive	Very frequent, core feature
Dysarthria	HP:0001260	Progressive	Frequent
Dysmetria	HP:0001310	Progressive	Frequent
Tremor (postural/action)	HP:0001337	Progressive; can be prominent in TACH phenotype	Frequent
Dystonia (generalized in severe cases)	HP:0001332	Progressive, later-onset feature	Variable; can be treatment-refractory
Pyramidal/spasticity signs	HP:0002061 (spastic paraparesis) / HP:0007256	Mild, later	Present in a subset
Cognitive decline/intellectual disability	HP:0001256 / HP:0000750	Typically later in course (except late-onset subtype, where cognitive plateau/academic difficulty is presenting)	Progressive over time
Seizures	HP:0001250	Minority	Uncommon
Optic atrophy	HP:0000648	Later course	Uncommon

Non-neurologic phenotypes

Phenotype	HPO term	Notes
Hypodontia / oligodontia	HP:0000668 / HP:0000677	Delayed eruption, abnormally shaped/malpositioned teeth
Hypogonadotropic hypogonadism	HP:0000044	Delayed/absent puberty; most common endocrine feature
Short stature	HP:0004322	~50% of individuals; some with growth hormone deficiency
Progressive myopia	HP:0000545	Nearly universal; progresses over years then stabilizes at severe degree
Cataracts	HP:0000518	Rare (4 cases reported in literature)
Dysphagia	HP:0002015	Progressive, variable day-to-day due to cerebellar dysfunction; can require gastrostomy
Hypersalivation/sialorrhea	HP:0100751	Managed via multidisciplinary approach

Severity/progression: Universally progressive; a minority (~10%) have later-onset, slower-progression disease presenting with academic difficulties/cognitive plateau. Conversely, a severe early-infantile subgroup (onset 1–3 months) with failure to thrive and severe dysphagia has been reported, with high early mortality (4 of 6 children died before age 3 in one case series).

Quality of life impact: Progressive motor deterioration impairs activities of daily living early; cognitive involvement is typically milder than and lags behind motor dysfunction. No disease-specific validated QOL instrument was identified in the searched literature; a 2025 qualitative study captured caregiver-reported burden (Pediatric Neurology, "POLR3-Related Leukodystrophy: A Qualitative Study on Parents' Experiences With the Health Care System").

Suggested HPO terms for the core tetrad: HP:0002079 (Hypoplasia of the corpus callosum), HP:0001272 (Cerebellar atrophy), HP:0002517 (Polymicrogyria — reported in rare POLR3B cases), HP:0012443 (Abnormal brain FDG PET, not typical), HP:0002015 (Dysphagia), HP:0002514 (Yawning — not applicable).

4. Genetic/Molecular Information

Causal genes: - POLR3A (HGNC:30074; OMIM 614258) — chromosome 10q22.3; encodes the largest catalytic subunit of Pol III (RPC1). - POLR3B (OMIM 614366) — chromosome 12q23.3; encodes the second-largest subunit of Pol III (RPC2), which together with POLR3A forms the catalytic core and DNA-binding cleft. - POLR1C (OMIM 610060) — chromosome 6p21.1; encodes a subunit shared between Pol I and Pol III. - POLR1A (HGNC:17264; OMIM 616404) — chromosome 2p11; encodes the largest catalytic subunit of RNA polymerase I (RPA1); causes a related but molecularly distinct leukodystrophy (some classifications term it HLD27) as well as acrofacial dysostosis, Cincinnati type (AFDCIN, OMIM #616462) via a different mutational/dominant mechanism. - POLR3K — very recently implicated (Perrier et al. 2024); encodes a small Pol III subunit; only 3 cases reported worldwide as of 2024–2025.

Pathogenic variant characteristics: - Type: Missense, nonsense, splice-site variants, and small intragenic insertions/deletions predominate; no biallelic complete-null genotypes reported for POLR3A/POLR3B (embryonic-lethal hypothesis). - Classification: Pathogenic/likely pathogenic per ACMG/AMP criteria in ClinVar (e.g., ClinVar RCV000024140 for POLR3A c.1909+18G>A). - Allele frequency: The POLR3A hypomorphic splice allele c.1909+22G>A reaches ~0.2% (289/129,138 alleles) in gnomAD v2.1 European (non-Finnish) — unusually high for a leukodystrophy allele, explained by its markedly attenuated phenotype (adolescent-onset spastic ataxia, sometimes without overt hypomyelination) when found with a second null-like allele. - Origin: Exclusively germline (constitutional), autosomal recessive. - Functional consequence: Loss of function / hypomorphic reduction of Pol III activity — reduced protein stability/steady-state levels (Western blot shows significantly reduced POLR3A protein, more pronounced in cerebral white matter than cortex), impaired catalytic cleft formation, impaired POLR3A–POLR3B interaction, and/or impaired nuclear assembly/import of the Pol III holoenzyme.

Genotype–phenotype correlations (GeneReviews NBK99167; Wolf et al. 2014, PMID 25339210): - POLR3A variants → later disease onset, but more rapidly progressive course. - POLR3B variants → earlier onset, slower progression; more likely to show cerebellar atrophy on MRI with relatively preserved corticospinal tract myelination. The common hypomorphic variant c.1568T>A (p.Val523Glu) produces very mild disease; homozygotes may be minimally symptomatic into early adulthood. - POLR1C variants → clinically heterogeneous, including presentations reminiscent of Treacher Collins syndrome craniofacial features (see below); molecularly distinct from the classical TCOF1/POLR1D/POLR1A Treacher Collins mutations. - The POLR3A c.1909+22G>A hypomorphic allele → attenuated, adult-onset spastic ataxia phenotype (with or without dystonia), sometimes lacking classical leukodystrophy imaging, expanding the phenotypic spectrum beyond childhood-onset 4H (PMC11187961, "POLR3A-related disorders: From spastic ataxia to generalised dystonia and long-term efficacy of deep brain stimulation"). - A 2020 AJHG report also describes de novo monoallelic POLR3B variants causing ataxia, spasticity, and demyelinating neuropathy — a distinct, non-recessive allelic disorder. - A 2025 preprint describes monoallelic (heterozygous) POLR3A variants causing a Pol III-related disorder with peripheral neuropathy, further expanding allelic heterogeneity beyond the classical recessive model.

Modifier genes: No confirmed disease-modifier genes distinct from the causal locus itself; allelic severity (null vs. hypomorphic) is the dominant driver of phenotypic variability.

Epigenetic information: No disease-specific epigenetic (DNA methylation/histone) mechanism has been described; pathogenesis is protein-level (Pol III assembly/stability), not epigenetic dysregulation, although Pol III transcribes some regulatory noncoding RNAs.

Chromosomal abnormalities: Large exonic deletions in POLR3B have been reported as a cause of disease (PMC4520020, "Large exonic deletions in POLR3B gene cause POLR3-related leukodystrophy"), underscoring the value of copy-number-sensitive testing (e.g., chromosomal microarray or exome CNV calling) in addition to sequence-variant analysis; no recurrent aneuploidy/translocation mechanism is known.

Related allelic disorders (same genes, different phenotype): - POLR3A, POLR3B, and POLR3GL biallelic variants → Wiedemann–Rautenstrauch syndrome (neonatal progeroid syndrome; OMIM #264090) — growth retardation, lipodystrophy, distinctive triangular facies, natal teeth, sparse hair (Wambach et al., AJHG, "Bi-allelic POLR3A Loss-of-Function Variants Cause Autosomal-Recessive Wiedemann-Rautenstrauch Syndrome"; also POLR3B: Ital J Pediatr 2021, PMC8296688; POLR3GL: EJHG 2019, PMC7080780). - POLR1A heterozygous (dominant) variants → Acrofacial dysostosis, Cincinnati type (AFDCIN, OMIM #616462; PMID 25913037) — mandibulofacial dysostosis with limb anomalies, distinct mechanism from the biallelic leukodystrophy-causing variants.

5. Environmental Information

POLR3-HLD is a fully genetically determined Mendelian disorder. No environmental toxin, occupational exposure, lifestyle factor, or infectious trigger has been implicated in disease causation. There is no known infectious agent association. This section is largely not applicable for this disease.

6. Mechanism / Pathophysiology

Molecular pathway — RNA polymerase III transcription: Pol III is one of three eukaryotic nuclear RNA polymerases. It transcribes a set of short, essential noncoding RNAs: tRNAs (protein synthesis), 5S rRNA (ribosome biogenesis), 7SL RNA (signal recognition particle/protein translocation), 7SK RNA (Pol II regulation via P-TEFb sequestration), vault RNAs, Alu elements, and certain microRNAs. Despite the ubiquity of these RNA products across all cell types, disease-causing Pol III subunit mutations produce a tissue-restricted phenotype dominated by CNS white matter and oligodendrocyte dysfunction, plus dental, gonadotropic, and ocular abnormalities.

Causal chain (upstream → downstream): 1. Biallelic hypomorphic variant in POLR3A/POLR3B/POLR1C/POLR3K → 2. Impaired Pol III holoenzyme assembly, nuclear import, catalytic cleft integrity, or DNA-binding capacity (GO:0006383, transcription by RNA polymerase III) → 3. Reduced/altered steady-state Pol III protein and reduced tRNA/5S rRNA/other noncoding-RNA output (particularly evident by Western blot as region-specific POLR3A protein reduction, greatest in cerebral white matter vs. cortex) → 4. Impaired oligodendroglial cell differentiation — HLD7 (POLR3A R140X) and HLD8 (POLR3B) mutant constructs show defective oligodendroglial morphological differentiation with reduced myelin marker protein expression (PMC8788570; PMC8884015). The POLR3A mutant mechanism specifically involves mislocalization of mutant protein to lysosomes with decreased mTOR signaling, inhibiting oligodendrocyte morphological maturation. Notably, ibuprofen (an mTOR-signaling activator/NSAID) reverses the undifferentiated phenotype in cellular models for both HLD7 and HLD8 mutations — a leading candidate small-molecule mechanism-based intervention, not yet validated in vivo/in patients. 5. →Hypomyelination (deficient/arrested initial myelin deposition, distinct from demyelination) of the CNS, evident on MRI as diffuse T2 hyperintensity/T1 iso- to hyperintensity of white matter, with a characteristic pattern of relative preservation of myelination in the dentate nuclei, anterolateral thalami, globi pallidi, pyramidal tracts (posterior limb of internal capsule), and optic radiations. 6. → Progressive cerebellar/pyramidal/extrapyramidal neurodegeneration — cerebellar atrophy, corpus callosum thinning, and (in a subset) striatal/red nucleus involvement, correlating with the clinical ataxia, dystonia, tremor, and later cognitive decline. 7. In parallel, Pol III dysfunction independently impairs tooth development (hypodontia/oligodontia — ameloblast/odontoblast lineages are highly proliferative and Pol III-output-dependent) and the hypothalamic-pituitary-gonadal axis (hypogonadotropic hypogonadism), and lens/ocular development (progressive myopia).

Cellular processes involved: Oligodendrocyte precursor cell proliferation/differentiation arrest (a cell-autonomous CNS-lineage defect); ribosome biogenesis impairment shared with the Pol I pathway for POLR1C-mutant disease (relevant to the POLR1C/POLR1A "ribosomopathy" overlap with Treacher Collins–spectrum craniofacial disorders); cellular senescence/nucleolar stress and p53 activation in POLR3A-mutated Wiedemann-Rautenstrauch fibroblasts (bioRxiv preprint: "Nucleolar disruption, activation of P53 and premature senescence in POLR3A-mutated Wiedemann-Rautenstrauch Syndrome fibroblasts").

Protein dysfunction: Loss-of-function/hypomorphic reduction rather than toxic gain-of-function or aggregation. Structural impact maps to the catalytic cleft (POLR3A/POLR3B interface), assembly/nuclear-import surfaces, and (for POLR1C) the Pol I/Pol III-shared assembly interface.

Immune system involvement: No primary immune/autoinflammatory component has been established, though ibuprofen's therapeutic effect operates via mTOR signaling rather than an anti-inflammatory mechanism per se.

Tissue damage mechanisms: Primary defect is a developmental/maturational arrest (failure of adequate initial myelin deposition = hypomyelination) with secondary progressive neurodegeneration (cerebellar atrophy) — this combination (developmental + degenerative) is characteristic of the Pol III leukodystrophies and distinguishes them from purely demyelinating disorders.

Biochemical abnormalities: Reduced steady-state Pol III subunit protein levels; no specific circulating biomarker/enzyme deficiency has been established (unlike lysosomal or metabolic leukodystrophies).

Molecular profiling: No large-scale disease-specific transcriptomic/proteomic/metabolomic dataset was identified in the literature reviewed; most mechanistic data derive from patient fibroblast studies, cellular oligodendrocyte differentiation assays, and mouse models (see Model Organisms, below).

Suggested GO terms: GO:0006383 (transcription by RNA polymerase III), GO:0032968 (positive regulation of transcription elongation by RNA polymerase II — for 7SK/P-TEFb axis), GO:0022008 (neurogenesis), GO:0042552 (myelination), GO:0048714 (positive regulation of oligodendrocyte differentiation), GO:0043524 (negative regulation of neuron apoptotic process).

Suggested CL terms: CL:0000128 (oligodendrocyte), CL:0002453 (oligodendrocyte precursor cell), CL:0000032 (odontogenic papilla?/ameloblast lineage — for dental phenotype), CL:0000473 (defensive cell — n/a).

7. Anatomical Structures Affected

Organ level: - Primary: Central nervous system (cerebral and cerebellar white matter, cerebellum, corpus callosum). - Secondary: Teeth/dentition; hypothalamic-pituitary-gonadal axis (gonads/pubertal development); eyes (lens/refractive apparatus, myopia); in rarer POLR1A/POLR1C-overlap cases, craniofacial skeleton. - Body systems: Nervous system (primary), endocrine system, dental/oral system, ocular system.

Tissue and cell level: - CNS white matter — oligodendrocytes (CL:0000128) and their precursors (CL:0002453) are the principal disease-relevant cell population; myelin sheaths fail to form/mature appropriately. - Cerebellar cortex — Purkinje and granule cell layers implicated in progressive cerebellar atrophy. - Odontogenic epithelium/mesenchyme — hypodontia/oligodontia. - Anterior pituitary gonadotrope cells and hypothalamic GnRH neurons — hypogonadotropic hypogonadism. - Lens/retina — progressive myopia (axial elongation), occasional cataract.

Subcellular level: Nucleus (site of Pol III transcription and holoenzyme assembly; GO:0005666 DNA-directed RNA polymerase III complex); mutant POLR3A protein shown to mislocalize partly to lysosomes (GO:0005764) in cellular models, distinct from its normal nuclear localization; nucleolus (for POLR1C/POLR1A shared Pol I biogenesis functions, relevant to the ribosomopathy/craniofacial overlap).

Localization (UBERON terms): - UBERON:0002316 (white matter of central nervous system) / UBERON:0002450 (cerebral white matter) - UBERON:0002037 (cerebellum) - UBERON:0002336 (corpus callosum) - UBERON:0003057 (dentate nucleus) - UBERON:0002420 (globus pallidus) - UBERON:0002298 (brainstem/pyramidal tract region) - UBERON:0001456 (tooth) - UBERON:0000992 (ovary)/UBERON:0000473 (testis) — hypogonadism - UBERON:0000970 (eye)/UBERON:0002417 (lens)

Lateralization: Bilateral and symmetric — a distinguishing MRI feature versus acquired/asymmetric white-matter disease.

8. Temporal Development

Onset: - Typical: early childhood, median age at onset ~9 months in cohort data, with the large majority (85.7%) presenting with motor delay/abnormal gait/intellectual disability within the first 2 years of life (per natural history cohort summarized in the literature review). - Atypical/severe: neonatal-to-early-infantile onset (1–3 months) with failure to thrive and severe dysphagia — associated with high early mortality. - Atypical/late: ~10% of cases present beyond age 10 years, sometimes in adulthood, with academic difficulties/cognitive plateau and slower progression (notably including the hypomorphic POLR3A c.1909+22G>A allele, producing adolescent/adult-onset spastic ataxia). - Onset pattern: insidious/subacute developmental plateau or regression rather than acute presentation.

Progression: - Disease course is invariably progressive, though rate varies substantially by genotype: POLR3A → later onset but faster progression; POLR3B → earlier onset but slower progression. - No formal numeric staging system (e.g., AJCC-style) exists; clinical staging is descriptive (early motor/gait involvement → progressive cerebellar/pyramidal/extrapyramidal dysfunction → dysphagia/nutritional compromise → in severe cases early mortality). - Progressive myopia typically stabilizes once it reaches a severe degree. - Cognitive decline typically emerges later in the disease course (except in the late-onset subtype, where cognitive difficulty can be an early presenting feature).

Patterns: - No spontaneous remission is described; this is a monotonically progressive neurodegenerative disorder. - No clearly defined "critical window" for intervention has been established in humans, though the cellular mechanism data (oligodendrocyte differentiation arrest reversible in vitro by ibuprofen) suggest a hypothetical developmental window during active myelination when intervention could theoretically be most impactful — unproven in patients.

9. Inheritance and Population

Epidemiology: Prevalence and incidence are not formally established — POLR3-HLD is an ultra-rare disorder. More than 100 affected individuals have been reported in the medical literature to date (largest single cohort: 105 individuals, Wolf et al. 2014). No national registry-based prevalence/incidence estimate was located.

Inheritance pattern: Autosomal recessive for the classical POLR3-HLD phenotype (POLR3A, POLR3B, POLR1C, POLR3K). Recently described allelic variants include a de novo monoallelic POLR3B cause of an ataxia-spasticity-demyelinating neuropathy phenotype, and reports of monoallelic POLR3A variants causing a peripheral-neuropathy-predominant Pol III disorder — indicating expanding, non-recessive allelic mechanisms outside the core recessive leukodystrophy. The related POLR1A-driven acrofacial dysostosis, Cincinnati type is autosomal dominant (heterozygous), mechanistically and clinically distinct from the recessive POLR1A-leukodystrophy allele class.

Penetrance: Complete for biallelic null/severe-hypomorph genotypes; markedly reduced/attenuated for hypomorphic alleles such as POLR3A c.1568T>A or c.1909+22G>A, where homozygotes/compound heterozygotes may be minimally symptomatic (e.g., isolated hypodontia) into adulthood.

Expressivity: Highly variable — ranging from neonatal-lethal severe phenotypes to adult-onset spastic ataxia with minimal or absent classical leukodystrophy features, driven largely by the specific allele combination (null vs. hypomorphic).

Genetic anticipation: Not reported/applicable (not a repeat-expansion disorder).

Germline mosaicism: Not specifically documented in the literature reviewed, though standard recurrence-risk counseling for autosomal recessive disease assumes possible parental germline mosaicism as a low-probability caveat.

Founder effects: The original TACH/POLR3A families were ascertained via a French-Canadian founder population (Bernard et al. 2011); the POLR3A c.1909+22G>A hypomorphic splice allele shows population enrichment in individuals of European ancestry per gnomAD data.

Consanguinity: As an autosomal recessive disorder, consanguineous unions increase risk; multiple reported affected families (e.g., in case reports from Chinese, Japanese, Indian, and Russian cohorts) include consanguineous pedigrees, consistent with typical AR-disease demographic patterns.

Carrier frequency: Formal population carrier-frequency estimates were not identified for POLR3A/POLR3B pathogenic (severe) alleles; the hypomorphic POLR3A c.1909+22G>A allele reaches an unusually high ~0.2% allele frequency (implying a carrier frequency of roughly 1 in 250) in European non-Finnish gnomAD data, though this specific allele in isolation produces attenuated disease only when paired in trans with a more severe allele.

Population demographics: Reported worldwide across diverse ancestries (French-Canadian, European, Chinese, Japanese, Indian, Russian, and others per case reports cited above); no strong sex predilection has been reported (autosomal recessive, so expected ~1:1 male:female ratio); age distribution reflects predominantly pediatric-onset disease with a recognized adult-onset minority.

10. Diagnostics

Clinical/laboratory tests: No specific blood/urine biomarker or enzyme assay exists for POLR3-HLD (unlike metabolic leukodystrophies); diagnosis rests on clinical phenotype + neuroimaging + molecular genetic confirmation. Standard neurophysiology (EMG/nerve conduction studies) is characteristically normal, helping exclude peripheral neuropathy-predominant leukodystrophies.

Imaging (the diagnostic cornerstone): Brain MRI shows a highly characteristic hypomyelinating pattern (Wolf et al. 2014, PMID 25339210): - Diffuse white matter T2 mild hyperintensity with T1 hyperintensity, isointensity, or mild hypointensity relative to gray matter (indicating hypomyelination rather than demyelination/gliosis). - Relative preservation of myelination signal in: dentate nuclei, anterolateral thalami, globi pallidi, pyramidal tracts (posterior limb of internal capsule), and optic radiations — this selective-sparing pattern is considered a diagnostic hallmark. - Cerebellar atrophy and corpus callosum thinning (variable). - Atypical patterns occasionally seen: selective corticospinal tract hypomyelination; striatal/red nucleus involvement; polymicrogyria and cataracts reported in some POLR3B cases (PMID 26478204).

Genetic testing: - Diagnosis is confirmed by identification of biallelic pathogenic variants in POLR3A, POLR3B, POLR1C, or POLR3K. - Recommended approaches per GeneReviews: sequential single-gene testing (informed by ancestry/founder-variant likelihood), a leukodystrophy/hypomyelination-focused multigene panel, or comprehensive exome/genome sequencing — the latter increasingly favored given the genetic and phenotypic heterogeneity of leukodystrophies broadly (see the NCT02699190 "LeukoSEQ" whole-genome-sequencing-as-first-line-diagnostic-tool study for leukodystrophies). - Copy-number analysis (chromosomal microarray or exome-based CNV calling) is important given documented large exonic POLR3B deletions (PMC4520020) that would be missed by sequence-only analysis. - Chromosomal microarray/karyotype/FISH are not primary diagnostic tools for this single-gene disorder but may be used in the broader differential-diagnostic workup. - Mitochondrial DNA testing and repeat-expansion testing are not indicated (not a mitochondrial or repeat-expansion disorder).

Clinical diagnostic criteria: No formal consensus scoring system exists; diagnosis requires the combination of (1) compatible neurologic + non-neurologic (dental/endocrine/ocular) clinical features, (2) the characteristic hypomyelinating MRI pattern, and (3) confirmatory biallelic pathogenic variants.

Differential diagnosis: PLP1-related disorders (Pelizaeus-Merzbacher disease/spastic paraplegia type 2) and Pelizaeus-Merzbacher-like disease (GJC2); Cockayne syndrome; trichothiodystrophy; free sialic acid storage disorders; hypomyelination with congenital cataract (FAM126A); TUBB4A-related leukodystrophy (hypomyelination with atrophy of basal ganglia and cerebellum, H-ABC); SOX10-related peripheral neuropathy with CNS involvement.

Screening: No population-based newborn screening exists (not amenable to biochemical newborn screening); carrier screening and prenatal diagnosis are available via targeted variant testing once the familial pathogenic variants are identified, per standard AR-disease genetic counseling practice.

11. Outcome / Prognosis

Survival/mortality: No formal population-level survival statistics (e.g., Kaplan-Meier 5-/10-year survival) were located; POLR3-HLD is considered life-limiting, with prognosis strongly dependent on genotype/phenotype severity and quality of supportive care: - Earlier-onset (infantile) cases carry higher mortality risk in young adulthood; a severe early-infantile subgroup (onset 1–3 months, failure to thrive, severe dysphagia) had 4 of 6 children die before age 3 years in one reported series. - Later-onset/slower-progression cases (including hypomorphic-allele carriers) may survive into the 4th–5th decade of life. - Disease-specific mortality is largely attributable to secondary complications (aspiration pneumonia from progressive dysphagia, nutritional failure) rather than a direct lethal CNS event, underscoring the importance of proactive multidisciplinary supportive management.

Morbidity/function: Progressive motor disability (ataxia, spasticity, dystonia) dominates the functional burden; cognitive decline is generally milder and later than motor deterioration except in the late-onset subtype. No validated disease-specific quality-of-life instrument was identified; caregiver-reported burden is documented qualitatively (2025 Pediatric Neurology parent-experience study).

Complications: Dysphagia (progressive, day-to-day variable) with aspiration risk, often requiring gastrostomy; hypersalivation; progressive visual impairment from severe myopia; dental complications from hypodontia/oligodontia requiring specialized dental/orthodontic management; endocrine complications from untreated hypogonadotropic hypogonadism (delayed puberty, reduced bone density risk).

Prognostic factors: Causal gene (POLR3A vs. POLR3B vs. hypomorphic alleles) is the single strongest known prognostic determinant; age of onset (earlier = generally worse, with the notable exception that POLR3A has later onset but faster progression than POLR3B); presence/severity of dysphagia as a marker of advanced disease and aspiration risk.

12. Treatment

No disease-modifying or curative therapy currently exists. Management is symptomatic and supportive, coordinated by a multidisciplinary team (pediatric neurologist, clinical geneticist, physiotherapist, occupational therapist, speech-language pathologist, neuropsychologist, physiatrist, dentist/orthodontist, endocrinologist, ophthalmologist, otolaryngologist, primary care).

Pharmacotherapy (symptomatic): - Anticholinergic medications and/or botulinum toxin injections for severe hypersalivation (MAXO term candidate: botulinum toxin injection, treatment_term NCIT:C15986 Pharmacotherapy + therapeutic_agent botulinum toxin, CHEBI/NCIT-bound). - Standard antispasticity/antidystonic pharmacologic approaches, individualized. - Critical medication caution: Dopamine D2 receptor blockers (typical/atypical neuroleptics such as haloperidol, risperidone; also metoclopramide) should be avoided, as they exacerbate extrapyramidal (dystonic) features in this population — an important negative-treatment-interaction flag for the KB.

Advanced/interventional: - Deep brain stimulation (pallidal DBS) has been used for treatment-refractory dystonia and dystonic tremor in POLR3A-related disease, with long-term efficacy reported in a case series (PMC11187961) — two patients with dystonic arm tremor showed a favorable DBS response; broader evidence remains limited to small case series. - Surgical ductal relocation for severe, refractory hypersalivation in selected cases. - Gastrostomy tube placement for progressive dysphagia/nutritional failure.

Investigational/mechanism-based approaches (preclinical, not yet in patients): - Ibuprofen rescues defective oligodendroglial morphological differentiation in cellular models of both HLD7 (POLR3A R140X, PMC8788570) and HLD8 (POLR3B, PMC8884015) mutations by restoring mTOR signaling — a mechanistically grounded repurposed-small-molecule candidate, but not validated in clinical trials or patients to date. This is discussed as a "potential therapeutic approach" in the 2020 Frontiers review (PMC7902007, "POLR3-Related Leukodystrophy: Exploring Potential Therapeutic Approaches"). - No gene therapy, cell therapy, RNA-based therapy (ASO/siRNA), or targeted molecular therapy has reached clinical trials specifically for POLR3-HLD as of this writing; the LeukoSEQ study (NCT02699190) is diagnostic (whole-genome sequencing), not therapeutic.

Supportive/rehabilitative: - Physical, occupational, and speech-language therapy for motor and swallowing dysfunction. - Dietary modification and swallowing therapy for dysphagia. - Regular ophthalmologic monitoring/refractive correction for progressive myopia. - Endocrinology follow-up with individualized decisions on growth hormone or sex hormone replacement therapy for hypogonadotropic hypogonadism and short stature. - Dental/orthodontic management for hypodontia/oligodontia.

Suggested MAXO terms: MAXO:0000011 (physical therapy); MAXO:0000950 (supportive care); MAXO:0000077 (behavioral counseling, swallowing therapy component); MAXO:0000079 (genetic counseling); NCIT:C15986 (Pharmacotherapy, generic action term for symptomatic drugs); DBS would map to a device/surgical-procedure NCIT/MAXO term (e.g., NCIT:C15329 Surgical Procedure, therapeutic_modality DEVICE).

13. Prevention

Primary prevention: Not applicable in the population-health sense (no modifiable environmental risk factor); at the family level, genetic counseling and reproductive options (carrier testing, prenatal diagnosis, preimplantation genetic testing) constitute the primary preventive strategy for at-risk families once a proband's pathogenic variants are identified.

Secondary prevention: Early recognition via the characteristic MRI hypomyelination pattern plus clinical tetrad can shorten diagnostic odyssey and enable earlier initiation of supportive/multidisciplinary care, though this does not alter the underlying molecular disease course.

Tertiary prevention: Proactive multidisciplinary surveillance (dysphagia/aspiration monitoring, ophthalmologic follow-up, endocrine monitoring, dental care, dystonia/spasticity management) is aimed at preventing secondary complications (aspiration pneumonia, nutritional failure, vision loss progression, dental complications) and is credited with extending survival in later-onset/slower-progression cases.

Screening: No population-based (e.g., newborn) screening program exists. Carrier screening and prenatal/preimplantation genetic diagnosis are available on a familial basis once causative variants are known, following standard ACMG-aligned practice for autosomal recessive Mendelian disorders.

Genetic counseling (recurrence risk, per GeneReviews): For carrier parents of an affected child, each subsequent pregnancy carries a 25% chance of an affected child, 50% chance of an asymptomatic carrier, and 25% chance of an unaffected non-carrier. Heterozygous carriers are asymptomatic and not at increased disease risk. All offspring of an affected individual are obligate heterozygous carriers.

Immunization/prophylaxis/behavioral/public health interventions: Not applicable — this is a non-infectious, non-lifestyle-driven Mendelian disorder.

14. Other Species / Natural Disease

No naturally occurring POLR3-related leukodystrophy has been reported in companion animals or wildlife in the literature reviewed (no OMIA entries identified in the searches conducted). This section is primarily populated by engineered model organisms rather than natural veterinary disease (see Section 15).

Orthologous genes: Polr3a (mouse, MGI), polr3b (zebrafish, ZFIN) are the orthologs used experimentally; NCBI Gene IDs for human POLR3A/POLR3B/POLR1C/POLR1A are well annotated (NCBI Gene, GeneCards) but a specific veterinary/naturally-occurring disease counterpart was not identified.

15. Model Organisms

Mouse models: - Conditional Polr3a hypomyelinating-mutation mice (Olig2-Cre-driven, oligodendrocyte-lineage-restricted expression of pathogenic Polr3a variants) show impaired growth and developmental delay, deficits in cognitive, sensory, and fine sensorimotor function, and hypomyelination in multiple regions of the cerebrum and spinal cord — directly supporting a neural-lineage-specific (not merely ubiquitous-transcription) role for Pol III in myelination (cited via PNAS 2021, "Defective myelination in an RNA polymerase III mutant leukodystrophic mouse," DOI 10.1073/pnas.2024378118). - A separate Polr3a G672E knock-in mouse model was reported to show an absence of neurological abnormalities despite carrying a human hypomyelinating-leukodystrophy-associated mutation (Molecular Brain 2017, doi 10.1186/s13041-017-0294-y) — an important human-model mismatch: this global hypomorphic knock-in did not recapitulate the human CNS phenotype, unlike the oligodendrocyte-lineage-restricted conditional model, suggesting cell-type-restricted expression/dosage is critical to phenotype recapitulation in mice. - A Polr3b mouse model (2023, Brain, academic.oup.com/brain/article/146/12/5070) recapitulates hypomyelination, hypodontia, and craniofacial abnormalities, closely mirroring the human 4H triad and representing the most complete murine phenocopy reported to date. - An eLife reviewed preprint (2024, "Molecular basis of neurodegeneration in a mouse model of Polr3-related disease") extends mechanistic characterization of neurodegeneration in Polr3-mutant mice.

Zebrafish models: - A zebrafish polr3b splice-site mutant (in-frame 41-amino-acid deletion) shows impaired intestinal and exocrine pancreas development but no CNS or myelination defects — illustrating that this particular model captures a different (non-neural) aspect of Pol III dysfunction and does not recapitulate the leukodystrophy phenotype, a further human-model-fidelity caveat relevant to interpreting non-mammalian model data for this disease.

Cellular models: - Patient-derived fibroblasts (Western blot showing reduced POLR3A protein, most pronounced in white matter vs. cortex in autopsy tissue) and transfected oligodendroglial cell lines (used in the ibuprofen-rescue experiments for both HLD7/POLR3A and HLD8/POLR3B mutant constructs) are the principal in vitro systems. - S. cerevisiae RPC160 (the yeast POLR3A homolog) has been used for functional characterization of specific POLR3A hypomyelinating-leukodystrophy variants (bioRxiv/ScienceDirect, "Functional characterization of Polr3a hypomyelinating leukodystrophy mutations in the S. cerevisiae homolog, RPC160"), providing a tractable system for variant-level functional classification (relevant to VUS resolution in genetic testing).

Model limitations (for KB "human model mismatch" annotation): - The Polr3a G672E global knock-in mouse fails to reproduce the human neurological phenotype despite carrying a validated human pathogenic allele, whereas oligodendrocyte-lineage-conditional expression of pathogenic Polr3a does reproduce hypomyelination — indicating that cell-type-specific dosage/expression context, not just the presence of the pathogenic allele, determines phenotype recapitulation in mice. This is a strong candidate for a HUMAN_MODEL_MISMATCH discussion entry in a dismech pathophysiology node modeling the oligodendrocyte-differentiation-arrest mechanism. - Zebrafish polr3b mutants recapitulate the non-neural (pancreatic/intestinal) but not the neural (myelination) phenotype, again cautioning against over-generalizing model-organism findings to the human CNS phenotype without confirmation.

Applications: These models collectively support study of (1) oligodendrocyte-lineage-specific Pol III requirements in myelination, (2) genotype-severity relationships (null vs. hypomorphic alleles), (3) candidate small-molecule rescue (ibuprofen/mTOR pathway), and (4) variant-level functional classification (yeast RPC160 system) — but no model to date fully recapitulates the complete human tetrad (neurologic + dental + endocrine + ocular) simultaneously, with the partial exception of the 2023 Polr3b mouse model (hypomyelination + hypodontia + craniofacial abnormalities).

Summary of Key Primary-Literature Citations

Citation	PMID/DOI	Contribution
Bernard G et al., Am J Hum Genet 2011;89:415–423	PMID 21855841	Original POLR3A mutation discovery (TACH, French-Canadian founder families)
Tétréault M et al., Am J Hum Genet 2011;89:652–655	PMID 22036172	Original POLR3B mutation discovery
Wolf NI et al., Neurology 2014;83:1898–1905	PMID 25339210	Clinical spectrum in 105 individuals; unifying "4H" phenotype and MRI criteria
Dorboz I et al., Neurol Genet 2018;4:e289	(PMCID available; PMID not confirmed in search)	POLR1C biallelic missense variants cause childhood-onset HLD
Vanderver A et al./Terao M et al., Brain 2023;146:3513	academic.oup.com/brain/article/146/8/3513	Homozygous POLR1A variant causes leukodystrophy, protein-homeostasis mechanism
Weiss K et al., Am J Med Genet A 2015 (Cincinnati AFD)	PMID 25913037	POLR1A heterozygous variants → acrofacial dysostosis, Cincinnati type
Perrier J et al., Human Mutation 2024	DOI 10.1155/2024/8807171	Novel pathogenic POLR3K variants — third reported case worldwide
Choquet K et al./Sawaguchi S et al., 2022	PMC8788570 / PMC8884015	Ibuprofen rescues oligodendroglial differentiation defect in HLD7/HLD8 cellular models
Wambach JA et al., Am J Hum Genet 2018	S0002-9297(18)30362-8	Biallelic POLR3A LOF variants cause Wiedemann-Rautenstrauch syndrome
Currier AGB et al., Front Cell Neurosci 2020	PMC7902007	Review of potential therapeutic approaches for POLR3-HLD
Cayami FK et al./PMC11187961	PMC11187961	POLR3A-related disorders spectrum incl. dystonia and DBS outcomes

Notes on evidence gaps: Population prevalence/incidence, formal survival curves, and a validated disease-specific QOL instrument were not found in the literature searched and should be marked as "not established" rather than estimated, per the dismech evidence-discipline conventions.

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

External Assertions

Medical Actions

Diagnosis

Imaging Findings

Prevalence

Differential Diagnoses

Animal Models

Source YAML

References & Deep Research

References

Deep Research

POLR-Related (POLR3-Related) Leukodystrophy — Comprehensive Research Report

1. Disease Information

2. Etiology

3. Phenotypes

Neurologic phenotypes

Non-neurologic phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Summary of Key Primary-Literature Citations